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Chronic obstructive pulmonary disease (COPD) is a major public health prob-
lem. It is a prevalent disease in the general population and a major cause of 
morbidity and mortality worldwide. It is estimated that it will be the third lead-
ing cause of death by 2030 (1). GOLD defines COPD as ‘a preventable and treat-
able disease with some significant extrapulmonary effects that may contribute 
to the severity in individual patients. Its pulmonary component is character-
ized by airflow limitation that is not fully reversible. The airflow limitation is 
usually progressive and associated with an abnormal inflammatory response of 
the lung to noxious particles or gases (2). A clinical diagnosis confirmed with 
spirometry (FEV1/FVC<0.70) should be considered in patients with dyspnea, 
chronic cough, and sputum production and history of exposures to risk factors 
(2). Traditionally COPD management was based on spirometry values and until 
recently the decision on therapeutic options was based mainly on which GOLD 
stage patients were classified as well as whether they had frequent annual exac-
erbations or not (2). 
The disease often presents with shortness of breath, increased sputum produc-
tion and significant reduction of exercise tolerance. A need for measuring exer-
cise tolerance and health status has been raised. Several measures as: exercise 
tolerance, BODE index, symptom/control scores, quality of life and health status 
tools generic or COPD specific have been proposed in addition to spirometry to 
monitor and manage COPD (3-9). The use of quality of life tools to assess and 
properly manage COPD has been highlighted as a research need for future years 
in the recent IPCRG (International Primary Care Respiratory Group) joint publi-
cation of the 2010 research needs statement (10). 
COPD and health-status
COPD patients often suffer from dyspnea, cough, mental, sleep and functional 
disorders. Some patients can continue their life almost untouched by the disease, 
some are unable to perform certain daily life activities, and others are complete-
ly handicapped. Often there is a clear misunderstanding between patients and 
physicians regarding the overall impact of the disease. Most of the times when a 
clinician ask his COPD patient if he is feeling well most probably will answer yes 
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as he feels that symptoms as dyspnea, sputum production and cough are normal 
for him and that he will have to live with them for the rest of his life. Therefore 
it is important that clinicians find a common way to evaluate patients’ health 
status changes within different visits. To that direction several tools either ge-
neric, either COPD specific measuring health status or quality of life have been 
designed (5-9). 
Health status represents an overall evaluation of the patient’s health and quality 
of life, it reflects the patient’s ability to maintain a normal life and perform daily 
life activities. Disease specific quality of life is the quality of life affected or not 
by the specific disease, in our case COPD. Most of the time the terms quality 
of life, health-related quality of life, disease specific quality of life and health 
status are interchangeable terms. 
The assessment of quality of life or patient’s health status has been suggested 
to be used in daily clinical practice in order to properly manage patients with 
COPD. However some doctors are only restricted to spirometry while others use 
quality of life instruments routinely in their daily clinical practice. FEV1 while 
being essential for the diagnosis and classification of COPD patients gives us 
little information regarding the patients’ ability to be active in work, home or 
social activities. 
Symptoms strongly influence the quality of life of COPD patients. This is expect-
ed as patients with COPD frequently suffer from dyspnea, cough and sputum 
production. All these factors have been extensively proven to influence quality 
of life and almost all quality of life questionnaires include relevant questions. 
Dyspnea however is one of the most important factors. Stucki et al has made a 
content comparison of different COPD quality of life instruments and identified 
548 included concepts. Only the single category ‘dyspnea’ was covered by all 
instruments, while 21 categories were unique to specific instruments (11).  
The impairement in health status in COPD is not only limited to patients with se-
vere-very severe COPD but is also often present in patients with mild or moder-
ate COPD (12). Apart from the scheduled annual consultations, patients do not 
visit their physicians when FEV1 has declined, but when they have an impaired 
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health status reflected in deterioration of symptoms, cough, phlegm, shortness 
of breath, and awaking because of symptoms. This can also be seen by the fact 
that patients undereport and do not give the same importance as clinicians in the 
rate and burden of exacerbations (13). 
The burden of the disease and the patients’ quality of life is only weakly correlat-
ed with the FEV1 or with the calculated Tiffenaud index. Indeed several studies 
until now have highlighted the weak association of FEV1 with several quality of 
life instruments as the Clinical COPD Questionnaire (CCQ) (5,14,15), the Air-
way Questionnaire (AQ-20) (16), the Saint George Respiratory Questionnaire 
(SGRQ) (16,17), the Cronic Respiratory Questionnaire (CRQ) (18,19) and the 
COPD Assessment Test (CAT) (6). Primary care physicians diagnosis and treat-
ment plans are mainly based on spirometry values in conjuction with the annual 
exacerbation rate. Only recently the GOLD suggested that COPD treatment plans 
should also be based on quality of life or health status assesments (2). It has 
been shown that several treatment strategies; long acting beta agonists (LABA) 
(20-22), combinations of inhaled corticosteroids with LABA (23-25), long act-
ing antimuscarinic agents (LAMA) (26,27) improve health status and quality 
of life (28). To that direction the recent GOLD revised report showed that to 
properly manage COPD, dyspnea symptoms and health status should always be 
assessed and managed (2). 
Telehealth services-COPD and health status
Health care systems worldwide attempt to find new ways of managing patients 
with respiratory diseases. Telehealth services that include spirometry and auto-
matic use and calculation of quality of life instruments scores can be of great 
value for clinicians all over the world. Recent publications suggest that tele-
monitoring could help in preventing hospital admissions, as prompt diagnosis 
and exacerbation assessment in COPD is crucial (29). The role of tele-monitor-
ing in COPD management remains to be established in the future. As well as if 
it’s use could improve COPD prompt diagnosis, quality of life and reduce admis-
sions (10). Questions such as in which patients this is more effective, and in 
what way, remain unanswered (10). 
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Telehealth care services have been proven to change outcomes such as exac-
erbation rates, emergency department visits, hospitalizations, mortality, lung 
function, cost, patient satisfaction and quality of life (29-33). Quality of life 
as assessed either with SGRQ (29-31) or with CRQ (32) has been proven to be 
improved with telehealth care services although more research is needed. A re-
cent meta-analysis showed improvement in health status by a mean difference 
in SGRQ score of -6.57 (95% confidence interval -13.62 to 0.48), more than the 
minimal clinically important difference known for the SGRQ, defined as -4.00 
points, when an internet based approach was applied (33). 
Functional status
Functional status in addition to health status is needed to achieve intergated 
care for COPD patients. The improvement in functional status is one of the ma-
jor treatment goals for patients with COPD (34,35). Exercise testing laboratory 
or not have been proposed by the recent GOLD reccomendations as indicators of 
health status impairement and prognosis prediction (2). Improvement of exer-
cise tolerance has been proven to reduce breathleseness even in severly disabled 
COPD patients (36). 
The importance of the functional status can be seen also by the fact that it has 
been included in the widely used composite BODE index (Body Mass Index, Ob-
struction, Dyspnea, Exercise) (4). 
However the definition of ‘functional status’ and the ways to assess it have not 
received proper attention in the literature and a grading system with suggestions 
on which tool to select is missing. Functional status estimation is considered a 
cornerstone in deciding whether to include patients in pulmonary rehabilitation 
programmes (2). 
COPD instruments to measure health status  
It is rather difficult to decide which tool to select to measure quality of life/
health status in COPD patients. There are several reasons for this. It is up to 
the physician to decide if he/she will use generic health status instruments or 
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COPD-specific health status instruments. Cazzola et al. (on behalf of the ATS/
ERS task force on outcomes of COPD) suggested instruments for generic health 
status (SF-36, SIP, NHP), long disease-specific health status and HRQoL (CRQ, 
SGRQ), short disease-specific health status and HRQoL (CRQ-SAS, AQ-20, BPQ), 
disease-specific health status and HRQoL for patients with respiratory failure 
(Maugeri Foundation respiratory failure questionnaire) and the CCQ (37). CAT 
a new promising tool with only 8 questions has been also suggested as an alter-
native but there are currently very few studies to support its efficacy as it was 
only developed in 2009 (2,6). However it is the only one currently included in 
the updated 2011 GOLD guidelines (2). SGRQ is the most widely used question-
naire until now and all other quality of life questionnaires have used SGRQ as 
a gold standard in their psychometric properties evaluation (5-7). A need for 
a head to head comparison of simple and easy to complete questionnaires is 
needed to help clinicians to decide which tool will select. 
Which tool to select for measuring health status
There are several tools assessing health status and or quality of life in patients 
with COPD. More than forty tools are available. Criteria that should be taken in 
consideration to decide which tool to select are: validity/reliability, responsive-
ness, practicality, available in many translations and tested in practice. One fur-
ther factor that clinicians should keep in mind before deciding is which tool is 
more easily obtained and whether it needs special permission for its use, as not 
all questionnaires are easily obtained and most of them require permision for 
use. CCQ and CAT are COPD specific health status questionnaires that have the 
main advantage of being easy to complete in less than two minutes and they are 
both tested for use in primary care (5,6). SGRQ is widely used in both research 
and daily life practice but it is rather complicated, time consuming and needs 
excel spreadsheets to be calculated (7). 
With this thesis we will try to shed some more light on the differences between 
CCQ and CAT in an attempt to help physicians as well as researchers decide 




COPD: Chronic Obstructive Pulmonary Disease, GOLD: Global Initiative for 
Chronic Obstructive Lung Disease, FEV1: Forced Expiratory Volume in one sec-
ond, FVC: Forced Vital Capacity, BODE: Body mass index, bronchial Obstruc-
tion, Dyspnea, Exercise, IPCRG: International Primary Care Respiratory Group, 
CCQ: Clinical COPD Questionnaire, AQ-20:Airways Questionnaire 20, SGRQ: 
St George Respiratory Questionnaire, CRQ: Cronic Respiratory Questionnaire, 
CAT: COPD Assessment Test, LABA: Long Acting Beta Agonists, LAMA: Long 
Acting Antimuscarinic Agents,  ATS/ERS: American Thoracic Society/European 
Respiratory Society, SF-36= Short Fort Health questionaire, SIP=Sickness Im-
pact Profile, NHP=Nottingham Health Profile scale,  BPQ=Breathing Problems 
Questionnaire.
Main research question of this thesis
Which are health status and functional status measurements currently used in 
COPD patients? Which tool should clinicians use? How can a telehealth project 
for assessing health status be implemented? Is it important to assess health sta-
tus in patients in all stages of COPD severity?
Outline of this thesis
The factors known to influence disease specific quality of life and or health sta-
tus in COPD patients were estimated by a review and a meta-analysis of pearson 
weighted correlations and are described in chapter two. The description of a 
telehealth integrated asthma-COPD service for primary care that includes also 
the COPD Clinical Questionnaire (CCQ) and it’s future application in Greece is 
described in chapter three.  A pilot feasibility study is presented. The impor-
tance of functional status measurement in COPD, the available methods and 
their feasibility in primary care as determined by a review is described in chap-
ter four.  Chapter five presents a COPD wellness tools guide focused to prima-
ry care. The wellness tools guide is based on a review and a ranking by experts 
in primary care recruited by IPCRG. Chapter six describes a head to head com-
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parison between the COPD assessment Test (CAT) and the Clinical COPD Ques-
tionnnaire (CCQ) in an attempt to help physicians decide which tool to select 
for measuring health status in COPD. This has been a cross-sectional study that 
included also follow up data from 3 consecutive visits.  Chapter seven presents 
the research protocol and a short report of an international database on health 
status measurement as assessed with the CCQ. This has been a cross-sectional 
study that unified different databases from three European countries. Chapter 
eight summarizes the results of all chapters and discusses the importance of as-
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Factors that influence disease 
specific quality of life or health status
 in patients with COPD: a systematic review
and meta-analysis of Pearson correlations
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Abstract
Background: A major goal in the management of chronic obstructive pulmo-
nary disease (COPD) is to ensure that the burden of the disease for patients with 
COPD is limited and that patients will have the best possible quality of life.
Aim: To explore all the possible factors that could influence disease-specific 
quality of life and health status in patients with COPD.
Methods: A systematic review of the literature and a meta-analysis were per-
formed to explore the factors that could have a positive or negative effect on 
quality of life and/or health status in patients with COPD.
Results: Quality of life and health status are determined by certain factors in-
cluded gender, disease severity indices, lung function parameters, body mass 
index, smoking, symptoms, co-morbidity, depression, anxiety, and exacerba-
tions. Factors such as dyspnea, depression, anxiety and exercise tolerance were 
found to be more correlated with health status than the widely used spirometric 
values. Forced expiratory volume in one second had a weak to modest Pearson 
weighted correlation coefficient which ranged from –0.110 to –0.510 depend-
ing on the questionnaire used.
Conclusions: The broad range of determining factors suggests that, in order to 
reach the management goals, health status should be measured in addition to 
lung function in patients with COPD.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease in the 
general population and a considerable burden for patients with the disease. This 
burden differs between patient groups. Some patients can live their lives almost 
untouched by the disease, while others are almost completely handicapped. The 
burden of the disease does not follow the classic Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) severity grades based on spirometry, as pos-
tulated by the current guidelines (1). It is widely accepted that the burden of 
the disease is determined by more than pulmonary function measured by the 
Tiffeneau index and forced expiratory volume in one second (FEV1). One way 
to indicate the burden of the disease to patients is assessment of health-related 
quality of life (HRQoL) and health status. Quality of life (QoL) in general refers 
to the patient’s ability to enjoy normal life activities (Webster’s New World-
Medical Dictionary). HRQoL is more specific and is related to the part of the 
QoL that is determined by health. It may include dimensions such as general 
health status, mental, psychological and sleep status, ability to proceed with 
daily life, and social activities. Disease-specific QoL is that related to a certain 
disease. COPD-related QoL is considered to be the potential impact of COPD on 
HRQoL. Health status represents an overall evaluation of the state of the health 
of a person. When related to a specific disease, it is almost interchangeable with 
disease-specific QoL. 
Health status measurement is becoming an important issue for the day-to-day 
management of COPD patients in both primary and secondary health care (2-9). 
Studies report that a shorter survival is related to worse health status/HRQoL 
(10-12). Since health status is considered a major goal in managing the disease 
(13) physicians should be focused on improving it. The implementation of short 
instruments to measure health status has significantly improved their usage in 
daily clinical practice (14-24). However, the currently available health status 
questionnaires have a number of differences in the concepts included, and vari-
ous items are unique in some questionnaires (25,26).
The theoretical model of factors that potentially have an influence on health 
status includes factors such as age, gender, disease severity, lung function, body 
mass index (BMI), smoking status, symptoms, exercise capacity, co-morbidity, 
depression, anxiety, and exacerbations (27-38).
The aim of the present review and meta-analysis is to present and discuss the 
published data of factors that could possibly play a role in COPD-related QoL or 
health status. The existing literature provides information on various factors that 
could be positively or negatively associated with COPD-related QoL although, to 
date, no literature exists that aggregates this knowledge in one report.
Methods
A systematic literature search was performed from 1984 to September 2009 
in Pubmed, Embase and the Cochrane Collaboration for the keywords COPD, 
health status or quality of life, in conjunction with questionnaires, age, gender, 
BMI, smoking, COPD severity, FEV1, symptoms, exercise capacity, comorbidity, 
depression, anxiety, and exacerbations. Further articles were identified from the 
reference lists of the included articles.
In our review we included studies that used general health status questionnaires 
such as the Short Form Health Survey Questionnaire (SF-12) and SF-36, the 
Quality of Well Being scale (QWB), the Sickness Impact Profile scale (SIP), the 
Nottingham Health Profile scale (NHP), the European Quality of Life question-
naire (EuroQOL) and studies that used specific health status and QoL question-
naires such as the Chronic Respiratory Questionnaire (CRQ), the St George’s 
Respiratory Questionnaire (SGRQ), the COPD Control Questionnaire (CCQ), the 
Quality of Life in Respiratory Illness Questionnaire (QoL-RIQ), and the Airways 
Questionnaire 20 (AQ-20) for the assessment of COPD. 
The number of potentially relevant studies identified and screened for retrieval 
was 2391 for COPD and factors relating to quality of life and 1497 for COPD 
and factors relating to health status. A total of 3717 studies were excluded 
because the title or abstract showed that they were not relevant or because of 
duplications in keyword searching. Those most frequently excluded were in-
terventional studies that were not within the goals of this review. Studies that 
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reported comparisons of QoL questionnaires but did not report information on 
factors relating to quality of life or health status were also excluded. A total of 
171 studies were retrieved for evaluation and are included in this review; 66 
studies reported Pearson or Spearman correlation coefficients and are included 
in the meta-analysis. 
Statistical analysis
A meta-analysis was conducted only of the 66 studies for which Pearson or 
Spearman correlations were available. In some questionnaires a high score indi-
cates a good health status while in others a high score indicates a bad health sta-
tus. To enable a comparison to be made between the correlation coefficients of 
the different questionnaires, the correlation coefficients were multiplied by –1 
when the direction of the scoring was from bad (low score) to good (high score) 
(figures 1 and 2). The following questionnaire scores were transformed: Chinese 
35-Item Quality of Life Instrument, CRQ, EuroQoL, EuroQol-Five-Dimension 
visual analogue scale (EQ-5D VAS), Mental Component Summary (MCS-12) 
and Physical Component Summary (PCS-12) of SF-12, Multidimensional Index 
of Quality of Life (MIQL), Perceived Quality of Life Scale (PQoL), QoL-RIQ, 
Quality of Life Scale (QoLS), QWB, and the Visual Simplified Respiratory Ques-
tionnaire (VSRQ). As a result, a high score on a questionnaire indicates much 
impairment/worse health status. 
Pooled estimates of the correlation coefficients were calculated by transform-
ing the correlation coefficients to Fisher’s z values. The resulting values were 
weighted with the inverse of the variance of the correlation coefficients. The 
95% confidence intervals of the pooled weighted Fisher’s z values were also 
calculated, after which all the values were back-transformed to the metric of the 
correlation coefficients (39).
Results
Factors that influence COPD HRQoL and health status
The factors presented here have been mentioned in the literature in relation to 
QoL and health status in patients with COPD. Pearson weighted correlations and 
confidence intervals between various factors and questionnaires are reported 
in Table 1. In order to make Table 1 readable, we only show the relations be-
tween questionnaires and factors when at least three studies reported on these 
outcomes. All Pearson weighted correlations are shown in the Appendix (avail-
able online at www.thepcrj.org). Figure 1 shows Pearson weighted correlations 
between FEV1 and various QoL or health status questionnaires. Figure 2 shows 
the highest Pearson weighted correlations between different factors and ques-
tionnaires. Some factors such as gender and COPD severity are not included in 
Figures 1 and 2 or the Appendix because the studies did not provide correlations 
but only comparisons between groups (p<0.05). Studies that used the SF-36 
questionnaire were not included in Figures 1 and 2 or the Appendix because of 
the large number of different domains. However, their impact on health status 
is reported in the text.
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Figure 1. Pearson weighted correlations, FEV1 and various Health status/ Quality of 
life questionnaires. * The score was transformed so that a high score on a questionnaire 




Legend: AQ20=Airways Questionnaire 20; BPQ=Breathing Problems Questionnaire;CCQ=COPD 
Control Questionnaire; CRQ=Chronic Respiratory Questionnaire;FEV1=Forced Expiratory 
Volume in one second; MIQL=Multidimensional Index of Quality of Life; PCS=Physical 
Component Summary; PQoL= Perceived Quality of Life Scale; QoLS=Quality of Life Scale; 
QWB=Quality of Well Being scale; SGRQ=St George’s Respiratory Questionnaire; VSRQ=Visual 
Simplified Respiratory Questionnaire.
Figure 2. Highest Pearson weighted correlations between various Health status/ 
Quality of life questionnaires and factors that influence QoL or health status are 
figured. * The score was transformed so that a high score on a questionnaire indicates much 






Legend: AQ20=Airways Questionnaire 20; BMI=Body Mass Index; BODE index=Body mass in-
dex (B), bronchial Obstruction (O), Dyspnea (D), Exercise (E); BPQ=Breathing Problems Ques-
tionnaire; CCQ=COPD Control Questionnaire; CRQ=Chronic Respiratory Questionnaire; EQ-
5D-VAS=EuroQol-Five-Dimension Visual Analogue Scale; FEV1=Forced Expiratory Volume 
in one second; GOLD=Global Initiative for Chronic Obstructive Lung Disease; HADS=Hospital 
Anxiety and Depression Scale; 6MWD=6-Minute Walk Distance; NHP=Nottingham Health 
Profile scale; PaCO2=Arterial Carbon Dioxide tension; PaO2=Arterial Oxygen tension; 
QWB=Quality of Well Being scale; RQLQ=Modified Asthma Respiratory Quality of Life 
Questionnaire; SGRQ=St George’s Respiratory Questionnaire; SIP=Sickness Impact Profile; 
TLCO=Carbon Monoxide Diffusing Capacity.
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Table 1. Meta-analysis results from correlations from three and more studies are re-
ported. Pearson weighted correlations between questionnaires and factors, upper and lower 
limits, total number of patients included in the meta-analysis and the lower and upper number 
of patients that was mentioned in the studies are reported. * The score was transformed so 
that a high score on a questionnaire indicates much impairment / worse health status. In () 














of patients in the 
studies. Lower and 
upper number
SGRQ total (29)
{17, 32, 35, 42, 49, 50, 61, 62, 
67, 70, 76, 80, 82, 84, 87, 96, 
98, 104, 109, 111, 113, 117, 
118, 119, 121, 124, 126, 127, 
129}
FEV1 -0.285 -0.156 -0.404 5288 (30-751)
CCQ total (3)
{19, 75, 79}
FEV1 -0.405 -0.285 -0.513 562 (58-329)
CRQ* (4)
{105, 114, 116, 129}
FEV1 -0.294 -0.023 -0.525 206 (44-62)
SGRQ total (5)
{72, 98, 99, 100, 104}
BODE 0.441 0.572 0.289 583 (64-253)
SGRQ total (19)
{17, 35, 42, 49, 53, 58, 61, 67, 
70, 76, 87, 96, 104, 109, 111, 
113, 117, 121, 124}
Dyspnea 0.507 0.622 0.371 2510 (30-560)
SGRQ total (15) 
{35, 50, 58, 61, 70, 76, 84, 
104, 109, 111, 121, 113, 117, 
127, 144}
6 MWD -0.342 -0.221 -0.453 2454 (30-1217)
SGRQ total (5)
{17, 50, 56, 96, 150}
HADS 
anxiety
0.462 0.610 0.283 574 (41-218)
Legend: BODE=Body mass index (B), degree of airway Obstruction (O), level of functional 
Dyspnea (D), and Exercise capacity (E); CCQ=COPD Control Questionnaire; CRQ=Chronic 
Respiratory Questionnaire; FEV1=Forced Expiratory Volume in one second; HADS=Hospital 
Anxiety and Depression Scale; 6MWD=6-Minute Walk Distance; SGRQ=St George’s Respira-
tory Questionnaire.
1. Demographic and anthropometric factors
a) Age
The results relating to age are controversial. Higher age was reported as a nega-
tive predicting factor for the health status of patients with COPD in 17 studies 
(7,20,28,29-32,38,40-48). In eight studies we found no significant correlation 
between age and health status (49-56) and, in another eight studies, it was 
reported that younger patients had worse health status (33,57-63). The meta-
analysis includes only a small number of studies that reported correlations since 
the large majority of studies only reported comparisons between age groups. In 
the meta-analysis, age was found to be weakly associated with impairment of 
health status (Table 1, Figure 2).
b) Gender
In 18 studies female patients with COPD reported worse health status than male 
patients (7,29,30,33,35,37,38,41,43,48,51,64-70) both on total scores and on 
physical condition scores as assessed by the SF36 (29,35). Ten studies reported 
no gender differences in health status (40,50,52-55,71-74). Only one study re-
ported the opposite that is, worse health status in men (28).
c) Body weight and body mass index 
Body weight and BMI are related to health status, with underweight patients 
having worse health status than patients of normal weight (28,43,53,75-79). 
Four studies reported that health status tends to be worse also in overweight 
patients (53,63,75,80). Some studies reported no correlation between health 
status and BMI (31,49,58). The Pearson weighted correlation ranged from weak 
to modest, depending also on the questionnaire used. The strongest correlations 
were reported with the SGRQ and CCQ (Figure 2). Low lean body mass abnor-
malities and a low fat free mass index have also been associated with activity 
impairment and worse health status (53,81). In one study, worse health status 
was associated with a smaller proportion of type I fibres in peripheral muscles 
(80).
Factors that influence disease specific quality of life or health status in patients with COPD: 
a systematic review and meta-analysis of Pearson correlations
Factors that influence disease specific quality of life or health status in patients with COPD: 




Current smoking and a higher number of pack-years have a weak negative influ-
ence on health status (7,28,31,46,55,61,79,82-87). Some studies reported no 
correlation (40,43,51,53) and one study found that smokers had a better health 
status (29). Second-hand smoke was also reported to be associated with poorer 
health status in patients with COPD (88).
b) Social class
Some studies reported a relation between socioeconomic status and health status 
(83,89), but others did not confirm this finding (40,52).
3. Disease-driven determinants
a) Severity of COPD (GOLD-ATS-BTS-Canadian staging, BODE index) 
Most of the published studies suggest that COPD severity measured by recom-
mendations from the ATS, BTS, GOLD, and the severity score is related to health 
status (8,29-31,38,40,43,46,67,75,90-102).
With minor exceptions, health status became more significantly associat-
ed with disease severity as the disease passed to a more severe stage (8,29-
31,38,40,43,46,67,75,90-102). Yeo et al. (103) reported no significant asso-
ciation between health status and GOLD stages. COPD severity assessed by the 
composite BODE index – body mass index (B), degree of airway obstruction (O), 
level of functional dyspnea (D), and exercise capacity (E) – showed a better 
correlation with health status. This relation was stronger than the relation with 
pulmonary function parameters and GOLD stages (Table 1, Figure 2) (72,98-
100,104). A new composite index, the DOSE index – dyspnea (D), airflow ob-
struction (O), smoking status (S), and exacerbation frequency (E) – showed a 
modest correlation with QoL in COPD patients (79).
b) Physiology (lung function values, PaO2, PCO2, exercise capacity)
Most studies showed a non-significant or weak association between FEV1 and 
health status (28,30-31,33,35,42,43,45,47-49,53,56-59,61-64,67,68,70,76,
82,84,87,89,98,104-127). Some of the studies revealed a moderate association 
between health status and FEV1 (7,19,32,50,60,75,80,123,128-132). The dif-
ferences in the strength of the correlation might be due to the different question-
naires used (Table 1, Figure 1). The strongest correlations were shown mainly 
with the QWB, CRQ dyspnea and CCQ questionnaire while, in all other question-
naires, the correlations were rather weak.
Other lung function values investigated included the inspiratory to total lung 
capacity (IC/TLC) ratio (35), forced expiratory volume in one second/forced 
vital capacity (FEV1/FVC) ratio (31,42,80,105), FVC (33,42,61,64,107), vital 
capacity (VC) (31,50,61,112,133), IC (67,114), and residual volume (RV)/TLC 
ratio (63), most of which showed a weak association with health status. Maximal 
inspiratory respiratory muscle pressure (MIP) (31,58,64), maximal expiratory 
respiratory muscle pressure (MEP) (64) and carbon monoxide diffusing capacity 
were also found to be weakly associated with health status (31,50,63,64,96,105). 
Arterial oxygen tension (PaO2) was either not significantly associated or mod-
estly positively associated (35,49,50,56,80,81,83,89,104,108,109,117,128,
129,134).  A weak negative association or a non-significant association was also 
reported with carbon dioxide tension (PCO2) (32,35,47,50,56,109).
4. Symptoms and exercise performance
The key symptom in COPD is dyspnea. Dyspnea, which is usually measured 
with the transitional dyspnea index (TDI) or the baseline dyspnea index (BDI), 
was found to be strongly negatively associated with health status and had the 
highest correlations with health status questionnaires (Table 1, Figure 2), 
(20,28-30,35,42,45,48-53,57,58,60,61,63,65,67,70,75,76,79,81,87,93,94,
96,97,101,104,105,106,107,108,109-114,117,123,124,131,133,135-141). 
Sputum production, chronic cough (29,102) wheezing (54,57), and fatigue 
(58,110,139,142) were also negatively associated with health status. 
Impairment of exercise performance tolerance was associated with impairment 
in health status and mainly with the functional status or activity domains. The 
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most used instrument to assess the exercise tolerance was the 6-minute walk dis-
tance which was weakly to modestly correlated with health status measurement 
questionnaires (Table 1, Figure2) (35,50,52,53,54,58,59,60,61,64,70,73,76,
81,83,84,87,104,105,109,111,113,114,116,117,121,127,133,138,143,144). 
Only one study reported no association between health status and exercise ca-
pacity (145).
5. Co-morbidity: depression, anxiety
Co-morbidity influences the health status of patients with COPD (28,35,38,41,
48,51,62,91,92,103,115,146,147).  Heart disease, hypertension, locomotive 
disorders, diabetes, and sleep disturbances are among the most common co-mor-
bidities reported to be associated with impaired health status (38,41,51,87,92,
103,146,147). In only two studies was co-morbidity not associated with im-
paired health status (53,99).
Depression and anxiety strongly impair health status and QoL in patients with 
COPD, as reported in several other studies (17,34,50,56,61,62,63,67,73,83,
89,92,96,103,113,115,131,133,138,148-154). Depression and anxiety were 
assessed in most of the studies by the Hospital Anxiety and Depression Scale 
(HADS) and the Beck Depression Inventory Scale (BDI) and Anxiety Scale (BAI). 
The meta-analysis showed that depression and anxiety had among the highest 
correlations with various questionnaires for the assessment of health status (Ta-
ble 1, Figure 2).
6. Other factors
Previous exacerbations and hospital admissions have a weak negative impact 
on health status (11,33,35,40,42,43,46,49,57,62,123,124,126,133,155-168). 
Lower education and non-compliance with medication and medical interven-
tions are associated with a worse health status (7,28,29,43,46,169) as well as 
an increased number of medications for controlling COPD (42,77,132,170) and 
a longer disease duration (42,46,120). Living alone was associated with poorer 
QoL (132).
Seasonal variation in health status – with a better health status in spring/sum-
mer than in winter has been reported (157). In one study, a home temperature 
of at least 21°C for at least 9hrs/day was associated with better health status 
(171). There is also variability in health status between northern and southern 
countries and between urban and non-urban areas, with worse health status re-
ported in southern countries and urban areas (28,42,172). 
Finally, psychological and psychosocial factors, and coping strategies are associ-
ated with health status (33,48,52,120,173-175). The patient’s illness perception 
is also associated with several domains of QoL (175). One study found that the 
patient’s coping strategies and health status were not significantly related (176). 
Holm et al. reported that a poor quality  family relationship was associated with 
more psychological distress and dyspnea resulting in a worse QoL (177). One 
study reported that employment status and, more specifically, COPD patients 
who were too disabled to work had worse QoL than paid workers (125). 
Discussion
Health status in patients with COPD is influenced by many different factors. 
However, the level of influence on health status of each factor is difficult to 
estimate because of the many different questionnaires used and because some 
factors influence different parts or domains of the available questionnaires. This 
metaanalysis shows that the most significant factors that determine QoL/health 
status in COPD patients are dyspnea, depression, anxiety, and exercise tolerance. 
Since almost all instruments used to assess health status include items directly 
related to the disease – such as dyspnea or other symptoms – this will automati-
cally result in these strong associations. This meta-analysis also indicated that 
spirometry values are only weakly associated with health status. This finding 
supports the idea that health status should therefore be measured in addition to 
spirometry.
The results relating to age are controversial. Poorer health status was reported in 
both older and younger patients. Although the meta-analysis showed a trend for 
a worse health status in older COPD patients, the correlation was rather weak. 
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The impairment of health status in older people is to be expected because ageing 
by itself leads to a deterioration in the health status of the general population 
and also impairs lung function (178). The presence of significant co-morbidi-
ties and/or an increased number of medications taken by older people leads to 
a further deterioration in health status (7,59,67,77,92,103). The fact that in 
some studies younger people reported worse health status may be explained by 
a larger gap between the health status experienced and that expected (59).
Female patients with COPD report a poorer health status (7,29,30,33,35,37,38,
41, 43,48,51,64-70). Foy et al. investigated the effect of rehabilitation on health 
status in men and women and suggested that gender differences in physiologi-
cal and psychological impairment explain the differences in health status (66). 
Other suggestions are an increased burden of symptoms (65), different coping 
mechanisms (37), more intense restriction of activity (33), an airway predomi-
nant phenotype (179) or a greater psychosocial impairment (69) in women. 
Women are also known to be more susceptible to depression, a disease that re-
sults in deterioration in health status in COPD patients (66,180). 
Many studies assessed the effect of underweight on the health status in patients 
with COPD. Underweight patients have impaired health status mainly because 
of the deterioration in dyspnea (53). This is well known in COPD patients. Over-
weight patients also have impaired health status (53,75). Shoup et al. reported 
that overweight patients with COPD had increased dyspnea and worse scores 
on both the impact and total domains (53). Obesity leads to worse respiratory 
symptoms and less exercise capacity, factors that are impaired in patients with 
COPD (181). 
Smoking and pack-years are considered important factors for health status 
(7,31,106). Ex-smokers and smokers had significant differences in health status 
mainly because of the improvement in a range of respiratory symptoms after 
smoking cessation (29,85,86). Ferrer et al. reported that, in smokers, mainly the 
impact and symptoms scores were impaired (7). Only Wijnhoven et al. reported 
that current smoking was associated with better QoL (29). The authors of that 
study suggested that this contradictory result could be due to confounding by 
severity. Patients in the study who continued to smoke were those with less 
severe disease (29). Although we expected that smoking would be among the 
best predictors of health status, the correlation was only weak but the number 
of studies was too small to make firm conclusions. 
Most of the studies mentioned that disease severity was associated with health 
status (8,29-31,38,40,43,46,67,75,90-102). Ferrer et al. reported that HRQoL 
varied greatly within each stage of severity, even after stratification for co-mor-
bidity (92). In the one study that reported no significant correlation between 
disease severity and health status, there was a trend towards higher scores in 
severe COPD which indicated a poorer quality of life (103). The BODE index 
was found to have a stronger correlation with health status than FEV1 (Table 1). 
This strong correlation is not surprising since the BODE index is composed of 
factors such as dyspnea and exercise capacity that are domains of many health 
status questionnaires.
Although spirometry is traditionally seen as the most important determinator of 
the diagnosis and severity of COPD, this meta-analysis showed that the relation 
between health status and all spirometric values – mainly FEV1 – is weak (Fig-
ure 1). This indicates that assessment of COPD severity in clinical practice could 
benefit from the additional measurement of health status. 
Pearson weighted correlations from numerous studies revealed dyspnea as a 
very important determinant of health status (Figure 2, Table 1, Appendix). The 
strong relation between dyspnea and health status could in part be artificial be-
cause all reported questionnaires have questions or a domain about symptoms 
including dyspnea. In a comparison of 11 instruments used for the assessment of 
health status in COPD, Stucki et al. reported that there was a large heterogeneity 
between questionnaires, but dyspnea was the only factor present in all of them 
(26). 
Co-morbidity – especially depression and anxiety – has one of the greatest influ-
ences on the impairment of health status (34,50,56,61-63,67,73,83,89,92,96, 
103,115,131,133,138,148-154). An increased number of chronic diseases is 
associated with a worse HRQoL in the general population (182). Few studies 
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mentioned all the related co-morbidities in COPD patients with an impaired 
health status (38,41,51,92,103,146,147). Special attention has been given to 
depression and anxiety in a significant number of papers. Depression and anxi-
ety have a significant impact on health status. All the questionnaires showed a 
good correlation with depression and anxiety questionnaires, but only the CCQ 
was reported to have a sufficiently good correlation to be used to predict de-
pression and anxiety (34). Anxiety significantly influences the health status of 
patients with COPD and is strongly dependent on dyspnea (61). The high cor-
relation with depression and anxiety found in this meta-analysis highlights their 
important role in health status impairment and underlines the need for their 
estimation in daily clinical practice. 
Surprisingly, both emotional and rational coping strategies impaired health sta-
tus (52,173). Osman et al. reported that younger patients suffered more because 
of the psychological impact of their disease (33). Patients who deny their disease 
are less influenced by it (52). Those with positive beliefs and a less strong emo-
tional reaction to the illness have better QoL (175). 
Since improvement in health status is a pivotal treatment goal, physicians should 
be informed about a patient’s individual health status. Since only a very small 
part of health status is determined by spirometric values, the need for simultane-
ous assessment of health status by a proper instrument is crucial. However, it is 
difficult to select an instrument that is appropriate for use in clinical practice. 
Cazzola et al. (on behalf of the ATS/ERS task force on outcomes of COPD) sug-
gested instruments for generic health status (SF-36, SIP, NHP), long disease-
specific health status and HRQoL (CRQ, SGRQ, QoL-RIQ), short disease-specific 
health status and HRQoL (CRQ-SAS, AQ-20, BPQ), disease-specific health status 
and HRQoL for patients with respiratory failure (Maugeri Foundation respira-
tory failure questionnaire) and the CCQ (25). Only a few of these instruments 
– such as the CCQ and AQ-20 – are applicable in daily clinical practice. In the 
future, the newly developed COPD Assessment Test (CAT) (183) might be an 
alternative, although data comparing the psychometric properties with other 
questionnaires are too limited to include in this review.
Conclusions
Quality of life and health status are determined by a significant number of fac-
tors, the strongest of which are dyspnea, depression, anxiety, and exercise toler-
ance. The results of this meta-analysis indicate that the health status of patients 
with COPD is only weakly associated with spirometric values. We consider it 
advisable to measure health status in addition to spirometry in order to be better 
informed about the influence of the disease on typical health status issues such 
as symptoms, impairment, and mental state.
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Abstract
Background: Chronic obstructive pulmonary disease (COPD) and asthma are 
considered underdiagnosed and misdiagnosed chronic diseases. In The Nether-
lands, a COPD-asthma telemedicine service has been developed to increase GPs’ 
ability to diagnose and manage COPD and asthma. A telemedicine COPD-asthma 
service may benefit Greece as it is a country, partly due to its geography, that 
does not have easy access to pulmonologists. 
Findings: Therefore, a pilot feasibility study has been designed in Greece in 
order to establish this telemedicine service. Ten rural practices, in the island of 
Crete, with an average population of 2000 patients per practice will pilot the 
project supported by three pulmonologists. This paper presents the translated 
interfaces, the flowcharts and the steps that are considered as necessary for this 
feasibility study in Crete, Greece.
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Background
Chronic obstructive pulmonary disease (COPD) and asthma are common diseas-
es with significant prevalence in the general population (1,2). COPD and asthma 
consultations represent a large proportion of the total primary care consultations 
(3,4). Studies have reported a considerable number of underdiagnosed and mis-
diagnosed cases in primary care clinical settings worldwide (1,5). 
Despite the high prevalence of COPD and asthma in Greece (6,7), these diseases 
are thought to be underdiagnosed (6). Greece is a country with more than 200 
inhabited islands, with the smallest islands having high percentages of elderly 
residents. Most of the islands lack regular secondary care access. In the main-
land, there are a lot of rural and remote areas that also lack easy access to sec-
ondary care assistance. Often the General Practitioner (GP) or, at times, a non 
certified physician are the only health care providers for these patients. In ad-
dition, integration of primary health care in the country is not currently a high 
priority in the health care agenda (8).
Good quality spirometry is the key to the management of these common respira-
tory conditions and can be accomplished in primary care (9,10). However, the 
lack of availability of spirometry and lack of knowledge and training regarding 
interpretation of spirometric results have been cited as barriers to the early di-
agnosis and treatment of COPD and asthma in primary care (11). An additional 
barrier identified is the lack of secondary care support and availability of spe-
cialized physicians (pulmonologists) to general practitioners (GPs), especially in 
remote and rural areas. In that field telemedicine services have been proved a 
great help (12,13).
 Telemedicine involves the transfer of medical information via telecommunica-
tion technologies for the purpose of consulting or to aid in remote medical pro-
cedures or examinations (en.wiktionary.org/wiki/telemedicine). In remote and 
rural areas, telemedicine services have been shown to be effective in supporting 
healthcare (12,13). Services have been successfully implemented to help GPs in 
the diagnosis and management of several diseases such as asthma, diabetes, skin 
disorders and emergency cases (14-17). 
In The Netherlands, a telemedicine supported asthma-COPD service was de-
veloped for increasing the diagnosis and improving the management of asthma 
and COPD patients in primary care. The service assessed 1022 patients through 
a telemedicine collaboration of GPs with pulmonologists from March 2007 to 
November 2008. It identified 182 patients with COPD (18%), 557 patients with 
asthma (55%) and 103 patients with combined asthma and COPD (10%). In 
180 patients (10%), the diagnosis was unclear or lung function tests were not 
possible or other diagnoses (except of asthma and COPD) were made. Level 
of disease control was also examined with 47% of asthma patients and 28% 
of combined asthma-COPD patients identified as well-controlled. Twenty seven 
percent of the COPD patients were unstable (unpublished data). This service has 
improved diagnosis and management of COPD and asthmatic patients in The 
Netherlands. 
Although telemedicine services related to primary health care have been tested 
in Greek islands there has been nothing specifically for COPD or asthma (18). 
We would argue that development of a COPD-asthma telemedicine service in 
Greece could be an effective provision for GPs and patients. Telemedicine of-
fers the possibility of reducing consultations with secondary care and delays in 
communication and treatment (14-17), issues that are extremely important for 
Greece due to its particular geographical situation.
This study aims to carry out a feasibility study in Crete, Greece using the frame-
work of the telemedicine service previously developed and established in The 
Netherlands. If the service works as well as in The Netherlands, attempts to ex-
pand the service nationally will be made, subject to government support.
The primary objective of this study will be to evaluate the feasibility and accept-
ability of the Dutch asthma-COPD telemedicine service in Crete. 
Design of the feasibility study
The design of this COPD-asthma service is based on the Dutch COPD-asthma 
service (prototype) developed by the Northern Laboratory service for GPs (Lab-
noord) in cooperation with the UMCG (University Medical Centre Groningen) in 
Groningen, The Netherlands. The service has been adapted to the Greek context. 
The English version of the main flow-charts governing the software interface 
(part of the service) can be seen in figures 1,2,3,4.
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 Figure 1. Assessment of health status by CCQ and ACQ.
  
Figure 2. Spirometric values and inhalation technique. 
 
Figure 3. The service provides GP a diagnosis.
Figure 4. The pulmonologist gives precise advice to the GP.
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Participants
Ten General Practitioners from around Crete and three Pulmonologists from the 
University Hospital in Heraklion, Crete, will be recruited into the study. During 
the course of the study, we will also recruit up to 20 respiratory patients who 
have been seen through the service. The patients will be sampled purposively to 
enable as wide a range of views as possible e.g. asthma/COPD, range of severi-
ties, from straightforward cases to those who were referred to secondary care 
via the service. 
This telemedicine project is considered a new technology for Greece so further 
issues, such as appropriateness, clearness, adherence, compliance, patient and 
doctor’s satisfaction will be estimated with the use of interviews. 
Procedures
The general practitioners and pulmonologists will attend a joint training of two 
full days on the asthma-COPD telemedicine service.
The steps of the procedure that will be followed regarding the application part 
are described in Table 1. In addition to spirometry, patients will have to com-
plete three short questionnaires either at home or shortly before the spirometry. 
The first questionnaire (Table 2) that would be used contains a limited number 
of items about medication (dosage-frequency), employment, smoking behavior, 
exacerbations, history, allergy, hyper-reactivation and family history. Secondly 
patients will complete the Asthma Control Questionnaire (ACQ) and the COPD 
clinical questionnaire (CCQ) questionnaires (19,20). Data are then entered into 
the software programme by the general practitioner (Figure 1) who will then 
perform spirometry and check inhalation technique (Figure 2). Spirometry data 
is automatically entered into the computer via the spirometer. All data will then 
be available real-time to the Consulting Pulmonologist through the network. 
Table 1. Steps regarding the procedure. 
Step 1. First visit questionnaire will be feedeed to the system. 
Step 2. CCQ and ACQ scores will be incorporated to the system.
Step 3.
Spirometric values and curve will enter the system 
(example fig 2). 
Step 4.
Supported by the built of the service based in guidelines, the 
GP will receive diagnosis and management support. 
Step 5.
All the previous details will be sent to pulmonologists when-
ever needed.
Step 6.
The pulmonologists will reply with a diagnosis, advice and 
recommendations for treatment.
Step 7.
The general practitioner will have the pulmonologist assess-
ment and clear advices about diagnosis and therapy. 
Step 8.
Second visit. Assessment of the medicine and patient compli-
ance. The system will give the opportunity for comparison 
between previous and current results.
Step 9.
If needed the GP will ask for new specialist assessment, and 
then will manage the patient.
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Table 2. Questionnaire used for the assessment of history, smoking habit, family 
history and treatment.
The GP and the pulmonologist will have access to the flow charts on screen con-
taining patients’ data, spirometric values and health status assessment. Support-
ed by the built of the service based in guidelines, the GP will receive diagnosis 
and management support. The pulmonologist will go through the system advice 
with the GP whenever the GP asks for advice i.e. complicated cases.  The first 
step in the process is assessment of the spirometry results and deciding whether 
the presented flow volume curve is acceptable. The GP then makes the appro-
priate diagnosis, in consultation with the pulmonologist in less straightforward 
cases i.e. asthma, COPD, both or currently unknown (Figure 3). In addition to 
the diagnosis, the pulmonologists can advise on medication changes, exercise, or 
assessment of depression. The pulmonologist will give in details, advices about 
the treatment and will, in conjunction with the GP, determine the time of the 
next follow-up (Figure 4). If the diagnosis is not certain, the pulmonologist will 
suggest a referral to secondary care for a more expert approach. The GP will 
continue the follow-up and can ask for further assistance from the pulmonolo-
gist, if needed.
In the follow up second visit a flow chart with details about medicine, compli-
ance, smoking behavior, motivation to quit and health status will be assessed. 
The system will allow for comparisons in spirometric values, health status, body 
mass index (BMI) and symptoms from initial visit to follow up visit. Similarly to 
the first visit, the GP will have the opportunity to ask the pulmonologists for a 
second assessment and further advice, if necessary. 
Evaluation/analysis
A qualitative approach will be used to evaluate the study, using interviews and 
focus groups (21). GPs (n=10) and patients (n=20) will each take part in focus 
groups. Individual interviews will be offered for those who are unable to attend 
the scheduled focus group (either face to face or by telephone). The pulmonolo-
gists (n=3) will also be interviewed. Topics to be explored will cover; training, 
use of the technology, use of the flow charts, experience of using the telemedi-
cine service, barriers and problems encountered and acceptability of the process 
from all view points. The topic guide is currently in development. Both inter-
A telehealth integrated asthma-COPD service for primary care: 
a proposal for a pilot feasibility study in Crete, Greece 
A telehealth integrated asthma-COPD service for primary care: 
a proposal for a pilot feasibility study in Crete, Greece 
68 69
70 71
views and focus groups will be recorded and transcribed.   
The data from the interviews and focus groups will be coded descriptively and 
analysed using the framework approach to map out the range of experiences 
and views and to also aid in comparisons between participants (especially those 
with different experiences of attitudes towards the service) (21,22). Data from 
the questionnaires and spirometry will also used to supplement the qualitative 
data.
Conclusions 
In Greece, a tailored asthma-COPD telemedicine service has the potential to be 
of great help to GPs and could spare patients potentially long trips across the sea 
to the secondary care. Furthermore, it may also reduce feelings of professional 
isolation experienced by GPs and improve access to, and communication with, 
secondary care colleagues. It is anticipated that it will improve early diagnosis 
and appropriate management of asthma and COPD in primary care settings in 
Crete, Greece.  
List of abbreviations
GP: General Practitioners, COPD: Chronic Obstructive Pulmonary Disease; CCQ: 
COPD Clinical Questionnaire; ACQ: Asthma Control Questionnaire.
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Abstract
Background: Guidelines advocate that improvement in functional status should 
be a major goal in COPD treatment. Many tools are available to assess aspects 
of functional status. This review aims to categorise systematically the available 
tools based on their construct (i.e. what the tool intends to measure) and to rate 
the tools for use in the primary care setting. 
Methods: PubMed was searched with the keywords ‘functional status’ or ‘physi-
cal capacity’ or ‘functional capacity’ and ‘COPD’. All tools were categorised and 
rated on their measurement properties, feasibility, and usage in primary care 
COPD patients. The tools were divided into four constructs – functional capac-
ity, functional performance, functional reserve, and capacity utilisation – and 
used the following modes of measurement: laboratory tests; semi-laboratory 
tests; field tests; and patient-reported outcomes.
Results: The PubMed search resulted in 364 articles. Thirty-two tools were 
identified and rated.
Conclusions: In primary care, the 6-minute walking distance test is the most 
reliable semi-laboratory functional capacity test, but is not very practical. The 
pedometer is the best functional performance field test. The Medical Research 
Council (MRC) dyspnea questionnaire and the functional status domain of the 
Clinical COPD Questionnaire (CCQ) are the best patient-reported outcome tools 
to assess functional performance.
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Introduction
The amount of physical activity possible and the functional status of COPD 
patients predict exacerbations (1,2), hospital admissions (2) and mortality (3). 
Therefore, guidelines advocate the need to designate improvement in functional 
status as one of the major treatment goals for patients with COPD (4,5). How-
ever, most guidelines do not define “functional status”, nor do they define how 
to assess it. In routine clinical practice, functional status can be measured by 
several different methods representing different constructs. The “construct” of a 
measurement or questionnaire is what the tool intends to measure. Functional 
status, functional capacity, exercise capacity, and exercise tolerance are terms 
which are often used interchangeably, but they represent different constructs. 
Leidy defined a theoretical framework of functional status, exercise capacity 
and functional capacity (6), and defined functional status as a ‘multidimensional 
concept characterizing one’s ability to provide for the necessities of life; that is, 
those activities people do in the normal course of their lives to meet basic needs, 
fulfil usual roles, and maintain their health and wellbeing’. The framework la-
bels and clearly defines four distinct, but related, constructs of functional sta-
tus: functional capacity, functional performance, functional reserve, and capacity 
utilisation. Functional capacity is defined as ‘one’s maximum potential to per-
form activities’ and can be tested, for example, using cycle ergometry. Functional 
performance is defined as the physical, psychological, social, occupational, and 
spiritual activities people actually do in the normal course of their lives to meet 
basic needs, fulfil usual roles, and maintain their health and well being. Func-
tional reserve is the difference between capacity and performance, and capacity 
utilisation is the effort used to reach the functional performance. This framework 
is graphically represented in Figure 1.
It is important to keep this framework in mind when selecting tools for research 
or clinical practice. For research purposes the improvement in functional capac-
ity may be the most important factor and be directly related to the intervention, 
but for clinical management an indication of the limitations that patients experi-
ence in daily life – i.e. their functional performance– is more informative. For 
research purposes, measurement properties such as validity and responsiveness 
are of great importance in order to detect even the smallest effects of treatment. 
These high standards often lead to intensive, time-consuming and costly tests. 
For clinical practice, high measurement standards are equally important, but so 
too is feasibility. Measurement tools that are not easy to administer will not be 
used in routine practice (7,8). Therefore measurement tools should be feasible 
and easy to interpret. 
Measurement tools can also be categorised according to the methods and re-
sources needed to perform the measurement. In this article we have categorised 
measurement tools into:
1) laboratory tests – e.g. cycle ergometry (9) 
2) semi-laboratory tests – e.g. the 6-minute walking distance test (10)
3) field tests – e.g. the accelerometer (11), and
4) patient-reported outcomes – e.g. the MRC dyspnea scale (12) and the St 
George’s Respiratory Questionnaire (SGRQ) (13).
Putting measurement tools into a framework based on the construct they meas-
ure and the resources needed should help clinicians make better choices regard-
ing the tools they use in routine practice. However, since the number of tools 
used to measure functional status for patients with COPD is large, and each tool 
has its own measurement properties, we conducted a literature search to com-
pare the various tools available. This review summarises and rates the tools in a 
framework – based on the construct they measure and the resources needed – to 
create an overview of functional status measurements in primary care clinical 
practice.
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Figure 1. Theoretical framework of functional status constructs by Leidy et al.6 Re-
printed with permission from N.Leidy; Functional status and the forward progress of merry-




We searched PubMed using the following keywords: ‘functional status’ or ‘physi-
cal capacity’ or ‘functional capacity’ and ‘COPD’. The timeframe for the literature 
search was the last 15 years, i.e. from 1st January 1995 to 1st July 2010. Studies 
published in languages other than English were excluded. No attempt to assess 
the quality of the studies was made as this was beyond the scope of this article. 
The resulting titles, abstracts and texts were screened by three authors (JWHK, 
GMA, TvdM) for tools that were used in patients with COPD to assess exercise 
capacity, functional status or functional capacity. This resulted in the identifica-
tion of a set of relevant tools. Following the identification of these tools, the 
article describing the development or implementation of the corresponding tool 
was reviewed for further information. To complete the PubMed search, articles 
that referenced the development article were searched using the “citing articles” 
function on ISI web of science.
Data collection and scoring of tool properties
For all tools, information was obtained about the time to complete, time for the 
patient to recover after performing the test, the test properties (reproducibility, 
reliability, validity, and responsiveness), the existence of the minimal clinically 
important difference (MCID), and about data in different COPD severity groups. 
Based on this information, scoring of the tools was done according to the previ-
ously-used International Primary Care Respiratory Group (IPCRG) rating system 
(14). This system was developed to compare quickly the usefulness for clinical 
practice of ‘COPD wellness tools’. Tools were attributed the following scores: 
 = very poor/unknown;   = Not good enough, if this criterion is important; 
 = Good enough;   =Recommended;   =Highly recommended. 
For all tools, scores were given in the following categories:
Validity/reliability: articles reporting the development of the tool and further 
validation of instruments were used to rate the validity and the reliability. For 
questionnaires, a high Crohnbach’s alpha is suggested (> 0.9) for use in individ-
ual patient care (15). If a tool scored highly on these items, preferably in several 
papers, the rating was “highly recommended”.
Responsiveness: if a tool had been shown to be able to measure changes in 
the patient’s situation – for example, during exacerbations or upon efficacious 
treatment – the tool was rated “recommended”. If a tool appeared to be very 
responsive in multiple events (e.g. exacerbations, smoking cessation, pulmonary 
rehabilitation), the rating was “highly recommended”.
Primary care population: if a tool was developed in patients with mild to mod-
erate COPD, or the tool had successfully been used in this population, the tool 
was rated “recommended” or “highly recommended” based on the number and 
size of the studies.
Practical/Easy to administer: a tool was rated “highly recommended” when the 
application of the tool results in completion within 5 minutes, the scores/val-
ues are easy to calculate and interpret, no or very little additional resources are 
needed (e.g. additional rooms or (electronic) devices), and the patient recovery 
time is limited.
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Tested in practice (COPD): if according to published articles tools are used in 
clinical practice or if guidelines recommend their use, these tools received “rec-
ommended” or “highly recommended” ratings.
MCID known: if the minimal clinically important difference is published, the rat-
ing was “highly recommended”. If the tool is part of a larger questionnaire, and 
the total questionnaire’s MCID is known, but not the part/domain’s MCID, the 
tool was rated “recommended”.
Results
The PubMed search resulted in 364 articles. Thirty-two tools were identified. 
The tools were divided into four categories:
1. laboratory tests
2. semi-laboratory tests
3. field tests, and
4. patient-reported outcomes.
The tools and ratings are presented in Table 1. References mentioned in the table 
are development articles, further validation articles, manuals or reviews describ-
ing the properties of the tools.
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Legend: Description of label:   =very poor/unknown;  =Not good enough, if this crite-
rion is important;   =Good enough;   =Recommended;   =Highly recommended. 
Lab=laboratory tests; semi= semi laboratory tests; field= field tests; and PRO= patient re-
ported outcomes; cap=functional capacity, per= functional performance.
References refer to manuals, development- or validation studies.
Discussion
This review is the first that has systematically organised tools measuring func-
tional status in COPD within a framework by assessing the exact construct that 
they measure as well as the resources needed for their use. The measurement 
properties of each tool were graded based on the existing literature, and feasibil-
ity was graded on predefined criteria.
To assess functional status in COPD patients, this study revealed that although 
there is a variety of tools to assess functional status in COPD no one tool meets 
all the criteria for it to be highly recommended for primary care use. The 6-
minute walking distance test is the most reliable, but not a very practical semi-
laboratory functional capacity test. The pedometer is the best functional per-
formance field test, and the MRC and the CCQ functional status domain are the 
best patient-reported outcome tools. 
The number of published studies measuring functional status in COPD patients 
has increased rapidly in the past years. In 2000, 18 articles were found using 
our search strategy, whereas in 2009 there were 40. This increase in publica-
tions reflects the increasing awareness that something more than lung function 
is impaired in COPD patients, and that functional status is one of those impaired 
dimensions. There are only two conceptual frameworks currently available in 
which functional status is described – Leidy’s model (6), and a model described 
by Larson (45). Given the increased attention on functional status, it is likely 
that more conceptual frameworks will be developed. An example is the new con-
ceptual framework being developed as part of the PROactive program (personal 
communication M. Puhan, www.proactivecopd.com).
The framework we created is based on an existing framework developed by 
Leidy (6), and we extended this by adding aspects on the resources needed to 
perform the test. Leidy et al. divided functional status into functional capac-
ity, functional performance, functional reserve and capacity utilisation. Since 
functional reserve is the difference between capacity and performance, no spe-
cific tests have been developed to measure this theoretical construct. Capac-
ity utilisation – which represents the effort that the patient needs to reach the 
functional performance – might be one of the most important constructs but 
it is not represented as a separate tool in the literature. We therefore ended 
up dividing the measurement tools into “functional capacity” and “functional 
performance” tools. However, two tools – the Glittre ADL(19) and the Energy 
Expenditure (20) – were categorised as being both capacity and performance 
tests. The 6-minute walking distance test (6MWD) shows characteristics of both 
functional capacity and functional performance, although it is considered a test 
for functional capacity (10). The 6MWD has shown good correlation with func-
tional performance measures such as motion sensors (46,47) and is indeed more 
related to functional performance – measured with patient reported outcomes 
– than exercise capacity, as measured by cycle ergometry in patients with severe 
emphysema (48). 
In addition to the categorisation into constructs, we divided the tools into meth-
ods according to the resources needed i.e. laboratory tests, semi-laboratory tests, 
field tests, and patient-reported outcome tests. Using this framework we rated 
the most important measurement features which include validity and reliability, 
responsiveness, the validation in primary care COPD patients, the feasibility, the 
usage in primary care, and the availability of the MCID. 
Despite the difficulty in categorising certain tests, the combination of Leidy’s 
framework (6) and our resources framework gives a good overview of avail-
able current functional status measurement tools and a guide for choosing tools 
which are feasible for use in primary care. 
This study focussed on tools for patients with mild to moderate COPD, and in 
Table 1 the rating for this patient group is shown. Internationally, there is con-
siderable variation between countries in terms of where patients are treated – ei-
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ther in primary or in secondary care.  In some countries, all stages of COPD are 
treated mainly in primary care, whereas in others – such as in The Netherlands 
– most patients with severe COPD are managed in secondary care. Most tools 
have been developed in more severe COPD patients, and therefore we explic-
itly focused in our rating system on mild to moderate COPD; in milder patients 
the measurement properties are more difficult to obtain from the literature. 
Nevertheless, within the group of mild patients (as defined by lung function), 
patients with more impaired functional status may benefit most from interven-
tions (49). 
Categorisation can help to select the most appropriate measurement in specific 
situations. In clinical settings, it is important that physicians realise what they 
measure in a patient, why they measure it, and how valid this measurement is. 
For example, a capacity test like cycle ergometry is very valid and can reveal 
true (limitations in) maximum capacity. In COPD, the limitation of capacity can 
be linked to the loss of pulmonary function. When the capacity limitation cannot 
be explained by pulmonary function loss, this might be a reason to re-examine 
the patient for co-morbidities. Although laboratory capacity tests might be very 
useful in hospital-based clinical settings, for primary care the field tests and 
patient-reported outcomes (PROs) are more feasible. However, field tests and 
PROs always test performance and not capacity. Clinical conclusions drawn from 
these tests might therefore differ from conclusions based on (laboratory-based) 
capacity tests. An additional complication of functional status PROs is that al-
though categorised as performance tests, most PROs measure patient-perceived 
performance limitations and/or symptom burden during performance. Correla-
tions between motion sensors measuring actual performance and functional sta-
tus PROs are therefore moderate (11). Only the SQUASH measures the amount 
of physical activity; the MRADLQ measures whether or not activities are per-
formed (with or without help). But both show poor measurement properties. 
Not all tests are standardised, making it difficult to compare them between set-
tings and between studies. For example, the stair climbing test was performed 
in a hospital setting with 16 flights of stairs and was stopped after exhaustion 
or chest pain and conducted at the patient’s own pace (18) or at maximal speed 
(50) or after 35 seconds counting the maximum number of stairs (51). Although 
the test is cheap (and if you have stairs in your practice, can easily be per-
formed), it lacks standardisation. However, for individual follow-up of patients 
in the same setting it might be useful.
Standardised health status questionnaires with a separate functional status do-
main were included in this review (SGRQ, CRQ, CCQ). These domains are often 
separately described in studies. However, it is not advisable to create a “new” 
questionnaire that only uses the separate domain, because that creates new tests 
and alters the validity (52). The advantage of a domain within a health status 
scale is that with one tool, different aspects of the health impairment caused by 
the disease are measured.
Like many medical tests, functional status examination tests can be used to sup-
port the diagnostic trajectory but can also be used for monitoring purposes only. 
In clinical practice, capacity tests like cycle ergometry are often used as a diag-
nostic tool (9), whereas PROs are suggested as evaluation tools. Since patient-
reported outcomes are “precision instruments” (52), and instruments are being 
developed (26,53) and validated (54) for use in daily clinical practice, these 
instruments are more often used for evaluation purposes. Although information 
gleaned from questionnaires is often more comprehensive and more reliable 
than from oral history-taking, the benefits in terms of clinical practice have yet 
to be established.
A limitation of this study is that the grading of the tools was done based on the 
literature review by JWHK and GMA. Although we had pre-defined criteria to 
rate the measurements, it was difficult on several occasions to rate according 
to the 5 “smilie” grades. For example, when a measurement was used in a large 
study population which included a low number of GOLD I and II patients, we 
discussed between the authors if “primary care population” should be rated as 
“good enough”, or “recommended”. This resulted in a less objective rating (for 
example, “MCID known”), but the agreement between the authors improved 
the validity in scoring. Where JWHK and GMA disagreed on the scoring, TvdM 
reviewed the literature as well and discrepancies were discussed. The ratings on 
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“Practical/ Easy to Administer” and “Tested in Practice (COPD)” are based on 
the literature and not on real life experience. Our method was different from 
that used in an overview of COPD wellness tools for the IPCRG where research-
ers and clinicians were asked to rate the several COPD wellness tools. The latter 
method might have resulted in different scoring because of unpublished experi-
ences.
In addition, we limited our search to PubMed, which will have resulted in most, 
but not all available articles (55). We have used our search to identify tools, not 
to review individual studies. Nevertheless, we are confident that important tools 
that are used in scientific work were included in this review. 
In conclusion, for primary care, the 6-minute walking distance test is the most 
reliable, but not very practical, semilaboratory functional capacity test. The ped-
ometer is the best functional performance field test. And the MRC and the CCQ 
functional status domain are the best patient-reported outcome tools to measure 
functional performance in primary care. 
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Introduction
As well as being a lung disease, chronic obstructive pulmonary disease (COPD) 
is an illness with complications that are experienced in different ways by pa-
tients. There are over 80 tools that have been developed to measure different 
aspects of COPD. This users’ guide reviews nine of the more than 42 tools that 
measure the illness or wellness experience of the patient with COPD. It includes 
tools that measure health status or quality of life as well as tools that measure 
COPD features such as dyspnea and breathing problems.
It has been produced by the International Primary Care respiratory Group (IPCRG) 
as a practical guide for healthcare professionals working in their everyday clini-
cal practice rather than for academic research use. Another guide which is cur-
rently in preparation contains the tools for assessing the disease severity and the 
third guide in the series will contain tools that measure associated features such 
as depression in COPD.
In the “Wellness in COPD” tool table/grid, there are nine tools named on the left 
that we, as international primary care clinicians, judged likely to be most useful 
in routine management of our patients with COPD. Each of the vertical columns 
refers to a desirable criterion for choosing a wellness tool for use in primary 
care. How each tool performs for that criterion is shown by the “smiley face” in 
that square. (The key for the faces is given above the grid.)
These criteria are:
1. Validity/Reliability: Does this tool have face and content validity – has it 
been shown to actually measure what it is designed to measure? Is it sufficiently 
reliable?
2. Responsive: Is it adequately responsive to changes in the patient’s condition 
– does it indicate deterioration when the patient’s condition deteriorates clini-
cally?
3. Primary Care Population: Is it applicable to a primary care population that 
includes people with the full range of mild to very severe COPD?
4. Practical/Easy to Administer: Is it practical for daily clinical assessment? 
International Primary Care Respiratory Group Users’ Guide to COPD ‘’Wellness’’ Tools 
Does it have scores that are easy to use for reassessment in follow-up? Is it easy 
to use by interview or telephone? Can it be self-completed in the waiting room, 
by post or e-mail? Is it sufficiently economical of time to be used in daily prac-
tice?
5. Tested in Practice: Have the IPCRG authors of this review used the tools in 
their practice – what was their experience? Is it applicable in daily primary care 
clinical practice? Is it easy to complete within a routine primary care consulta-
tion?
6. Other languages: Has it been translated and validated in other languages? Is 
it easy for busy clinicians to find those translations in websites?
Time to complete the tools was considered extremely important, and has been 
taken into consideration and incorporated in criterion four.
Which tool to select?
Depending on which criterion is most important for your particular need at the 
time of choosing, the guide will assist your choice. We did not weight these 
criteria but you could do that. You are advised to read the notes at the bottom 
of the table 1 before choosing your tool. With this guide our intention is to 
give suggestions but not recommendations on tools.  The purpose is to offer the 
reader our analysis of what could be considered by a practising clinician, and of 
how the tools perform against a set of criteria.
In the notes on each of the tools provided on Table 2, there is information on 
where to obtain the tools and conditions for using them.
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Legend for Table 1. All of the tools reported above need no training or equipment to com-
plete. Some questionnaires require you to request permission before you use them, and some 
may be subject to charges. Unless specified, please contact the authors if you wish to use any 
of these tools in your routine practice or for research. AQ20=Airways Questionnaire, BPQ-
S=Breathing Problems Questionnaire – Short, CARS=COPD Activity Rating Scale, CAT=COPD 
Assessment Test, CCQ=Clinical COPD Questionnaire, CRQ=Chronic Respiratory Disease 
Questionnaire, MRC-D=Medical Research Council, Dyspnea, RIQ-MON10=10 Item Respira-
tory Illness Questionnaire – Monitoring, SGRQ=St. George Respiratory Questionnaire. 




Correlates well with SGRQ and has only 20 items (yes/no). Short and easy to 
complete in 2 minutes. Useful in a clinical setting. Self-administered. Responds to 
changes, less discriminating in mild COPD. 
Spanish and Japanese versions available. High score indicating poor QOL.
Where you can get this tool: Professor Paul Jones, Professor of Respiratory 
Medicine, Head of Division of Clinical Sciences,St. George’s University of London. 
Email: pjones@sgul.ac.uk 
See also: Yvonne Forde, Academic Secretary, Cardiac and Vascular Sciences, St. 
George’s University of London. Email: yforde@sgul.ac.uk
Cost/Conditions of use: Permission must be obtained from the authors. For more 






Short form of the BPQ. Not COPD specific. Self-administered, used in mild to mod-
erate COPD. The BPQ-S is more discriminating for COPD than the longer form.
Where you can get this tool:
M.E. Hyland at: mhyland@plymouth.ac.uk. For a direct link to the questionnaire 
visit:http://www.psy.plymouth.ac.uk/research/mhyland/ or
http://www.psy.plymouth.ac.uk/research/mhyland/bpq.pdf




Measures life-related activities in COPD. Validity and reliability tested but discrim-
inating power not tested. 4 factors (self-care, domestic activities, outdoor activities 
and social interaction) with 12 items. Easy three-point scale. Limited literature/
studies available. Higher scores indicate less impairment.
Where you can get this tool:
Michiko Morimoto, Faculty of Health Science, Okayama University Medical 
School, 5-2-1 Sikata-cho Okayama-shi, Okayama 700-8558, JAPAN. 
Email: mmichiko@md.okayama-u.ac.jp
Cost/Conditions of use:
Permission must be obtained from the authors.





Short, simple questionnaire for monitoring long-term follow-up of COPD. Aimed at 
primary care practice. Validated in 3 international studies. 8 items, six-point scale, 
responds to exacerbations. Self-administered. Covers a wide range of symptoms. 
Not been widely used yet as only published in 2009. Available in many transla-
tions, although not all validated. Total score can be calculated on the website. 
Higher scores represent worse health.
Where you can get this tool: http://www.catestonline.org/
Cost/Conditions of use:
Free for use by professionals and patients in daily clinical practice. It requires 
permission if organisations wish to use it for academic or commercial use or other 
professional reasons.





Well validated and reliable. Responds to stopping smoking and detects mild from 
moderate and severe states. Measures functional and mental capacities as well as 
symptoms. Specific to COPD, as it measures COPD-related health status. Self-ad-
ministered in daily practice. 10 items on previous week’s symptoms are easy to 
apply. Also available in a 24h version. Practical and widely used. More than 53 
translations: not all are validated. Higher scores represent worse health.
Where you can get this tool:
www.ccq.nl
Cost/Conditions of use:
The use of the questionnaire in daily clinical practice is free of charge. Copyright: 
not to be altered, sold, translated, and used in international research without the 






Well validated and reliable in testing. Responds to changes over time and long-term 
use as well as changes in condition after Emergency Department treatment of ex-
acerbations. 20 items, 4 domains: Dyspnoea, fatigue, emotional function, mastery. 
Has been used by interviewer, telephone or selfadministered.
Many translations. Higher scores indicate better health-related quality of life.
Where you can get this tool:
Contact for all matters relating to the CRQ is Mr Sunita Asrani: 
Email: asranis@mcmaster.ca
Cost/Conditions of use:
Permission must be obtained from the authors.







Widely used to assess how symptom (dyspnoea) limits activities of daily living. 
Well validated. Five simple items but ONLY measures dyspnoea, not other out-
comes. Portuguese version validated in Brazil.
Where you can get this tool:
For online access, visit:
http://www.nice.org.uk/usingguidance/commissioningguides/pulmonaryrehabili-
tationserviceforpatientswithcopd/mrc_dyspnoea_scale.jsp
Since this is a long link, you may need to re-type it to ensure the link is not broken.








A reduced tool from the 55 item QoL RIQ tool. Well-validated against SF-36 and 
MRC scales. Sensitive to change in stable and improving mild to moderate patients. 
2 factors (physical + emotional complaints and physical + social limitations) five 
items each. Not COPD specific.
Tested in primary care.
Where you can get this tool:
J.E. Jacobs. Radboud University Medical Centre, 114 IQ healthcare, PO Box 9101, 
6500 HB Nijmegen, The Netherlands. Email: j.jacobs@iq.umcn.nl






The most widely used quality-of-life instrument in the literature especially the 
“symptoms” domain that can be used alone. Compares to the AQ20 and CRQ. A 
gold standard but long, not simple enough for daily use. It takes 8-10 minutes to be 
completed. Scores are calculated for three domains: symptoms, activity and impact 
(psychosocial), and also for total score.
Telephone or self-administered. Sensitive to changes in the patient’s condition. 
Many translations. Not COPD specific. Scores range from 0 to 100, with higher 
scores indicating poor health.
Where you can get this tool (and the spreadsheet needed to calculate the 
score):
Professor Paul Jones, Professor of Respiratory Medicine, Division of Physiologi-
cal Medicine, St. George’s Hospital Medical School, London SW17 0RE, United 
Kingdom
Email: pjones@sghms.ac.uk
See also: Yvonne Forde, Academic Secretary, Cardiac and Vascular Sciences, 
St. George’s University of London. Email: yforde@sgul.ac.uk
For direct access, visit: http://www.healthstatus.sgul.ac.uk
Cost/Conditions of use:
No cost for use. Copyrighted, permission required.
For more information, see American Thoracic Society at:
http://qol.thoracic.org/sections/instruments/pt/pages/george.html
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Chapter 5 - Part II
Assessment of COPD wellness tools for use in primary 




Chronic obstructive pulmonary disease (COPD) is considered a complex disease 
and global problem that is predicted to be the third most common cause of death 
by 2030. While managing this chronic condition, primary health care praction-
ers are faced with the ongoing challenge of achieving a good quality of life and 
overall “wellness” for those affected. As such, a practical tool for monitoring 
quality of life in a clinical setting is required. However, due to the wide variety 
of general and disease-specific tools from which to choose, primary healthcare 
practitioners are given minimal guidance as to which tool may be most appro-
priate. To address these challenges, the International Primary Care Respiratory 
Group (IPCRG) proposed the creation of a user’s guide for primary healthcare 
practitioners to assess “wellness” in COPD patients in an everyday clinical set-
ting. This short report outlines the process by which the IPCRG Users’ Guide to 
COPD “Wellness” Tools was developed. It also describes why this guide has the po-
tential to be of great value in guiding primary healthcare practitioners improve 
patient wellness.
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Introduction
Chronic obstructive pulmonary disease (COPD) is considered a complex disease 
that, according to the World Health Organisation, is one of the most prevalent 
diseases worldwide and is predicted to be the third most common cause of death 
by 2030 (1). As with other chronic diseases, one of the main goals in managing 
COPD is achieving a good quality of life and overall “wellness” for those affected 
(2). In achieving and maintaining “wellness”, primary healthcare practitioners 
are faced with the challenge of choosing from appropriate tools that easily and 
effectively assess the severity of the disease, as well as measure its effect on 
improving the patient’s overall quality of life (3,4). However, primary health-
care practitioners must choose from a wide variety of the available general and 
disease-specific tools, while receiving minimal guidance as to which tool may 
be most appropriate (3). To address these challenges, the International Primary 
Care Respiratory Group (IPCRG) recently proposed the creation of a user’s guide 
for primary healthcare practitioners to assess “wellness” in COPD patients in an 
everyday clinical setting. The IPCRG has a special focus on research, manage-
ment and education in respiratory diseases in primary care. At the request of the 
Research Subcommittee of the IPCRG, the Family Physicians Airways group of 
Canada (FPAGC), an IPCRG member organization, accepted the task on IPCRG’s 
behalf. This short report outlines the development process of the IPCRG Users’ 
Guide to COPD “Wellness” Tools and describes why this guide has the potential to 
be of great value in guiding primary health care practitioners to improve patient 
wellness.
To date, COPD has mainly been monitored by lung function parameters that only 
weakly reflect patient wellness (5,6). To address this concern, there have been 
several recent reviews of tools used to evaluate the wellness of COPD patients 
(3,7-11). However, the tools evaluated address specific aspects of the condition, 
such as breathlessness in advanced cases of respiratory diseases, or the setting of 
treatment centres (10,11). Furthermore, some tools are broader than others in 
the aspects they address, which may complicate the decision-making process for 
primary health care practitioners when selecting appropriate tools (7). 
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In 2005, Fitzpatrick and colleagues performed a systematic review of health-re-
lated measures for a number of common chronic diseases, including COPD (3). 
They divided relevant health outcome tools into two groups: [1] generic (ap-
plicable to several diseases or populations) and [2] disease-specific (measuring 
health in only one condition), such as for COPD. For the purpose of our project, 
focus was on disease-specific tools, since they “may have greater clinical ap-
peal due to their specificity of content, and associated increased responsiveness 
to specific changes in condition” (3). Fitzpatrick and his colleagues identified 
key criteria for assessing the quality of tools and selecting appropriate outcome 
measures, which included: validity, reliability, responsiveness, precision, ac-
ceptability and feasibility. Using the available evidence, they provided useful 
guidance to primary healthcare practitioners to inform them of the range of 
tools available, relative to their setting (3). We built on and refined Fitzpatrick’s 
criteria to create a customized guide for the selection of the best disease-specific 
assessment tool for managing wellness in COPD in a primary care setting.
Methods
To get a sense of the number, type and quality of tools currently available in-
ternationally to primary healthcare practitioners managing patients with COPD, 
a comprehensive, systematic search was performed. Our search reviewed the 
English language literature published up to 2010.  
Searches were conducted in the following databases: MEDLINE, EMBASE, 
PubMed, PsycINFO, CINAHL, Health and Psychosocial Instruments, The Med-
ical Algorithms Project, The Cochrane Library, Science Direct, and ProQuest 
Dissertations and Theses. This list includes databases not searched in previous 
reviews (3). The search of these databases combined both controlled vocabulary 
and keyword terms (when appropriate) relating to the following core concepts: 
[1] chronic obstructive pulmonary disease, [2] measurement instruments (eg, 
questionnaires, evaluations, assessments, tests, measurements, health status in-
dicators, and severity of illness indices), and [3] wellness (eg, quality of life). 
Additional articles, subsequently identified from references cited in the included 
articles, were also included. Furthermore, a Google search helped identify ad-
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ditional resources as well as relevant grey literature. In this case, no date or lan-
guage restrictions were applied. Articles published prior to 1995, animal stud-
ies, as well as studies published in languages other than English were removed.
The results from each database were imported into a RefWorks database, (Re-
fworks-Cos Bethesda, USA), where duplicate articles were removed. (Further 
information on the detailed search strategies employed and results can be ob-
tained from the corresponding author).  The summary of results is presented in 
Table 1. 
Table 1: Summary of results.
Database Initial Results Final Resultsa
MEDLINE 1 1657 -
MEDLINE 2 (refined search) 385 377
EMBASE 1 46 -





The Medical Algorithms Project 165 165
The Cochrane Library 74 74
Science Direct 328 317
ProQuest Dissertations & Theses 80 80
Total  3554 1825
Legend: aWith duplicates and non-English articles removed. CINAHL: Cumulative Index to 
Nursing and Allied Health Literature, HaPI: Health and Psychosocial Instruments. 
A form of “rapid appraisal” was performed by two independent researchers, 
whereby the titles and abstracts of the selected articles were scanned and re-
viewed for relevance, and a list of tools that combined or discussed aspects of 
“COPD” and “wellness” was identified. In addition, the quality of the articles 
was assessed, with those that failed to meet a predetermined set of inclusion 
criteria culled from the database. Articles that [1] were peer-reviewed, [2] pro-
vided empirical evidence of measurement properties, and [3] were relevant to a 
primary care setting were included. Editorials/Commentaries and articles lack-
ing authority and/or currency were excluded.  
A logic chart was constructed to pool selected tools according to their purpose 
and approach. Overall, 1825 articles relating to 84 COPD-specific tools were 
identified. Of those 84 tools, 42 were associated with patient related health 
outcomes or “wellness”. 
Due to the wide range of articles employing a variety of quantitative and quali-
tative methods, the members of the IPCRG Research Subcommittee were invited 
to comment on the evaluation criteria and rank their preferred tools from the 
health outcomes/wellness group. When evaluating and ranking the tools, they 
were asked to consider supporting evidence from the research literature, as well 
as their own clinical and research experience. Seven of the twelve subcommittee 
members provided feedback, with one declaring a conflict of interest.  
Results
Tools that received three or more votes from the participating IPCRG Research 
Subcommittee members were selected for further assessment. This resulted in 
the identification of nine disease-specific tools that assess various aspects of 
“wellness”: [1] Airways Questionnaire (AQ-20), [2] Breathing Problems Ques-
tionnaire – Short (BPQ-S), [3] COPD Activity Rating Scale (CARS), [4] COPD 
Assessment Test (CAT), [5] Clinical COPD Questionnaire (CCQ), [6] Chronic 
Respiratory Disease Questionnaire (CRQ), [7] Medical Research Council, Dysp-
noea (MRC-D), [8] 10 Item Respiratory Illness Questionnaire - Monitoring (RIQ-
MON10), and [9] St. George’s Respiratory Disease Questionnaire (SGRQ) (12-
23).  Figure 1 illustrates the tool selection process.
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Figure 1. Summary of Tool Selection Process.
         
   
 
 
Given the feedback provided by the IPCRG Research Subcommittee, changes 
were made to the original evaluation criteria derived from Fitzpatrick and col-
leagues (3). They were expanded to include the following six categories: [1] 
validity/reliability, [2] responsiveness, [3] applicability to a primary care popu-
lation, (4) practicality/ease of administration, [5] testing in practice, and [6] 
other language versions.
The comments and rankings from the IPCRG Research Subcommittee, and the 
supporting evidence from the identified literature relating to each of the nine 
tools were used to evaluate each tool, using the six newly established and re-
fined evaluation criteria. Once all the supporting evidence had been evaluated, 
it was transferred into a spreadsheet and distributed to the IPCRG Research Sub-
committee for a second round of comments and feedback. Once reviewed and 
validated by the subcommittee, the supporting evidence spreadsheet was trans-
lated into an assessment grid, using a simple and effective visual ranking scale 
(Table 2). This visual ranking scale uses a display of five different color–coded 
smiling/sad faces used to rank each of the nine tools, according to the six crite-
ria. The five ranking possibilities include: [1] very poor, [2] not good enough (if 
this criterion is important), [3] good enough, [4] recommended, and [5] highly 
recommend. This visual ranking scale was patterned after a previously used 
system that successfully provided resources for asthma control tools (24). Full 
details for each tool, including tool description and limitations, as well as direc-
tions on where to find each tool and obtain user permission are available in the 
IPCRG Users’ Guide to COPD “Wellness” Tools (Appendix)(25).
Table 2. Visual ranking scale.
Very poor
Not good 









The variety of COPD measurement tools identified in the literature suggests that 
there are important differences between the tools, with no one tool meeting all 
requirements (6,10,11). This is largely due to each tool’s inherent design and 
purpose. We assessed each tool from the vantage point of patient wellness dur-
ing clinical care in a primary care setting. We were also mindful of the need for 
“appropriateness”, [see Fitzpatrick et al (3)], whereby the tool is acceptable to 
healthcare practitioners and patients (3). 
Therefore, for a tool to rank high on our visual ranking scale, it had to be dis-
ease-specific and it needed to provide satisfactory evidence relating to its psy-
chometric qualities (criteria 1 and 2). It also had to have a proven record of suc-
cessful use, if not in primary care, then at least in ambulatory care in a clinical 








20 Disease Severity 
Measures
22 “Other” Tools
Final 9 COPD Wellness Tools 
for Users’ Guide
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interpret, as well as inexpensive (criteria 4). While our search was conducted 
for English-language articles, the international members of the IPCRG Research 
Subcommittee noted the availability of tools described in other languages as 
well (criteria 6).
Of the top nine tools discussed in the Users’ Guide, the Clinical COPD Question-
naire (CCQ) scored well on all criteria for suitability for use in primary care 
(17,18). Its main benefits are that it is easy to use and it can be completed in 
approximately 2 minutes by the patient. The CCQ is available in more than 53 
languages (an ongoing process) and it addresses common outcomes, such as 
mental status. The COPD Assessment Test (CAT), also scored well, even though 
it was introduced relatively recently in 2009 (15,16). The CAT is a simple and 
straightforward questionnaire that addresses a range of issues related to COPD 
to assist primary healthcare practitioners in assessing patient overall wellbeing 
and quality of life. Although we lack sufficient data to assess CAT`s responsive-
ness over time, its main benefits are that it has been specifically designed for use 
in the primary care clinical setting, is not time consuming and is already avail-
able in many languages. Ongoing testing may show that it is among the most 
appropriate.
Two of the oldest and most widely-used tools, the Chronic Respiratory Ques-
tionnaire (CRQ) and the St. George’s Respiratory Disease Questionnaire (SGRQ), 
have been extensively used, resulting in some familiarity, especially in the clini-
cal trial setting (19,20,23). Despite their longevity and being ranked highly in 
the assessment grid, both have limitations: the CRQ has limited availability in 
languages other than English and the SGRQ is long and difficult to administer in 
primary care populations. 
Very few articles addressed the issue of the “ceiling” or “basement” limits of the 
tools. These terms refer to the ability of the tool to continue to measure changes 
in health status at the extremes of health. For example, if a patient scores a zero 
for health status on a tool (the basement score for that tool) but then clinically 
deteriorates, the tool cannot capture that deterioration. That tool therefore has 
a basement limitation. It may still be very useful in mild or moderately severe 
COPD patients, but not in the severe or very severe patient. Further, the con-
struction of most tools did not account for responsiveness to changes over time. 
Although we did not include it in the ranking criteria, some of the tools are not 
tested for use following an exacerbation and this may be important sometimes. 
A weakness of our approach may be the omission, albeit by design, of generic 
health outcome tools, such as the Short-Form Health Survey questionnaire or 
the Sickness Impact Profile scale. These tools could add value as they allow com-
parison with other conditions outside COPD (26,27). If healthcare practitioners 
are planning to compare wellness across a series of diseases, they might use 
these tools preferentially, but the scoring system makes comparisons difficult. 
Conversely, because these tools are general health status and quality of life in-
struments, their use may be of limited value for COPD, since they do not provide 
disease-specific information.
As stated by Fitzpatrick and colleagues, “although there are relatively clear cut 
and widely agreed criteria to assess measurement properties of instruments, 
there are no clear-cut explicit criteria for how to weigh the balance of evidence 
for instruments comparatively” (3). In our case, each tool was considered in 
detail by the IPCRG Research Subcommittee using their practitioner/practical 
judgement and experience as practicing clinicians and researchers. Therefore, 
we believe the “consensus” approach employed by the IPCRG Research Subcom-
mittee was a realistic alternative to formal evaluation by template. 
We had a moderate response from the collaborators. One of the collaborators 
declared a potential conflict of interest and did not provide scores, although that 
individual did comment on the findings and the analysis. Others were also in-
volved in the development of some of the highly ranked tools. Some of the arti-
cles suggest multiple variations of a tool, thus it was difficult in some articles to 
determine which version was being tested (eg, the Breathing Problem Question-
naire (BPQ) and its short form) (13). Furthermore, the identification of tools 
published in languages other than English was limited due to the margins of our 
initial search strategy. However, the IPCRG Research Subcommittee participants 
did consider that many of the articles included web-sites that provided support-
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ing information on the availability of articles published in other languages (eg, 
the CCQ and the CAT).
One of the strengths of this review is that we performed an extensive, targeted 
search of more databases and resources than previous investigations with a simi-
lar objective (3). Our search also included tools that were developed after the 
aforementioned studies were published (3).  Furthermore, we did not confine 
ourselves to just one aspect or symptom (eg, dyspnea), as is the case in other 
reviews (10,11). In this study we addressed relevance to clinical primary care 
settings and focused on and refined key criteria identified by Fitzpatrick and 
colleagues as being critical in assessing the quality and appropriateness of these 
tools (3). In addition, we presented each tool in a simple way, to facilitate prac-
titioner choice. Because most COPD cases are managed in primary care facilities, 
such a review of the existing tools was necessary, as was the resulting guide. 
Furthermore, our review of the existing tools may be of great use to those un-
dertaking research in this area.
 To follow up on this study, we propose that future work review tools that assess 
the severity of disease/clinical aspects of COPD in primary care and measure or 
predict associated features, such as depression and other related co-morbidities. 
We recommend that a repeat review be undertaken in 5-8 years, by which time 
some of the more recently introduced instruments (eg, the CAT) will have un-
dergone further evaluation and results will have been formally disseminated.  
Conclusions
We have identified useful, high quality tools relevant to the IPCRG initiative to 
create the IPCRG Users’ Guide to COPD “Wellness” Tools (25). It is our intention to 
provide suggestions, not recommendations, on tools. With this new, customized 
guide, we offer our analysis of what could be considered and how these tools 
perform against a set of refined criteria for use in a primary care setting. We 
have concentrated on “wellness”, placing the patient ahead of the disease, which 
is increasingly becoming a desirable health outcome measure for governments 
and policy makers. Above all, we provide valuable assistance to primary health 
care practitioners in choosing the right tools for use in the management of pa-
tients with COPD.  
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Chapter 6
Assessing health status in COPD 
A head-to-head comparison between the COPD 
assessment Test (CAT) and the Clinical COPD





Introduction: Health status provides valuable information, complementary to 
spirometry and improvement of health status has become an important treat-
ment goal in COPD management. We compared the usefulness and validity of 
the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ), 
two simple questionnaires, in comparison with the St. George Respiratory Ques-
tionnaire (SGRQ).
Methods: We administered the CAT, CCQ and SGRQ in patients with COPD 
stage I-IV during three visits. Spirometry, 6 MWT, MRC scale, BODE index, and 
patients perspectives on questionnaires were recorded in all visits. Standard Er-
ror of Measurement (SEM) was used to calculate the Minimal Clinical Important 
Difference (MCID) of all questionnaires.
Results: We enrolled 90 COPD patients. Cronbach’s alpha for both CAT and 
CCQ was high (0.86 and 0.89, respectively). Patients with severe COPD report-
ed worse health status compared to milder subgroups. CAT and CCQ correlated 
significantly (rho =0.64, p < 0.01) and both with the SGRQ (rho = 0.65; CAT 
and rho = 0.77; CCQ, p < 0.01). Both questionnaires exhibited a weak correla-
tion with lung function (rho = −0.35; CAT and rho = −0.41; CCQ, p < 0.01). Their 
reproducibility was high; CAT: ICC = 0.94 (CI 0.92-0.96), total CCQ ICC = 0.95 
(0.92-0.96) and SGRQ = 0.97 (CI 0.95-0.98). The MCID calculated using the 
SEM method showed results similar to previous studies of 3.76 for the CAT, 
0.41 for the CCQ and 4.84 for SGRQ. Patients suggested both CAT and CCQ as 
easier tools than SGRQ in terms of complexity and time considerations. More 
than half of patients preferred CCQ instead of CAT.
Conclusions: The CAT and CCQ have similar psychometric properties with a 
slight advantage for CCQ based mainly on patients’ preference and are both valid 
and reliable questionnaires to assess health status in COPD patients.
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease in the 
general population and it has been estimated that it will be the fourth leading 
cause of death by the end of 2030 (1). Apart of its high mortality, one main 
concern for physicians is that COPD strongly impairs health status and quality 
of life. Quality of life is an important goal in COPD management that has been 
highlighted as a future research need from the recent International Primary Care 
Respiratory Group (IPCRG) research needs statement (2). 
Patients with COPD often develop symptoms as dyspnea, cough, phlegm, chest 
tightness exercise intolerance, sleep and mental disorders as well as restriction 
of social activities. In every day practice COPD treatment and management guid-
ance is currently largely based on the spirometric assessment. Recently, GOLD 
guidelines proposed health status measurement and number of exacerbations as 
key elements in addition to spirometry in order to manage and treat COPD (3). 
This is mainly based on the fact that spirometry is only weakly associated with 
various health status questionnaires and does not give a real image of the COPD 
patients wellbeing (4). Numerous quality of life and/or health status question-
naire tools have been developed in an attempt to find an easy and reliable tool 
to use in every day clinical practice (5-10). Even though most COPD-specific 
health status questionnaires show similar basic content, there is heterogeneity 
in the amount and quality of the items addressed (11).
The IPCRG has recently published a ‘users guide to COPD wellness tools’ in 
order to provide physicians with the available questionnaires and rank them in 
terms of validity, reliability, responsiveness, usefulness in a primary care popu-
lation, practicality and tested in practice (12). From this wellness guide, both 
CAT and CCQ are the preferred questionnaires compared to the SGRQ that has 
been traditionally used as the gold standard for the assessment of health status 
in COPD. Although SGRQ reflects very well the COPD health status it is rather 
complicated, time consuming and requires complicated spreadsheets to calculate 
the scores (5). On the other hand the CAT and CCQ are practical, easy to use, 
and can be completed in 2 minutes at most. Both have been designed for use in 
primary care population, they are self-completed, available in many translations 
and free of charge either for clinicians or patients (9,10,12). CAT is the newest 
one developed in 2009 (10), while CCQ has been widely used since its develop-
ment in 2003 (9). The ‘IPCRG COPD users guide to wellness tools’ has ranked 
CCQ as best and CAT as second best for use in daily practice (12).
Both CAT and CCQ are considered valid instruments for measuring health status 
in COPD patients, but there has not been a formal study comparing these two 
practical health status questionnaires for use in daily clinical practice. The cur-
rent study aimed to make a head-to-head comparison between the two question-
naires (CAT-CCQ) taking SGRQ as the gold standard in order to help physicians 
to choose the tool that meets their needs taking in consideration psychometric 
properties and patient’s preference.
Methods
Subjects
Subjects participating were primary and secondary care patients diagnosed with 
COPD in Crete, Greece. We included patients 45 years of age and older with 
a smoking history of at least 10 years. Exclusion criteria were patients with 
concomitant asthma, unstable cardiovascular disease or any other respiratory 
disease other than COPD. GOLD guidelines were used to classify disease severity 
(3). We approached 101 patients. Eleven patients did not complete the study 
(one died after the 2nd visit, one did not meet the inclusion criteria and 9 pa-
tients were lost to follow-up). 90 patients completed all three visits. The study 
was approved by the local medical ethics committee of the University Hospital 
of Crete, Greece and the patients gave written informed consent. The study took 
place from July 2010 to June 2011.
Data collection
In order to assess the test-retest reliability of the CAT and CCQ questionnaires, 
CAT, CCQ and SGRQ were re-administered during two subsequent visits, at 
baseline and after 2 and 6 weeks from baseline.
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Demographic information and medical history were recorded. Baseline spirom-
etry was performed during each visit using a Microlab 2000 spirometer, Jaeger 
Germany, including post-bronchodilator lung function 20 minutes after inhala-
tion of 400 mcg salbutamol. GOLD criteria for COPD were followed. COPD 
diagnosis was based on chest physician examination including spirometry test 
after bronchodilation with FEV1/FVC ratio lower than 0.70. Pulmonary func-
tion predicted values were obtained from the standardized lung function test-
ing of the European Community for Steel and Coal Luxembourg 1993 (ECSC) 
(13). Body mass index (BMI), the 6-minute walking test (6MWT), the Medical 
Research Council dyspnea scale (MRC) (14) and pulse oxymetry before and after 
the 6MWT were assessed during each visit. Scores on the BODE-index {body 
mass index, airflow limitation (forced expiratory volume in one second), dysp-
nea and 6-min walk distance} were also divided into four quartiles (15). Quar-
tile 1 contains score 0–2, quartile 2 contains score 3–4, quartile 3 contains score 
5–6 and quartile 4 contains score 7–10 (15).
Health status questionnaires 
The St. George Respiratory Questionnaire (SGRQ) (5), the COPD Assessment 
Test (CAT) (10) and the Clinical COPD Questionnaire (CCQ) (9) were adminis-
tered to all subjects during each visit in a different order for each visit in each 
patient. All patients administered the Global Rating of Change scale in visits 2 
and 3 (GRC) (15). 
The SGRQ is a 50-item questionnaire. Three component scores are calculated: 
symptoms, activity, and impacts (on daily life), and a total score (5). The CAT 
has 8 items and raise questions like symptoms, energy, sleep and activity. The 
CCQ contains 10 items, divided into 3 domains (symptoms, functional and men-
tal state). The GRC used was a 7-point Likert scale ranging from much better to 
much worse. 
Patients view on questionnaires
A qualitative approach was used in which patients were asked by simple open-
ended questions to express their opinion on which questionnaire was easier to 
complete in terms of complexity and time needed to fill out, as well as which 
reflected better their personal well-being. 
Statistical analysis
The statistical analysis was performed using SPSS for Windows version 18 (SPSS 
Inc. IL, USA). Data are expressed as median (interquartile range) unless other-
wise stated. We used the Kruskal-Wallis test for normally distributed continu-
ous data, and using the Chi-square test for not normally distributed continuous 
data and categorical data. Normality of the data was evaluated using the Kol-
mogorov-Smirnov and Sapiro-Wilk test. CCQ and CAT internal consistency was 
evaluated by calculating Cronbach’s alpha coefficient.
Discriminant validity of the CAT and CCQ was determined with the non-para-
metric Kruskal-Wallis test in COPD GOLD stages I-IV, we subsequently used 
the Mann–Whitney U test to compare specific groups. Test-retest reliability was 
assessed by calculating the Intra-class Correlation Coefficient (ICC). Convergent 
and divergent validity were examined using Spearman’s rank correlations. Re-
sponsiveness of both the CAT and CCQ was determined using the Wilcoxon U 
test. A value of p < 0.05 was considered as statistically significant. The Minimal 
Clinically Important Difference (MCID) for the CAT and CCQ, the smallest cal-
culated change in score that is perceived as relevant was assessed by using the 
GRC and the Standard Error of Measurement (SEM).
In order to calculate the SEM of the CAT CCQ and SGRQ questionnaires we 
used (17) SEM = σx √1-rxx σx=standard deviation of the questionnaire at base-
line rxx= the reliability/Intraclass Correlation Coefficient (ICC) of the question-
naire.
Bland and Altman graphs were made to assess the agreement between ques-
tionnaires. This technique compares the scores of two measurements across the 
entire scaling range. Because the SGRQ, CAT and CCQ all have different scaling 
ranges, CAT and CCQ scores were transformed to a maximum score of 100 simi-
lar to the SGRQ range. CAT scores were multiplied by 2.5 (100/40) and CCQ 
scores by 16.67 (100/6). The adjusted scores were named adjCAT and adjCCQ.
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A total of 90 patients completed the study. The median age of the patients was 
67 years (58-75 years), 90% were male. 
The characteristics of our study population are displayed in Table 1. We found 
no differences among GOLD severity stages in terms of age, gender, BMI and 
pack-years smoking (Table 1). 











 N 15 42 27 6
Males (%) 86.7 86 96.3 100 0.41
Age (years) 68 (58-74) 67 (62-73) 68 (61-73) 63 (53-75) 0.78
Pack years 60 (42-75) 55 (34-81) 70 (40-92) 68 (50-151) 0.52
BMI (kg/m2) 27 (26-32) 29 (25-34) 26 (24-30) 25 (21-29) 0.12
Current 
smoking (%)
53.3 52.4 51.9 33.3 0.84
FEV1
(% predicted)
83 (81-86) 62 (56-70) 37 (33-44) 22 (20-27) p<0.01
6MWD (m) 450 (360-480) 420 (315-545) 360 (300-420) 375 (255-458) 0.07
MRC 
dyspnea grade
1 (1-2) 1 (1-2) 2 (1-3) 3 (2-4) P<0.01
BODE index 
quartile (n(%))
1 15 (100.0) 40 (95.2) 8  (29.6) 1 (16.7)
2 1 (2.4) 14 (51.9) 1 (16.7)
3 1 (2.4) 4  (14.8) 3 (50.0)
4 1  (3.7) 1 (16.7)
Legend for Table 1. Data represent median (interquartile range). BMI = Body Mass Index. 
Pack years: amount of cigarette packs smoked per day multiplied by the amount of years 
smoked. FEV1 = forced expired volume in one second. 6MWD = 6 Minute Walking Distance. 
BODE: body mass index, airflow limitation (forced expiratory volume in one second), dys-
pnea and 6-min walk distance. GOLD stages: COPD classification by post-bronchodilator 
spirometry according to GOLD guidelines. 
Health status questionnaires / GOLD stage
The CCQ total score and CCQ symptom score were normally distributed. The 
CCQ mental score and CCQ functional score as well as the CAT and SGRQ were 
skewed. Health status by COPD GOLD stage according to CAT, CCQ and SGRQ 
is depicted in figure 1.
Figure 1. COPD Assessment Test (CAT) and Clinical COPD Questionnaire (CCQ) scores 
for GOLD COPD stages.
 
Legend for figure 1. Numbers above lines represent p values. COPD Assessment Test (CAT) 
and Clinical COPD Questionnaire (CCQ) scores for GOLD COPD stages.
Relationship between questionnaires
The Bland and Altman plots reveal a stable relationship between the SGRQ and 
the CAT, with a mean bias of 1.8 CAT units. The relationship between SGRQ 
and CCQ show that the adjusted CCQ scores are lower across the scaling range 
and increasing with increasing health status impairment, with a mean bias of 0.6 
CCQ units. The CAT CCQ plot shows that with decreasing health status, CAT 
scores are higher than CCQ scores (Figure 2).
Figure 3 shows the Bland and Altman plots for the SGRQ domains symptoms, ac-
tivity and impact, compared with the CCQ domains sumptoms, functional status 
and mental status respectively. The CAT does not have domain scores.
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Figure 2. Bland and Altmant plots for SGRQ, CAT, CCQ.
 
Legend for figure 2. SGRQ: St George’s Respiratory Questionnaire, CAT: COPD Assessment 
Test, CCQ: Clinical COPD Questionnaire. CAT scores are multiplied by 2.5(adjCAT), CCQ 
scores by 17.67(adjCCQ). Right Y ax shows the original scale. Orange line is the regression 
line. Dashed lines represent the 95% confidence interval. Straight line represents the bias.




Legend for figure 3. SGRQ: St George’s Respiratory Questionnaire, CCQ: Clinical COPD Ques-
tionnaire. CCQ scores by 17.67(adjCCQ). Right Y ax shows the original CCQ scale.
Orange line is the regression line. Dashed lines represent the 95% confidence interval. 
Straight line represents the bias. 
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Cronbach’s alpha was 0.86 for the CAT score and 0.89 for the CCQ total score. 
Internal consistencies for the symptom, mental state and functional state domain 
of the CCQ were 0.71, 0.71 and 0.90 respectively. 
b) Discriminant validity
We compared health status questionnaires between all COPD GOLD stages, and 
all questionnaires showed significant different scores between GOLD stages (fig-
ure 1). 
Patients with severe COPD (stage III) showed significantly higher CAT and CCQ 
total scores compared to the patients with mild disease (stage I). More details 
are depicted in figure 1. 
c) BODE severity-index
Patients in BODE-quartiles 2 and 3 had worse CAT and CCQ scores than patients 
in the other quartiles, worst health status was reported by patients in BODE-
quartile 3. CAT CCQ and SGRQ scores differed significantly among the BODE-
quartiles (Figure 4). 
Figure 4. Box plot showing the distribution of the CAT, CCQ and SGRQ total scores, 
grouped by BODE-quartiles. 
 
Legend for figure 4. Box plot showing the distribution of the CAT, CCQ and SGRQ total scores, 
grouped by BODE-quartiles. SGRQ = St George’s Respiratory Questionnaire, CAT  =  COPD As-
sessment Test, CCQ  =  Clinical COPD Questionnaire. Horizontal bars represent median. Sta-
tistical significance between all three QoL scales: CCQ (p <  0.0001), CAT (p < 0.001) and 
SGRQ (p  < 0.001).
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Convergent validity
CAT, CCQ and SGRQ were strongly interrelated; correlations are depicted in 
Table 2. Further details are given on MRC and BODE index correlations with the 
questionnaires. 
Divergent validity
Results on questionnaires total scores and domains and their correlation with 
FEV1%pred are depicted in Table 2. 
Table 2. Spearman rank correlations between health status questionnaires (CAT, 











































































































































-0.365** -0.264* -0.255* 0.216**
BODE-
index
0.483** 0.556** 0.433** 0.347** 0.545** 0.609** 0.413** 0.524** 0.577** 0.732** -0.705**
Legend for Table 2. *Correlations are significant at the 0.05 level ** Correlations are signifi-
cant at the 0.01 level. ns =  not significant. Lung function is expressed as FEV1%predicted. 
CAT= COPD assessment Test. CCQ = Clinical COPD Questionnnaire. SGRQ = St. George Respi-
ratory Questionnaire. 6MWT  =  6-minute walking test. MRC =Medical Research Council dys-
pnea scale, BODE = body mass index, airflow limitation (forced expiratory volume in one 
second), dyspnea and 6-min walk distance.
Longitudinal validity 
a) Test-retest reliability
The Intraclass Correlation Coefficient for subsequent measures of all question-
naires were high; for CAT ICC=0.94 (CI 0.92-0.96), for total CCQ ICC=0.95 (CI 
0.92-0.96) and for SGRQ=0.97 (CI 0.95-0.98).
b) Responsiveness
Overall change in scores
The majority of patients in this study had stable disease without exacerbations. 
We were unable to find a change in health status as assessed with the CAT, CCQ 
and SGRQ between the second and third visit in the entire population of COPD 
patients. No changes in items neither in CAT neither in CCQ and SGRQ between 
the 3 visits were recorded (p>0.05). 
Minimal Clinically Important Difference
a) Anchor-based approach/Global rating of change
Since the number of patients reporting a change with the Global rating of change 
scale was low (2 and 7 patients at visit 2 or 3, respectively) it was not appropri-
ate to determine the MCID using this approach.
b) Distribution-based approach-Standard error of measurement
We used 1.96*SEM to calculate the MCID (10), this gives a MCID of 3.76 (SEM: 
1.92) for the CAT, 0.41 (SEM 0.21) for the CCQ and 4.84 for the SGRQ (SEM: 
2.47). 
Patients views on questionnaires (qualitative approach) 
All patients (100%) perceived the CAT and CCQ as more easy tools compared to 
SGRQ in terms of complexity and time to complete. The SGRQ was considered 
rather complicated and time consuming. On the question ‘which tool, CAT or 
CCQ, would you select for assessing your health status?’ 61.1% (55 patients) 
expressed the opinion that the CCQ reflected their status better than CAT as it 
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had more details on breathing problems which was more important for them 
than sleep or energy. Ten patients also expressed their opinion that the CCQ has 
a more easy to understand response option system as compared to the CAT. The 
other patients did not make any comments. 
Discussion 
This study showed that both CAT and CCQ exhibit excellent reliability, good 
discriminate validity and high reproducibility. Both questionnaires can be used 
as easy and reliable tools to assess health status in COPD patients in studies as 
well as in daily clinical practice. Patients however preferred the CCQ since it 
reflected their health status better than the CAT.
The most widely used questionnaire for measuring health status in COPD in a 
research setting is the SGRQ. The main disadvantage for clinical practice is it’s 
extent as it comprises 50 questions and scores can only be calculated using a 
computer-based scoring system. This is in accordance with the patient’s views 
that perceived the SGRQ as rather complicated and time consuming. Daudey 
et al. based on empirical data proposed that SGRQ is not able to provide a de-
tailed measurement of health status giving information mainly only in subjective 
symptoms and impairment (18).
The CAT and CCQ were designed to measure health status in COPD patients in 
clinical practice and are much shorter and easy to understand. Both can be in-
stantly calculated. Indeed patients in our study found that both are pretty easy 
and reflect well their status. The response option of CCQ was more clear for 
patients than the CAT rank system and patients thought that CCQ better reflects 
their health status. An advantage of CCQ is that it has been validated to be used 
in individual patients (19). In the above study patients were asked to fill in the 
CCQ and their results were compared to the opinion of 5 clinicians who had seen 
the transcripts of an in depth interview with the same patients. The CCQ out-
come of patients and clinicians was similar, supporting the individual validity.
The agreement between the questionnaire scores as reflected using Bland and 
Altman plot is high. The CCQ scores are generally lower at the higher end of the 
scales. For the comparison of the questionnaires, the scores had to be adjusted 
to a score of 100. The CCQ scores were multiplied by 16.67 for that purpose. A 
small difference in score magnifies using this calculation method. For the inter-
pretation of the results, calculating the difference to the original scale reveals 
that the differences can hardly be considered clinical relevant. For example, a 
CAT score of 13 (median CAT score in this study) shows a difference in adjCCQ 
of 2.82. This represents a difference in original CCQ score of 0.17 or CAT score 
of 1.13. These findings are in line with previous SGRQ/CATcomparisons (20).
Our study showed that CAT and CCQ are both reliable questionnaires in terms 
of internal consistency for measuring health status in COPD patients. Their high 
Cronbach’s alpha (α= 0.86 for CAT and α =0.89 for CCQ) indicate that there is 
homogeneity among the individual items in the questionnaires.
In terms of discriminant validity both CAT and CCQ showed a tendency to re-
flect the differences in COPD severity. Patients with more severe stages of COPD 
reported worse health status, measured with both CAT and CCQ similarly to oth-
er studies (21, 22). This is true for both severity scales GOLD and BODE used in 
this study. In order to examine if there is a type-1 statistical error, because of the 
small numbers in stages I & IV we compared CAT and CCQ scores in COPD pa-
tients GOLD stage I & II subgroup with those of stages III & IV (data not shown). 
Although the statistical significance difference in these comparisons remains 
larger studies are needed to confirm these observations. Even though FEV1 was 
associated with health status in this study, correlations were only weak to mod-
est. This was expected as the pulmonary function itself measured by FEV1, on 
which the GOLD classification of COPD stage is based, is not a good predictor of 
health status (4). These results are in keeping with findings in previous studies 
(CCQ; rho=-0.49 and rho= -0.57, CAT; rho = -0.23) (9,21,22).
Our study is the first study that assessed the variation of all three questionnaires 
in BODE quartiles. The BODE-index is a grading system developed to predict 
mortality in COPD (15). We found a great variation of health status in each 
BODE-quartile and surprisingly patients in the 3rd BODE-quartile reported worse 
health status as assessed with all questionnaires CAT, CCQ, SGRQ than patients 
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in the 4th quartile. An explanation is that patients might adjust their lifestyle 
when the disease progresses and have therefore fewer activities that provoke 
dyspnea than patients with less severe disease. However other studies with ap-
propriate design could answer this important question.
SGRQ and CCQ total scores showed good correlation (rho = 0.769, Table 2) 
highly indicative of convergent validity. CAT score showed a slightly weaker 
correlation with SGRQ (rho = 0.646). It is lower than this reported in the study 
of Jones et al. (10). The discrepancy of lower correlation between SGRQ and 
CAT presented in our study could be due to different COPD population studied 
in terms of severity, gender and nationality. CCQ total score and CAT score also 
have a strong correlation (rho  = 0.644; p < 0.01) supporting the theory that they 
measure the same construct. However, further studies are needed, including 
different clinical settings, to confirm the exact magnitude of correlation of CAT 
with the older quality of life instruments such as the CCQ and the SGRQ.
CAT is a one-dimensional questionnaire and it is very easy in calculation algo-
rithm. In contrast CCQ has more similarities with SGRQ. As the SGRQ the CCQ 
has a division in domains. In the present study CCQ domains showed a good 
correlation with the respective SGRQ domains. The advantage of domains is 
that individual management plans can not only be specified according to the 
impairment of health status in general but also to the individual domains. A 
patient with for example an impaired mental state might be managed different 
from a patient with an impaired functional status. The validity of the CCQ do-
mains is supported by our results that showed that the functional domain of the 
CCQ correlated significantly with the activity domain of the SGRQ (rho =0.753; 
p< 0.01). The Bland and Altman plot (Figure 3) shows this high correlation, 
while the functional status measured by the CCQ is consistently lower than with 
the SGRQ.
Longitudinal validity
Overall, health status scores in subjects followed for almost 6 weeks revealed no 
changes over time. The CAT and CCQ both showed high test-retest reliability, 
ICC of the CAT was 0.94 and ICC of the CCQ was 0.95 respectively proving that 
they are both stable over time and supporting their validity to be used in individ-
uals. This study reproduced the results of previous studies, where CAT and CCQ 
showed a similar high ICC (0.8; CAT) (10) and (0.91-0.99; CCQ) (9,22,23).
The Minimal Clinically Important Difference of the SGRQ is 4 points (24,25), 
while the MCID for the CAT has not been established officially but was esti-
mated to be around 2 points (26,27). The MCID of the CCQ has previously been 
calculated based on three methods and is 0.4 (28). In our study we were unable 
to use distribution-based methods to determine and compare the MCID of the 
three questionnaires. We compared changes in patient reported outcomes scores 
to measures of variability. The MCID calculated with the SEM of the CCQ and 
SGRQ is somewhat similar to the MCID’s found in previous studies. The estimat-
ed MCID of the CAT, however, was higher 3.76 points. Hence, further studies 
are needed to determine the MCID of this relatively new tool.
Strengths and limitations of the study
This is a real life study, the first that did a head to head comparison of CAT, 
CCQ and SGRQ in three continuous visits. Several other factors were also ex-
amined as spirometry, dyspnea, 6MWT and BODE index. This study has some 
limitations that should be reported. Firstly this study has been limited to one 
country and performed in one centre. Since no intervention was included many 
patients showed to be stable over time. This resulted in an unchanged health 
status making it impossible to calculate the MCID with anchor based methods 
and to compare the questionnaires responsiveness. Further this study was not 
designed to see if the CAT and CCQ both reflected indeed all the COPD patient’s 
relevant aspects. Larger studies with different design could answer this very 
important issue.
Conclusions
Our study showed that CAT and CCQ have similar psychometric properties. 
Compared to the much more often used but rather extensive SGRQ, they are 
both valid to assess health status. Patients preferred the CCQ since it reflected 
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their status better than the CAT as it had more details on breathing problems 
which was more important for them than sleep or energy.
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Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent disease in 
the general population resulting in a major impact on the daily life of patients 
suffering from COPD. A major goal in the management of COPD is to reduce 
the burden of COPD thus leading to the best possible quality of life and health 
status. COPD severity is graded using the GOLD classification which is based 
primarily on lung function impairment (FEV1/FVC and FEV1%pred) (1). These 
GOLD severity grades, however, do not necessarily reflect the burden of COPD. 
In addition the correlation between quality of life and health status with spiro-
metric values is rather weak in COPD patients (2). In patients with COPD, health 
status can be measured in clinical practice using a number of tools including the 
Clinical COPD Questionnaire (CCQ) (3). Real life data investigating the impact 
of COPD on health status and its correlation with the GOLD severity classifica-
tion (in particular GOLD stages I and II) are scarce.
Over the last 2 years the CCQ website has had 780 downloads from 53 lan-
guages per month. IPCRG (International Primary Care Respiratory Group) mem-
bers are currently using the CCQ as a useful tool for assessing health status in 
COPD patients. The CCQ is available in www.ccq.nl. The intention is to ask their 
collaboration to provide data from health status measurement, spirometry and 
medication prescription of their COPD patients. Data will include questionnaire 
data and patient characteristics. 
Objectives
The aim of this study is to assess the variability of impaired health status within 
each GOLD stage in patients with COPD in clinical practice. With this project 
we will evaluate health status as estimated with CCQ to examine differences 
between different GOLD stages.  
Study design/ Methods / Materials 
For this study clinicians from several European countries (ie; The Netherlands, 
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Sweden, United Kingdom, Greece) will provide us with CCQ data and additional 
information on lung function, demographics (age and gender) and smoking sta-
tus of their patient population. Differences in CCQ total and subdomain (symp-
tom, functional and mental state) scores (score range from 0 to 6 with higher 
score indicating worse health status) between GOLD stages will be tested. 
This will be a cross-sectional real-world database study. 
Study duration
Two years baseline period to collect databases from different European Coun-
tries. 
Inclusion criteria
Patients for whom we will collect data must also meet the following inclusion 
criteria:
• Aged: 40 and over who have a COPD diagnosis. 
• That clinicians have information on health status, age, sex, smoking status and 
lung function, CCQ total and domains.
Exclusion criteria
Patients will be excluded from the analysis if they have:
• Any chronic respiratory disease other than COPD.
Data source
Data will be collected from several clinicians that are IPCRG members in differ-
ent European Countries UK (David Price), The Netherlands (Thys van der Molen, 
Janwillem WH Kocks, Roland Riemersma, Daniel Kotz), Sweden (Ann-Britt Za-
crinson and Bjorn Stallberg), Greece (Ioanna Tsiligianni).  
The main benefit if this dataset as well as of the others databases collected from 
the other European Countries is the fact that will be completely anonymised, so 
there will be no concerns regarding patient identification.
We are planning to use this anonymised database from different European Coun-
tries in order to obtain useful information mainly on health status measure-
ment. 
Primary and secondary endpoints
Primary outcomes
What is the relationship between health status as assessed by CCQ with FEV1 and the 
GOLD suggested stages? Do patients with mild and moderate COPD have impaired 
health status? 
Secondary outcomes
How does the health status as assessed by CCQ changes according to exacerbations, 
different medication prescriptions, comorbidity.  
The dataset
Data will be extracted to permit characterization of the patients, including po-
tential predictors of COPD status: lung function (spirometry values including 
FEV1, FEV1/FVC), demographics (age and gender), smoking status and history, 
BMI, disease severity, hospitalisations, and exacerbations. Respiratory treatment 
and co-morbid factors will be extracted, where available, for all patients. All 
data available for the above measures in the year prior to the date of completion 
of the CCQ will be obtained. 
Data Analysis
Statistically significant results will be defined as p<0.05. All analyses will be 
carried out with SPSS for Windows version 20 (SPSS Inc. IL, USA). Summary 
statistics will be produced for all baseline and outcome variables, as a com-
plete dataset and by treatment groups. Mean and standard deviation (sd), range 
(minimum/maximum), median (Inter-quartile range:IQR) and percentages will 
be estimated for the different variables as appropriate. Associations between 
CCQ, GOLD stage and other parameters will be assessed using the chi square 
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test, independent t-test, Mann Whitney or other tests as appropriate. Multivari-
ate logistic regression analysis will be performed to identify the independent 
variables that best predict CCQ.  
Communication and publication strategy
The information study findings will be disseminated for the benefit of the re-
search fraternity through abstract presentation at appropriate respiratory confer-
ences and peer reviewed respiratory journals.
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Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent 
disease in the general population. The burden of COPD is not reflected by the 
classic spirometry values. A more reliable way to indicate the burden of COPD is 
to use health related quality of life and health status tools as the Clinical COPD 
Questionnaire.
Aim: The aim of this study was to assess the variability of health status (CCQ) in 
daily clinical practice within each GOLD stage in primary care in three European 
Countries. 
Methods: This study was a primary care European cross-sectional study that 
selected COPD patients from primary care in all GOLD stages. For this study 
clinicians from 3 countries (The Netherlands, Sweden and the United Kingdom) 
have participated. CCQ, GOLD stages and smoking habits were assessed. 
Results: 3489 patients participated (37% current smokers, 54% ex smokers, 
9% never smokers). The mean age ± sd was 68 ± 11, 55% were male. Impaired 
health status with CCQ total >2 (instable) was present in 40.9% of patient with 
GOLD I COPD, in 52% with GOLD II, in 63.8% with GOLD III, and in 77.2% 
with GOLD IV. A substantial impairment in health status with CCQ ≥ 3 was 
found in 19.3% of GOLD I, in 27.3% of GOLD II, in 36% of GOLD III, and in 
56.1% of GOLD IV. All differences in CCQ scores (total and domains) among 
GOLD stages were statistically significant (p<0.05).
Conclusions: This study gives evidence that impaired health status as assessed 
by the CCQ Questionnaire is found in a large proportion of patients including 
those with GOLD I and II lung function impairment. Assessing health status to-
gether with GOLD stage severity was found to be important since many patients 
with relatively mild –moderate pulmonary function impairment suffered from a 
severe impact of the disease.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease in the 
general population resulting in a major impact on the daily life of patients suf-
fering from COPD (1). In GOLD guidelines the severity of COPD is graded using 
the GOLD classification which is based primarily on lung function impairment 
(FEV1/FVC and FEV1%pred) (1). Until recently the approach to COPD manage-
ment was based only on which stage the COPD patient belonged as well as in the 
annual number of exacerbations. The updated guidelines kept the same staging 
while health status and dyspnea were officially introduced (1). 
A major goal in the COPD management is to treat the burden from COPD thus 
leading to the best possible quality of life and health status. This is because 
FEV1 is considered an unreliable measure that does not necessarily reflect the 
burden of COPD (1). Measurements of patient-centered outcomes like health 
related quality of life and health status may be more indicative for the burden 
from COPD. Therefore for the proper management of COPD an overall approach 
that will include symptoms assessment, dyspnea evaluation, exercise tolerance, 
health status measurement and annual exacerbations is recommended (1,2).  
To assess health status several COPD-specific tools have been developed: the St 
George Respiratory Questionnaire (SGRQ) (3), the Clinical COPD Questionnaire 
(CCQ) (4), the Chronic Respiratory disease questionnaire (CRQ) (5) and the 
COPD Assessment Test (CAT) (6). CCQ and CAT have the main benefit of being 
simple instruments with 10 and 8 questions respectively, to be easy to complete 
and to allow assessment in daily clinical practice in primary care (4,6). Real life 
primary care data investigating the impact of COPD on health status and its cor-
relation with the GOLD severity classification (in particular GOLD stages I and 
II) are scarce (7-12). This paper describes a European cross-sectional study re-
cruiting patients from primary care. CCQ has been used to assess health status. 
The aim of this study was to assess the variability of impaired health status 
(CCQ) within each GOLD stage in patients with COPD in primary care clinical 
practice.
Health status of COPD patients in clinical practice in three countries in Europe
Methods
This study was a primary care European cross-sectional study that selected COPD 
patients from primary care all GOLD stages. For this study clinicians from 3 
countries (The Netherlands, Sweden and the United Kingdom) provided us with 
CCQ data and additional information on lung function, demographics (age and 
gender) and smoking status of their COPD population. Each country and each 
clinician was responsible for the accuracy of the database. Ethical approval was 
provided from each country separately. 
Differences in CCQ total and subdomain (symptom, functional and mental state) 
scores (score ranges from 0 to 6 with higher score indicating worse health sta-
tus) between GOLD stages were tested. In addition, we defined 4 categories of 
impairment of health status according to the following criteria: CCQ < 1 (accept-
able health status), 1 ≤ CCQ <2 (acceptable health status for moderate disease), 
2 ≤ CCQ <3 (instable-severe limited health status), CCQ ≥3 (very instable-very 
severe limited health status) to test differences between GOLD stages.
CCQ questionnaire
CCQ is a short questionnaire that contains 10 items, divided into 3 domains 
(symptoms, functional and mental state). The CCQ total calculation of scores 
ranges from 0-6. The CCQ scores can easily be calculated by adding the indi-
vidual answers up and dividing them by the number of items (10 for total score, 
4 for the symptom domain, 4 for the functional domain and 2 for the mental 
state domain). It can also be calculated in an automatic way available on www.
ccq.nl. 
Statistical analysis
All statistical analyses were performed using SPSS v.20 (SPSS Inc. IL, USA) and 
p-values less than 0.05 were considered significant (two sided tests). Data were 
presented as mean (SD) or median (IQR) for normally or not normally distrib-
uted continuous variables, respectively and as percentages of patients in case of 
categorical variables. Differences in CCQ total and subdomain scores between 
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the different GOLD stages were analysed using the Jonckheere-Terpstra Test. 
Differences in distributions of categorical variables between GOLD stages were 
tested using the Chi-square test.
Results
A total of 3489 patients with COPD were included in this study. The characteris-
tics of the study population are shown in table 1. Table 2 shows the differences 
in CCQ scores between the different GOLD severity stages.
Table 1. Characteristics of study population (n=3489).
GOLD stage I (% of patients) 21%
GOLD stage II (% of patients) 51%
GOLD stage II (% of patients) 23%
GOLD stage IV (% of patients) 5%
Gender (% male) 55%
Mean age (SD) 68±11
Mean FEV1 (SD) (% pred) 63±21
Smoking (% of patients) current smokers 33%
Smoking (% of patients) ex smokers 54%
Smoking (% of patients) never smokers 9 %
Median CCQ total score (IQR) 2.1 (1.2-3.1)
Median CCQ symptom score (IQR) 2.3 (1.5-3.3)
Median CCQ functional score (IQR) 2.0 (0.8-3.3)
Median CCQ mental score (IQR) 1.5 (0.5-3.5)
Legend: GOLD: Global Initiative for Chronic Obstructive Lung Disease, FEV1: Forced Expira-
tory Volume in one second, CCQ: Clinical COPD Questionnaire, IQR: Inter-quartile range.  
Table 2. Median CCQ scores (IQR) in different GOLD stages. All differences in CCQ 






CCQ mental score 
GOLD I (n=730) 1.6 (0.9-2.6) 2.0(1.3-3.0) 1.3(0.5-2.8) 1.0(0-2.5)
GOLD II 
(n=1780)
2.0 (1.1-3.1) 2.3(1.5-3.3) 1.8(0.8-3.0) 1.5(0.5-3.0)
GOLD III 
(n=799)
2.5(1.6-3.6) 2.8(1.8-3.8) 2.5(1.5-3.5) 2.0(1.0-4.0)
GOLD IV (n=180) 3.3(2.0-4.1) 3.0(2.0-4.0) 3.3(2.0-4.5) 3.0(1.5-4.5)
Results regarding the impairment of health status based on CCQ demonstrated 
the presence of (very) instable-severe limited health status in 54% of patients. 
All differences in CCQ scores among GOLD stages were statistically significant 
(p<0.05).
 The variability of the health status within each GOLD stage is shown in figure 
1. Overall an association has been demonstrated between impairment in health 
status and GOLD severity stages (i.e. acceptable health status is more frequent in 
less severe GOLD stage categories and very instable-severe limited health status 
is more common in more severe GOLD stages). However, instable to very severe 
limited health status was present in 40.9% of patients in GOLD stage I, whereas 
in GOLD stage II in 52% of patients instable to very instable limited health sta-
tus was revealed.
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Figure 1. Health status impairement within GOLD stages. 
 
Legend: Health status categories: acceptable (CCQ < 1); acceptable for moderate disease
(1 ≤ CCQ <2); instable-severe limited (2 ≤ CCQ < 3); very instable-very severe limited
(CCQ ≥ 3).
Discussion
This study showed the correlation between CCQ and different GOLD stages in a 
European study that included the largest population of COPD patients assessed 
for health status until now in primary care. 
Results demonstrated an association between GOLD severity stages-grades and 
health status which have been shown also in other studies using other question-
naires such as SGRQ (7,9), CCQ (8) and CAT (12). With this study we highlight-
ed the high occurrence of very instable-severe limited health status in patients in 
GOLD stage I and II as well as the fact that CCQ total and domain scores change 
significantly within all GOLD stages. Our findings are contradictory to another 
study in which progression of chronic obstructive pulmonary disease severity 
up to stage IIa did not correspond to any meaningful difference in health status 
(11). Jones et al assessed the differences in CAT scores between GOLD stages 
and found no statistically significant differences between GOLD I and II contrary 
to our study (12). In our study CCQ has been found to be able to assess differ-
ences in health status even between GOLD stage I and II similarly to another 
study that also used CCQ to assess health status within GOLD stages (8). The 
high percentage of impaired health status in GOLD I and II and the fact that CCQ 
seems to be able to assess differences in health status between GOLD stage I and 
II shows that CCQ is a reliable tool for use in primary care. Further the idea that 
health status should always be assessed even in mild and moderate COPD has 
been affirmed. 
Recent GOLD guidelines suggested the use of the CAT questionnaire to assess 
health status in COPD patients (1). The International Primary Care Respiratory 
group produced a guide of tools taking into consideration issues such as validity, 
reliability, primary care population, practicality, tested in practice and avail-
ability in other languages. This guide has ranked CCQ as the most highly recom-
mended in all the criteria used (13,14). Our study added also another advantage 
which is the CCQ ability to assess differences within GOLD stages that are not 
restricted to the total score but also in the domains scores. Additionally CCQ has 
a well defined Minimal Clinically Important Difference as it has previously been 
calculated based on three methods and is 0.4 (15). All these make CCQ a reliable 
tool for assessing health status in patients with COPD in primary care.
Conclusions
This study provides evidence that impaired health status as assessed by the CCQ 
is present in a large proportion of patients including those with GOLD severity 
stage I and II, considered mild and moderate COPD. It is suggested that health 
status with CCQ, together with GOLD severity stage, be used to assess patients 
with COPD, since many patients with relatively mild lung function impairment 
suffer from a severe impact of the disease. The CCQ ability to assess differences 
between GOLD stages has been underlined. 
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COPD patients often have impaired quality of life (qol) and/or health status. A 
major goal in COPD management is to ensure that the burden of the disease is 
limited and that patients will have the best possible quality of life and health 
status. Several factors such as age, gender, lung function, depression, anxiety, 
comorbidity, seem to influence quality of life. Until now there wasn’t an organ-
ized approach to show which of these factors are most affected, and no clear 
evidence as to what extent these factors influence quality of life and health sta-
tus. The relationship between health status and different factors is analyzed in 
chapter two. This meta-analysis highlighted dyspnea, depression, anxiety and 
exercise tolerance as the most important factors that influence quality of life in 
COPD patients, showing the strongest association of these factors with different 
health status tools. 
Lung function traditionally considered as a key factor in the disease classifica-
tion and decision for management has been found to be weakly to modestly as-
sociated with health status as assessed with several different questionnaires in 
chapter two. 
Chapter three describes an attempt proposed for a pilot feasibility study that 
will take place in Greece and will utilize the already used Labnoord-Groningen 
model for a telehealth integrated COPD care. The whole framework is translated 
in Greek and a feasibility study will determine what should be changed in order 
for this attempt to be successful in Greece. This is considered extremely impor-
tant for Greece as spirometry and CCQ included in this teleservice will help GPs 
often serving rural and remote areas (350 islands with permanent inhabitants) 
to successfully treat COPD patients. 
Chapter four describes an attempt made to search and classify the available 
methods (laboratory tests – semi-laboratory tests – field tests – patient reported 
outcomes) for measuring functional status in COPD patients to help clinicians 
in primary care decide which method to select. The 6-minute walking distance 
test was found to be the most reliable, but with the primary disadvantage of not 
being a very practical semi-laboratory functional capacity test. The pedometer 
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was the best functional performance field test, and the MRC and the CCQ func-
tional status domain were found to be the best patient-reported outcome tools 
to measure functional performance in primary care.
Chapter five describes an attempt made from the IPCRG to help clinicians de-
cide which tool to select to assess COPD patient’s quality of life/well-being. 
Forty tools have been selected. Criteria used to rank the tools were validity, reli-
ability, primary care population, practicality tested in practice and availability 
in other languages. From the nine finally selected tools CCQ has been ranked as 
the best in all settled criteria followed by the CAT. The user’s guide is presented 
in the first part and the accepted article (second part) explaining the whole 
procedure to achieve this guide is presented. 
Chapter six continues the question discussed in chapter 5: Which tool to select? 
It describes a head to head comparison between CCQ, CAT and SGRQ.  Ninety 
patients have participated in the study conducted in Greece and information on 
the three quality of life questionnaires were gathered during three consecutive 
visits. CCQ and CAT were found to have similar psychometric properties with 
a slight advantage for CCQ mainly in terms of patient preferences. Both have 
been proven valid and reliable questionnaires to assess health status in COPD 
patients. 
Chapter seven describes an initiative to create a common international database 
for COPD patients collecting information on health status measurement with the 
use of CCQ. The study protocol (part I) and a short report (part II) with pre-
liminary results are presented. Three European Countries have until now partici-
pated in this study. The short report answered what was speculated in Chapter 
2: that spirometry values (FEV1 in particular) do not reflect COPD health status. 
This ongoing study showed that even patients with mild-moderate COPD often 
have an impaired health status and should be managed accordingly. 
General discussion
We started the studies in this thesis based on the idea that measurement of health 
status and quality of life is extremely important for the proper management of 
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COPD and therefore should be included in daily clinical practice. What we re-
ally wanted was to put forward the idea that quality of life should be assessed 
in addition to spirometry. The usual approach for COPD management for most 
clinicians is based mainly on the assessment of FEV1 and FEV1/FVC. With this 
thesis we have highlighted the need for health status assessment and its incorpo-
ration into daily clinical practice, and we have showed which instruments could 
be used to properly measure health status and/or quality of life. At the time 
this thesis has started the GOLD guidelines did not suggest the measurement of 
health status in routine daily clinical practice. They had a short reference for 
the health status importance, while now the updated end 2011 guidelines clas-
sify patients in 4 risk groups taking in consideration the patient’s symptoms and 
health status. This is in consistency with our hypothesis; that health status is 
important for COPD management. 
Several research questions have been raised from this protocol. Which are the 
known factors that influence quality of life/health status in patients with COPD? 
Which are the most important factors that influence COPD patients health sta-
tus that clinicians should always assess? Do the lung function tests correlate 
significantly with health status tools? And if yes which are the tools that better 
correlate with spirometry values and that could possibly be used preferably? In 
what way does a telehealth integrated asthma COPD service that will includes 
health status tools such as CCQ can be established in countries such as Greece? 
In what way can we incorporate the telehealth service proposed by labnoord and 
make it feasible in Greece? Which are the available quality of life and/or health 
status questionnaires for COPD? Which tool should clinicians select for use in 
primary care as more than 40 tools are available? How should a clinician decide 
which of these tools to select? Which are the basic criteria that should be used 
in primary care? Which is the best tool (CCQ or CAT taking SGRQ as the gold 
standard) for assessing health status in COPD patients? Do they have different 
psychometric properties and what are the patients’ preferences? Finally, when 
is it that primary care physicians should use health status instruments?  Is it 
necessary to measure quality of life in advanced COPD stages only, or is it also 
important in patients in earlier stages? 
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The results of our meta-analysis in chapter two showed that physicians should 
keep in mind that a lot of different factors should be taken into consideration as 
they influence their patient’s health status. FEV1 and FEV1/FVC are the corner-
stone for COPD diagnosis and follow up. However both are only weakly to mod-
estly associated with almost all quality of life and/or health status instruments 
(1-3). Although several studies have shown this, they have been mainly based 
on a small number of patients and have used different questionnaires without 
the possibility for the user to know in what way each questionnaire used is as-
sociated with spirometry values as FEV1. The meta-analysis presented in chapter 
two showed that all the questionnaires had a modest association and that the 
CCQ had modest correlations with the FEV1, but among the higher ones com-
pared with the other questionnaires while the SGRQ had among the lowest ones. 
CAT was not included in the meta-analysis as at the time the metaanalysis was 
conducted CAT was newly developed and data to be included were missing. 
This metanalysis comfirmed our hypothesis that spirometry does not reflect pa-
tients health status and highlighted the importance of other factors such as dysp-
nea. Dyspnea has been showed to have among the strongest correlations with all 
questionnaires examined. It has been found to strongly impair health status and 
that’s probably why almost all questionnaires include dyspnea in their content 
(4). The recent GOLD reccomendations highlighted the importance of assessing 
dyspnea in routine practice and recommended the use of the modified Medical 
Research Council Questionnaire (mMRC) to assess disability due to breathless-
ness (5,6). 
Apart from the dyspnea, which was expected to most likely influence health 
status, other factors such as depression and anxiety have also been found as 
strong determinants of the patients’ reported health status. All the question-
naires showed a good correlation with depression and anxiety questionnaires, 
but only the CCQ showed the higher correlation with the Hospital Anxiety De-
pression Scale (HADS) (7). That confirmed what was reported from a previous 
study that CCQ is also able to predict depression and anxiety (8). This high 
specificity of CCQ is probably because of its’ advantage in including other do-
mains, in particular the mental domain. The strong correlation of depression and 
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anxiety with health status (H.S.) could be considered important as depression 
and anxiety evaluation are not included in physicians’ daily clinical practice. We 
expect that clinicians maybe more aware in the future and also include scales 
such as the Hospital Anxiety and Depression Scale (HADS) (7) or the Beck Anxi-
ety Inventory Scale (BECK) (9) or the State-Trait Anxiety Inventory scale (STAI) 
(10) to properly identify and treat these common conditions in COPD patients. 
The recent GOLD guidelines suggest the primary care evaluation of mental dis-
orders (6). Unfortunately only the use of the selective serotonin reuptake inhibi-
tors (SSRIs) in quality of life has been explored, and this was not extensively 
explored as there are only two studies and a meta-analysis that examined the 
improvement of quality of life as assessed with the SGRQ (11-13). However the 
updated GOLD guidelines do not report any treatments for depression and anxi-
ety (6). So the fact that only a minority of patients with depression and anxiety 
receive treatment is expected as this issue has not received proper attention until 
now (14). Even in patients in palliative care, only 18% receive specific treat-
ment for depression and anxiety disorders (15). 
Further, with this meta-analysis health status has been found to be influenced 
by an enormous amount of factors such as demographic and anthropometric 
factors (age, gender, and body mass index), severity indexes, BODE index, ex-
ercise tolerance, and coping strategies. This means that physicians should not 
be restricted in providing the recommended therapys per GOLD recommenda-
tions, but also in providing antidepressants, psychological support, and rehabili-
tation programs whenever needed.  A holistic approach is suggested, trying to 
find ways that will change even patients’ coping abilities, that has not received 
proper attention until now. The patients’ illness perception has also been found 
to influence quality of life meaning that the clinician’s role should be oriented 
to the development of skills to efficiently investigate and manage issues such 
as psychological distress, as well as to deal with other family issues. Female 
patients reported worse health status and should be managed with more caution 
especially as they are also more susceptible to depression (16). 
Chapter three describes an attempt made for a pilot telehealth asthma-COPD 
feasibility study in Crete, Greece. Asthma and COPD are common diseases often 
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underdiagnosed and mistreated in primary care. Greece is in a difficult situa-
tion at the moment due to several reasons: it is a country with limited financial 
resources, as well as with limited number of GPs who primarily serve rural and 
remote areas, and with a geographical particularity with hundreds of islands and 
remote areas in the mountains. Although Greece has a high prevalence of COPD 
(17) it is estimated that both (COPD and asthma) are still underdiagnosed and 
undertreated, especially in remote areas with no access in secondary care and 
spirometry (17). 
Telehealth has been proven to be extremely useful in spectrums of diseases; in 
pediatrics, cardiology, diabetes, emergency medicine, asthma and COPD (18-
22). In the Netherlands a telemedicine supported asthma-COPD service from 
Labnoord and UMCG proved to increase the diagnosis and management of both 
COPD and asthma. Unpublished until now, results showed the system to be 
highly effective. We estimate that this service will help GPs, in collaboration 
with pulmonologists, to achieve an early diagnosis, to avoid delays in treatment 
and to establish a more integrated approach, as it will include health status tools 
as CCQ and ACQ. 
Chapter four describes an attempt to search and classify the available methods 
for measuring functional status. Physical assessment and improvement of activ-
ity is recommended for all COPD patients (6). Evidence for specific recommen-
dations is missing with the only exception of organized pulmonary rehabilita-
tion programs (6). In addition, daily physical activity is recommended not only 
because it improves COPD patients’ health status, but also because it improves 
cardiovascular disease prevention (6). Pulmonary rehabilitation programs have 
been proven to improve physical activity, decrease dyspnea and improve health 
status (23). Even if a pulmonary rehabilitation program is not available, a 20 
minute walk per day is recommended (6). The importance of physical exercise 
and pulmonary rehabilitation can been seen by the additional beneficial effect it 
can have on depression (24). 
Functional status, in addition to health status and spirometry, are needed to 
achieve proper integrated care in COPD patients. The improvement in functional 
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status is one of the major treatment goals for patients with COPD as underlined 
by the updated GOLD guidelines (6). In our study we have categorized measure-
ment tools into:1) laboratory tests – e.g. cycle ergometry (25)/2) semi-labora-
tory tests – e.g. the 6-minute walking distance test (26) 3) field tests – e.g. the 
accelerometer (27), and 4) patient-reported outcomes – e.g. the MRC dyspnea 
scale (5). 
The measurement properties of each tool were rated according to a novel rat-
ing system for primary care as: very poor/unknown; not good enough; good 
enough; recommended; highly recommended. Tests were classified according to 
validity/reliability, responsiveness, primary care population, practicality, tested 
in practice (COPD), and known MCID. To assess functional status in COPD pa-
tients, this study revealed that although there are a variety of tools (32 tools) to 
assess functional status in COPD no one tool meets all the criteria to be highly 
recommended for primary care use. The 6-minute walking distance test was 
found to be the most reliable, but with the primary disadvantage of not being a 
very practical semi-laboratory functional capacity test. The pedometer was the 
best functional performance field test, and the MRC and the CCQ functional sta-
tus domain were found to be the best patient-reported outcome tool to measure 
functional performance in primary care.
This thesis in chapter five aimed to also cover the gap in the existing literature 
regarding which are the available tools for measuring health status in COPD pa-
tients, which should be the criteria used to decide and which are the best tools 
for use in primary care. This was quite complicated as there are more than forty 
tools for this purpose. To that direction IPCRG has decided to provide clinicians 
with this guide so to make that search much easier. 
A questionnaire should not only meet quality standards in psychometric proper-
ties, but also be practical and easy to interpret. The SGRQ is a 50-item question-
naire which has been ranked among the 9 preferred tools, but not as the best, 
although it is the most extensively used questionnaire in the literature (28). 
Although it has good psychometric properties, it has not been ranked among the 
best as it is extremely time consuming and excel spreadsheets are necessary to 
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calculate the scores. It is divided into three components: symptoms, activity, and 
impacts (on daily life). The MRC was also included in the recommended tools al-
though not highly recommended as its value is restricted to dyspnea assessment 
and does not give information on the overall patients’ health status (5).  
CCQ followed by the CAT have been highlighted by primary care physicians 
in IPCRG as the best tools for use in primary care (29). The main criteria that 
have been used in this guide were validity/reliability-responsiveness-focused in 
primary care-practicality-tested in practice-and available validated in many lan-
guages. This guide was planned for use in primary care and aimed to save time 
for physicians that can now find systemized tools summary and decide which 
of the used criterion are most important for their particular needs. i.e; some 
questionnaires are easy to be completed in a routine consultation or be self-
completed in the waiting room or by email and therefore being useful for some 
clinicians who are mainly interested in the practicality issue. Other clinicians 
will need tools that will be available, translated and validated in their language. 
Where to find the questionnaires, the translations and from where to ask permis-
sion for use is another concern of most clinicians that is clearly stated in chapter 
five of this thesis at least for the most highly ranked questionnaires. CCQ has 
been proposed as highly recommended in all the criteria used. CAT is a prom-
ised new tool that has also been ranked as highly recommended in some criteria 
such as validity and the primary care population but it did not reach the ‘highly 
recommended’ that CCQ reached in all criteria as it fell short in responsiveness, 
practicality, tested in practice and other languages validation. The CCQ contains 
10 items, divided into 3 domains (symptoms, functional and mental state) (30). 
The CAT has 8 items, raises questions like symptoms, energy, sleep and activity, 
and has been developed as a unidimensional tool (2). 
Apart of the previous mentioned differences between the CAT and CCQ, they 
are both reliable and short instruments to measure health status in primary care. 
CCQ has been used extensively since its development in 2003. It can be found 
at www.ccq.nl where physicians can easily download for free the questionnaire 
translated in more than 53 languages. Both CAT and CCQ are practical, easy to 
use, and can be completed in 2 minutes at most. Both have been designed for 
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use in the primary care population, they are self-completed, available in many 
translations and free of charge either for clinicians or patients (2, 30). 
Chapter six attempted to expand what the user’s guide showed: that CCQ and 
CAT are both good choices for use in primary care. This has been the first study 
that performed a head to head comparison of CCQ and CAT in an attempt to 
help primary care clinicians select the best tool for daily clinical use. The com-
parison of the two questionnaires taking SGRQ as the gold standard showed that 
both questionnaires have excellent reliability, good discriminate validity and 
high reproducibility. Both questionnaires as well as the SGRQ showed a weak to 
modest association with FEV1, further supporting the data previously described 
in the meta-analysis. 
Their high Cronbach’s alpha indicates that there is homogeneity among the indi-
vidual items in both questionnaires. Both the CAT and CCQ were able to detect 
differences in severity of COPD as it has been shown by their good discriminant 
validity. Both questionnaires had a high correlation with the SGRQ confirming 
their optimal convergent validity. As expected CCQ total score and CAT score 
also had a very strong correlation supporting that they both measure the same 
construct. This shows that although both questionnaires have several differences 
in terms (energy and sleep for CAT and mental for CCQ) they overall correlate 
well between them. The findings of our study confirmed what the original de-
velopment of the questionnaires showed that both CAT and CCQ have strong 
associations with SGRQ (2,30).
In our study the CCQ domains, symptoms, and functionality correlated signifi-
cantly with the respective domains of the SGRQ (symptoms and activity). The 
content of CCQ has more similarities with SGRQ than the content of the CAT. 
Just like the SGRQ, the CCQ has a division in domains, whereas the CAT is de-
veloped as a unidimensional questionnaire. The advantage of domains is that 
individual management plans can be achieved based on the individual domains. 
For example, a patient with an impaired mental state might be managed differ-
ently from a patient with an impaired functional status. 
The MCID for CAT has been calculated officially for the first time in our study 
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and it has been found to be higher than what the CAT developers have specu-
lated (3.76 vs 2.00 respectively) (31) while the CCQ values were similar with 
previously published studies (32). 
One main advantage of our study is that we also conducted qualitative research 
by the use of simple open ended questions regarding the practicality and useful-
ness of all questionnaires. All patients (100%) perceived the CAT and CCQ as 
more easy tools compared to SGRQ in terms of complexity and time to complete. 
The SGRQ was considered rather complicated and time consuming. On the ques-
tion ‘which tool, CAT or CCQ, would you select for assessing your health status?’ 
61.1% (55 patients) expressed the opinion that the CCQ reflected their status 
better than CAT as it had more details on breathing problems which was more 
important for them than sleep or energy. Patients’ answers showed in that way 
the important impact that breathing problems (present in different questions in 
CCQ) have for determining health status in COPD patients. Ten patients also 
expressed their opinion that the CCQ has a more easy to understand response 
options system compared to the CAT. Our study is in accordance with a recent 
study that showed that the need for assistance while answering the two ques-
tionnaires (CCQ-CAT) in COPD was lower in CCQ confirming that CCQ is an 
easier tool (33). 
The last chapter describes an initiative to develop a common international 
COPD database. It has been the keystone for the UNLOCK development, an 
IPCRG initiative to develop a common international database to answer several 
research questions regarding COPD in primary care (34). The research protocol 
and first results are presented. As a part of this initiative we were interested to 
find out: what is the health status in COPD patients in several European Coun-
tries. The relationship between CCQ and FEV1 was assessed. 
This study demonstrated what we speculated from the meta-analysis that health 
status questionnaires in our case CCQ is often from instable-severely impaired 
to very instable-severe even in mild/moderate COPD. It is suggested to assess 
health status additionally to spirometry, since many patients with relatively mild 
lung function impairment suffer from a severe impact of the disease. Further 
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this study showed that CCQ can easily detect differences within GOLD stages. 
 This study is still in progress, and additional data from other countries such as 
Greece, Cyprus etc. are being collected. We speculate that when this study is 
complete, we will be able to also answer other questions as correlating health 
status (CCQ) and medication use/exacerbations/comorbidities as well as assess-
ing differences between countries. Although this is still an ongoing study, it is 
the first study that included such a high number of primary care patients that 
assessed simultaneously CCQ and spirometry values in COPD.  
Future perspectives
Until now the majority of clinicians focused mainly on the proper COPD man-
agement based on the GOLD stage and on the annual number of exacerbations 
as suggested by the precedent GOLD guidelines. The updated GOLD guidelines 
suggest the assessment of dyspnea with the mMRC and the assessment of health 
status with the CAT (6). The FEV1 has been recognized as an unreliable marker 
and health status although limited to CAT suggestion finds the place that should 
had from the beginning, underlined also by this thesis. 
The recent GOLD guidelines divides patients in groups as follows (6): 
Patient Group A-Low Risk, 
Less Symptoms
Typically GOLD 1 or GOLD 2 and/or 0-1 exacerbations per year 
and mMRC 0-1 or CAT score<10
Patient Group B-Low Risk, 
More Symptoms
Typically GOLD 1 or GOLD 2 and/or 0-1 exacerbations per year 
and mMRC ≥ 2 or CAT score ≥ 10
Patient Group C-High Risk, 
Less Symptoms
Typically GOLD 3 or GOLD 4 and/or ≥ 2 exacerbations per year 
and mMRC 0-1 or CAT score<10
Patient Group D-High Risk, 
More Symptoms
Typically GOLD 3 or GOLD 4 and/or ≥ 2 exacerbations per year 
and mMRC or ≥ 2 or CAT score ≥ 10
A new horizon has opened. It is expected that clinicians will use health status 
measurement in daily clinical practice. Our meta-analysis and the first report 
of the international study showed the weak association between FEV1 and vari-
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ous health status questionnaires as well as the significant percentages of COPD 
patients GOLD stage I and II that they had strongly impaired quality of life. We 
hope the results of this thesis in conjunction with the recent GOLD recommen-
dations will orientate clinicians toward an integrated health care approach in 
COPD patients that will include assessment of health status. CCQ has been found 
to be ranked as the best tool in the IPCRG workshop, to have good psychometric 
properties and to be preferred by patients. Further studies are needed and per-
haps the next GOLD guidelines will also include CCQ, taking in consideration 
it’s advantages presented in this thesis. Proper management of depression and 
anxiety, exercise capacity, family issues and coping strategies will ideally be 
included in an holistic COPD patients approach in the near future.
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COPD-patiënten hebben vaak een verminderde kwaliteit van leven (KvL) en/ 
of gezondheidstoestand. Een belangrijk doel bij COPD-management is ervoor 
zorgen dat de ziektelast beperkt is en dat patiënten de best mogelijke kwaliteit 
van leven en gezondheidsstatus hebben. Verschillende factoren zoals leeftijd, 
geslacht, longfunctie, depressie, angst, co morbiditeit, lijken de kwaliteit van 
leven te beïnvloeden. Tot nu toe was er geen georganiseerde aanpak om te zien 
welke factoren van invloed zijn en er is geen duidelijk bewijs in welke mate 
deze factoren invloed uitoefenen op de kwaliteit van leven en de gezondheids-
toestand. De relatie tussen de gezondheidstoestand en de verschillende factoren 
wordt geanalyseerd in hoofdstuk twee. Deze meta-analyse benadrukt dyspneu, 
depressie, angst en inspanningstolerantie als de belangrijkste factoren die de 
kwaliteit van leven beïnvloeden bij COPD-patiënten en het sterkste verband heb-
ben met verschillende metingen van de gezondheidsstatus. 
De longfunctie wordt traditioneel beschouwd als een belangrijke factor in de 
classificatie van ziekten en de besluitvorming voor het management. Er is een 
zwak tot matig verband gevonden van de longfunctie met de gezondheidstoe-
stand zoals gemeten met een aantal verschillende vragenlijsten in hoofdstuk 
twee.
Hoofdstuk drie beschrijft een voorstel voor een pilot haalbaarheidsstudie die 
zal plaatsvinden in Griekenland en waarbij het bestaande Labnoord-Groningen 
model gebruikt zal worden voor een telezorg geïntegreerde COPD-zorg. Het hele 
kader wordt vertaald in het Grieks en de haalbaarheidsstudie, die al begonnen 
is, is bepalend voor wat zal moeten worden gewijzigd om deze poging succesvol 
te laten zijn in Griekenland. Dit van groot belang geacht voor Griekenland om-
dat spirometrie en de CCQ in deze teleservice huisartsen vaak zal ondersteunen 
in landelijke en afgelegen gebieden (350 eilanden met permanente inwoners) 
COPD-patiënten met succes te behandelen.
Hoofdstuk vier beschrijft een poging om de beschikbare methoden te onder-
zoeken en te classificeren (laboratoriumtests - semi-laboratoriumonderzoek 
- veldproeven – door de patiënt gerapporteerde uitkomstmaten) om de func-
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tionele status bij COPD-patiënten te meten om daarmee artsen in de eerste lijn 
te helpen te beslissen welke methode te selecteren. De zes minuten loopafstand-
sproef bleek de meest betrouwbare, maar een nadeel van deze semilaboratorium 
functionele capaciteit test is dat deze niet zeer praktisch is. De stappenteller was 
de beste functionele prestatieveldtest, daarnaast waren het functionele status 
domein van zowel de MRC als de CCQ de beste patiënt gerapporteerde mee-
tinstrumenten om in de eerste lijn functionele prestaties te meten.
In hoofdstuk vijf word beschreven hoe de IPCRG kan helpen artsen te beslis-
sen welk meetinstrument te selecteren om de kwaliteit van leven/welzijn van 
de COPD-patiënt te beoordelen. Veertig meetinstrumenten zijn geselecteerd. 
Criteria die gebruikt zijn om de instrumenten te rangschikken waren validiteit, 
betrouwbaarheid, bevolking uit de eerstelijnszorg, praktische bruikbaarheid in 
de praktijk en de beschikbaarheid in andere talen. De CCQ scoorde als beste op 
de geselecteerde criteria, gevolgd door de CAT. De gebruikershandleiding wordt 
in het eerste deel weergegeven en in het tweede deel is het geaccepteerde artikel 
gepresenteerd waarin de gehele procedure is weergegeven hoe de gebruiker-
shandleiding tot stand te brengen.
In hoofdstuk zes volgt een voortzetting van de vraag waar de aandacht op 
gevestigd was in hoofdstuk 5: welk meetinstrument heeft de voorkeur? Dit be-
schrijft een één op één vergelijking tussen de CCQ en de CAT met de SGRQ als 
een gouden standaard. Negentig patiënten hebben deelgenomen aan de studie 
uitgevoerd in Griekenland. De informatie over de drie kwaliteit van leven vra-
genlijsten werd verzameld tijdens drie opeenvolgende bezoeken. Bij de CCQ en 
de CAT zijn soortgelijke psychometrische eigenschappen gevonden, was de CCQ 
licht in het voordeel, voornamelijk wat betreft de voorkeur van patiënten. Beide 
meetinstrumenten leveren bewezen valide en betrouwbare vragenlijsten op om 
de gezondheidsstatus bij patiënten met COPD te beoordelen .
Hoofdstuk zeven bevat een omschrijving van een initiatief om een gemeen-
schappelijke internationale database voor COPD-patiënten te creëren waarbij 
informatie wordt verzameld over de gezondheidstoestand met als meting de 
CCQ. Het studie protocol (deel I) en een kort verslag (deel II) met voorlopige 
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resultaten worden gepresenteerd. Drie Europese landen hebben tot nu toe deelg-
enomen aan deze studie. Het korte verslag geeft antwoord op wat er is gesp-
eculeerd in hoofdstuk 2, dat de spirometrie-waarden (FEV1 in het bijzonder) 
geen COPD gezondheidstoestand weergeven. Deze studie die voortbouwde op de 
vorige toonde aan dat zelfs patiënten met milde tot matige COPD vaak een ver-
minderde gezondheidstoestand hebben en dienovereenkomstig behandeld zou 
moeten worden.
Algemene discussie
De studies in dit proefschrift zijn gebaseerd op het idee dat het meten van de ge-
zondheidstoestand en de kwaliteit van het leven uiterst belangrijk zijn voor een 
goed management van COPD en zou daarom opgenomen moeten worden in de 
dagelijkse klinische praktijk. Belangrijk is naast de spirometrie tevens de kwal-
iteit van leven moet worden beoordeeld. De gebruikelijke aanpak van de meeste 
artsen bij COPD management is hoofdzakelijk gebaseerd op de beoordeling van 
de FEV1 en FEV1/FVC. Met dit proefschrift wordt gewezen op de noodzaak van 
het goed meten van de gezondheidstoestand en/of de kwaliteit van het leven, 
en de integratie daarvan in de dagelijkse klinische praktijk, voor de beoorde-
ling van de gezondheidstoestand. Welke instrumenten hiervoor gebruikt kunnen 
worden is duidelijk gemaakt. Op het moment van aanvang van dit proefschrift 
werd in de GOLD richtlijnen nog niet het routinematig meten van de gezond-
heidstoestand in de dagelijkse klinische praktijk onderschreven. Er was slechts 
een korte aantekening dat het voor de gezondheid van belang is, terwijl nu in de 
bijgewerkte richtlijnen staat dat er bij patiënten die geclassificeerd worden met 
risicogroep 4 er rekening gehouden moet worden met eventuele symptomen en 
de gezondheidstoestand van de patiënt. Dit heeft het idee ondersteund dat de 
gezondheidstoestand belangrijk is voor COPD management.
Verschillende onderzoeksvragen werden door het protocol opgeroepen. Wat zijn 
bekende factoren die de kwaliteit van leven van patiënten met COPD beïnv-
loeden? Wat zijn de belangrijkste factoren die gezondheidstoestand van COPD-
patiënten beïnvloeden en moeten clinici deze steeds beoordelen? Correleren de 
longfunctietesten significant met de gezondheidstoestandsmeting of niet? En zo 
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ja, welke instrumenten correleren beter met spirometriewaarden, die mogelijk 
bij voorkeur gebruikt kunnen worden? Op welke manier kan een telezorg geïn-
tegreerde astma COPD-dienst, die gezondheidstoestandsmetingen bevat zoals de 
CCQ, opgericht worden in landen als Griekenland? Op welke manier kunnen 
we de tele-gezondheidsdienst zoals voorgesteld door LabNoord integreren en 
uitvoeren in Griekenland? Wat zijn de beschikbare kwaliteit van leven en/of 
gezondheidstoestand vragenlijsten voor COPD? Welk instrument dient de arts 
te kiezen voor gebruik in de eerste lijn, aangezien meer dan 40 instrumenten 
beschikbaar zijn? Hoe moet een arts beslissen welke van deze instrumenten te 
selecteren? Wat zijn de basiscriteria die gebruikt moeten worden in de eerste lijn 
om te beslissen? Wat is het beste meetinstrument (CCQ of CAT nemen SGRQ 
als de gouden standaard) ter beoordeling van de gezondheidstoestand bij COPD 
patiënten? Hebben ze verschillende psychometrische eigenschappen en wat zijn 
de voorkeuren van de patiënt? Ten slotte wanneer moeten huisartsen instru-
menten voor het meten van gezondheidstoestanden gebruiken? Is het nodig om 
de kwaliteit van leven alleen te meten in een vergevorderd stadium van COPD of 
is het ook belangrijk dit te doen bij patiënten in de eerdere fasen?
Uit de resultaten van onze meta-analyse in hoofdstuk twee blijkt dat artsen 
in gedachten moeten houden dat een groot aantal verschillende factoren in 
aanmerking genomen moeten worden omdat ze invloed hebben op de gezond-
heidsstatus van patiënten. FEV1 en FEV1/FVC zijn de hoeksteen voor de COPD 
diagnose en follow-up, maar beide zijn slechts zwak tot matig geassocieerd met 
bijna alle instrumenten die kwaliteit van leven en/of de gezondheidstoestand 
meten. Hoewel er verschillende studies gedaan zijn, waren de resultaten voor-
namelijk gebaseerd op onderzoek met een klein aantal patiënten en werd er ge-
bruik gemaakt van verschillende vragenlijsten, zonder dat het voor de gebruiker 
mogelijk was om te weten op welke manier elke gebruikte vragenlijst samen 
hing met spirometrie waarden als FEV1. In de meta-analyse in hoofdstuk twee 
bleek dat alle vragenlijsten een bescheiden samenhang hadden en dat de CCQ 
een bescheiden correlatie had met de FEV1, maar dat het één van de hoogste 
was in vergelijking met de andere vragenlijsten, terwijl de SGRQ behoorde tot 
de laagste. De CAT is niet opgenomen in de meta-analyse omdat op het moment 
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dat de meta-analyse werd uitgevoerd de CAT nieuw werd ontwikkeld en de op 
te nemen gegevens ontbraken.
Deze meta-analyse bevestigde onze hypothese dat de spirometrie niet de ge-
zondheidstoestand van de patiënten weergeeft en het belang andere factoren te 
betrekken, zoals kortademigheid. Het is gebleken dat dyspneu de sterkste corre-
laties vertoont met alle onderzochte vragenlijsten. Het bleek de gezondheidstoe-
stand sterk te verminderen en dat is waarschijnlijk de reden waarom bijna alle 
vragenlijsten onder andere kortademigheid in hun inhoud hebben. De recente 
GOLD aanbevelingen duiden het belang aan van het beoordelen van dyspneu in 
de dagelijkse praktijk en daarbij wordt het gebruik aanbevolen van de gewijzigde 
British Medical Research Council Questionnaire (MRC) om arbeidsongeschikt-
heid als gevolg van kortademigheid te beoordelen.
Afgezien van de dyspneu dat de gezondheidstoestand beïnvloedde als verwacht, 
waren er andere factoren van invloed zoals depressie en angst die sterke deter-
minanten bleken te zijn van de gemelde gezondheidstoestand van patiënten. Alle 
vragenlijsten bleken een hoge correlatie te hebben met depressie en angstvra-
genlijsten, maar alleen de CCQ toonde een hogere correlatie met de Hospital 
Anxiety Depression Scale (HADS). Dit bevestigt wat werd vermeld in een eerd-
ere studie waarbij de CCQ zelfs in staat was depressie en angst  te voorspellen. 
Deze hoge specificiteit van de CCQ is waarschijnlijk te danken aan het gebruik 
van domeinen en met name het mentale domein. De sterke correlatie tussen de-
pressie en angst met health status kan als belangrijk worden beschouwd omdat 
de evaluatie van depressie en angst niet zijn inbegrepen in dagelijks klinische 
praktijk van artsen. We verwachten dat artsen zich misschien in de toekomst wel 
meer bewust zijn en ook schalen als de Hospital Anxiety and Depression Scale 
(HADS) of de Beck Anxiety Inventory Scale (BECK)  of de State-Trait Anxiety 
Inventory schaal (STAI)  gebruiken voor een juiste identificatie en behandeling 
van deze bij COPD-patiënten vaak voorkomende omstandigheden. Helaas is al-
leen het gebruik van de selectieve serotonine heropname remmers (SSRI’s) en 
kwaliteit van leven onderzocht en werd dit niet uitgebreid onderzocht omdat 
er slechts twee studies en een meta analyse zijn waarbij de verbetering van de 
kwaliteit van leven onderzocht werd zoals gemeten met de SGRQ. Maar de bi-
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jgewerkte GOLD richtlijnen vermelden geen behandelingen voor depressie en 
angst. Slechts een minderheid van de patiënten met depressie en angst kan be-
handeling verwachten omdat dit probleem tot nu toe nog niet de juiste aandacht 
heeft ontvangen. Zelfs bij patiënten in de palliatieve zorg krijgt slechts 18% een 
specifieke behandeling voor depressie en angststoornissen. 
Verder is met deze meta-analyse gevonden dat health status wordt beïnvloed 
door een grote hoeveelheid factoren zoals demografische en antropometrische 
factoren (leeftijd, geslacht en body mass index (BMI)), indexen voor ernst, 
BODE-index, geslacht, inspanningstolerantie en coping-strategieën. Dit betekent 
dat artsen niet mogen worden beperkt in het verstrekken van de door GOLD aan-
bevolen therapie, maar even zo in het verstrekken van antidepressiva, psycholo-
gische ondersteuning en rehabilitatieprogramma’s. Een holistische benadering 
wordt aanbevolen, in een poging een manier te vinden die zelfs de zelfredzaam-
heid van patiënten zal veranderen, wat tot nu toe niet de juiste aandacht heeft 
gekregen. De perceptie van de ziekte door patiënten beïnvloed de kwaliteit van 
leven, wat betekent dat de rol van artsen ook zodanig moet worden gekozen dat 
de ontwikkeling van vaardigheden om thema’s als psychologische problemen en 
ook het omgaan met familie problemen efficiënt onderzocht en beheerd kunnen 
worden. Vrouwelijke patiënten meldde een slechtere gezondheidstoestand en di-
enen met meer voorzichtigheid gemanaged te worden vooral omdat ze vatbaard-
er zijn ook voor een depressie.
Hoofdstuk drie beschrijft een poging van een pilot telehealth astma-COPD 
haalbaarheidsstudie op Kreta, Griekenland. Astma en COPD zijn veel voorko-
mende ziekten die vaak onder gediagnosticeerd en slecht behandeld worden in 
de eerste lijn. Griekenland verkeert in een lastige situatie op dit moment om ver-
schillende redenen: het is een land met beperkte financiële middelen, met ook 
een beperkt aantal huisartsen die de meeste tijd landelijke en afgelegen gebieden 
bedienen, en met een geografische bijzonderheid van honderden eilanden en af-
gelegen gebieden in de bergen. Hoewel Griekenland een hoge prevalentie heeft 
van COPD wordt geschat dat beide nog steeds onder gediagnosticeerd en onder 
behandeld worden vooral in afgelegen gebieden die geen toegang hebben tot de 
tweede lijn en spirometrie.
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Gebleken is dat telehealth extreem nuttig is bij een ander spectrum van ziekten 
dat wil zeggen; pediatrie, cardiologie, diabetes, noodgevallen, astma en COPD. 
In Nederland is bewezen dat een astma-COPD dienst van Labnoord en UMCG 
ondersteund door telegeneeskunde de diagnose en behandeling van zowel COPD 
en astma vergroten. De eerste ongepubliceerde resultaten tot nu toe tonen de 
effectiviteit van het systeem. Wij schatten dat deze dienst, waarbij een samen-
werking met longartsen plaats vindt, huisartsen zal helpen om een vroege diag-
nose te stellen, om vertragingen in de behandeling te voorkomen en een meer 
geïntegreerde aanpak te bereiken, omdat het gezondheidstoestandsmetingen als 
CCQ en ACQ bevat.
Hoofdstuk vier beschrijft een poging om de beschikbare methoden te zoeken 
en te classificeren om de functionele status te meten. Lichamelijk onderzoek en 
meer beweging wordt aanbevolen voor alle COPD-patiënten. Bewijs voor spec-
ifieke aanbevelingen ontbreken met als enige uitzondering de georganiseerde 
longrevalidatie programma’s. Daarnaast wordt dagelijkse fysieke activiteit aan-
bevolen, niet alleen omdat het de gezondheidstoestand van de COPD-patiënten 
verbetert, maar ook omdat het hart-en vaatziekten voorkomt. Van longrevali-
datie programma’s is aangetoond dat ze de fysieke activiteit verbeteren, korta-
demigheid verminderen en de gezondheid  verbeteren. Als een longrevalidatie 
programma niet beschikbaar is, wordt 20 minuten wandelen per dag aanbevo-
len. Het belang van fysieke oefening en longrevalidatie kan gezien het gunstige 
effect ook een verbetering van depressie opleveren.
Zowel functionele status als een meting van de gezondheidstoestand en spiro-
metrie zijn nodig om een goede geïntegreerde zorg te bereiken bij patiënten 
met COPD. De verbetering van de functionele status is een van de belangrijkste 
behandeldoelen bij patiënten met COPD zoals onderstreept door de bijgewerkte 
GOLD richtlijnen. In onze studie hebben we meetinstrumenten gecategoriseerd 
in: 1) laboratoriumtests - bv cyclus ergometrie 2) semi-laboratoriumtests - bi-
jvoorbeeld de 6-minuten loopafstand test 3) veldproeven - bv de acceleratiem-
eter en 4) de patiënt gerapporteerde uitkomsten - bijvoorbeeld de MRC dyspneu 
schaal.
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De eigenschappen van elk meetinstrument werden beoordeeld op basis van een 
nieuw beoordelingssysteem voor de eerste lijn als: zeer slecht / niet bekend; niet 
goed genoeg, goed genoeg, aanbevolen, ten zeerste aanbevolen. Er werden testen 
geclassificeerd volgens de validiteit/betrouwbaarheid, responsiviteit, populatie 
eerste lijn, functionaliteit, getest in de praktijk (COPD), en bekend MCID. Uit 
deze studie bleek dat om de functionele status bij COPD patiënten te beoorde-
len, er geen hulpmiddel voldoet aan alle criteria om sterk te worden aanbevolen 
voor gebruik in de eerste lijn hoewel er een verscheidenheid aan instrumenten 
(32 tools) was waarvan de functionele status bij COPD beoordeeld werd. De zes 
minuten loopafstandsproef bleek de meest betrouwbare, maar een nadeel van 
deze semilaboratorium functionele capaciteit test is dat deze niet zeer praktisch 
is. De stappenteller was de beste functionele prestatieveldtest, daarnaast waren 
het functionele status domein van zowel de MRC als de CCQ de beste patiënt 
gerapporteerde meetinstrumenten om in de eerste lijn functionele prestaties te 
meten.
Het doel van hoofdstuk vijf in dit proefschrift was het gat in de bestaande 
literatuur te beslaan met betrekking tot welke beschikbare meetinstrumenten er 
zijn voor het meten van de gezondheidstoestand bij COPD patiënten, voor in-
zicht in de beslissingscriteria en welke hulpmiddelen het best zijn voor gebruik 
in de eerste lijn. Dit was lastig omdat er meer dan 40 meetinstrumenten voor dat 
doel zijn. Daarom heeft de IPCRG besloten om artsen te voorzien van deze gids 
om zo het zoeken een stuk eenvoudiger te maken.
Een vragenlijst moet niet alleen voldoen aan kwalitatief goede psychometrische 
eigenschappen, maar ook praktisch zijn en gemakkelijk te interpreteren. De 
SGRQ is een vragenlijst met 50 items die valt onder de 9 meest geprefereerde 
meetinstrumenten. Hoewel deze lijst niet de beste is, is het de meest gebruikte 
vragenlijst is in de literatuur. De lijst heeft goede psychometrische eigenschap-
pen maar behoort niet tot de beste omdat er zeer tijdrovende en uitgebreide 
spreadsheats nodig zijn om de scores te berekenen. Het geheel is opgedeeld in 
drie componenten: symptomen, activiteit, en de gevolgen (op het dagelijkse lev-
en). De MRC werd ook opgenomen in de aanbevolen meetinstrumenten, hoewel 
niet sterk aanbevolen omdat de waarde beperkt is tot de dyspneu beoordeling en 
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geen informatie geeft over de algemene gezondheidstoestand van patiënten.
De CCQ gevolgd door de CAT zijn door huisartsen in IPCRG als de beste mee-
tinstrumenten naar voren gekomen voor het gebruik in de eerste lijn. De belan-
grijkste criteria die gebruikt zijn in deze handleiding waren validiteit/response 
gerichte betrouwbaarheid, getest in de eerste lijn praktijk, beschikbaar en gevali-
deerd in vele talen. Deze gids is bedoeld voor gebruik in de eerste lijn en is er 
op gericht tijd te besparen bij artsen die nu over een systematische samenvatting 
van meetinstrumenten beschikken en daarmee kunnen beslissen welk gebruik-
scriterium het belangrijkst is voor hun specifieke behoeften. Dat wil zeggen, 
sommige vragenlijsten zijn eenvoudig in te vullen in een routine consultatie of 
kunnen in de wachtkamer of per e-mail zelf ingevuld worden en dus handig voor 
artsen die vooral geïnteresseerd zijn in het praktische gebruik. Andere artsen 
hebben belang bij beschikbare meetinstrumenten die zijn vertaald en gevali-
deerd in hun eigen taal. Waar de vragenlijsten te vinden zijn, de vertalingen en 
waar om toestemming gevraagd moet worden voor het gebruik is een andere 
zorg van de meeste artsen die duidelijk wordt vermeld in het hoofdstuk vijf van 
dit proefschrift, in ieder geval voor de vragenlijsten die het hoogst gerangschikt 
zijn. De CCQ wordt sterk aanbevolen bij alle gebruikte criteria. De CAT is een 
veelbelovend nieuw meetinstrument dat pas ontwikkeld is in 2008 en tevens 
zeer aan te bevelen is bij een aantal criteria zoals de validiteit en de eerstelijns 
populatie, maar niet het ‘sterk aanbevolen’ label bereikt dat de CCQ bereikt voor 
alle criteria omdat het slecht scoort op responsiviteit, functionaliteit, praktische 
toepassing en validatie in andere talen. De CCQ bevat 10 items, onderverdeeld 
in 3 domeinen (symptomen, functionele en mentale toestand). De CAT heeft 8 
items, stelt vragen over symptomen, energie, slaap en activiteit, en is ontwikkeld 
als een eendimensioneel meetinstrument.
Afgezien van de eerder genoemde verschillen tussen de CAT en de CCQ, zijn het 
beide betrouwbare en korte instrumenten om de gezondheidstoestand te meten 
in de eerste lijn. De CCQ is uitgebreid sinds de ontwikkeling in 2003. Het is te 
vinden op www.theccq.nl waar artsen de vragenlijst, die vertaald is in meer dan 
53 talen, eenvoudig gratis kunnen downloaden voor gebruik. Zowel de CAT als 
de CCQ zijn praktisch, makkelijk te gebruiken en kunnen in maximaal 2 minuten 
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worden voltooid. Beide zijn ontworpen voor gebruik in de eerste lijn bevolking, 
ze kunnen zelfstandig ingevuld worden, zijn verkrijgbaar in vele vertalingen en 
gratis voor zowel artsen als patiënten.
In hoofdstuk zes is geprobeerd om uit te breiden wat in de handleiding bleek, 
namelijk dat de CCQ en de CAT beide goede keuzes zijn voor gebruik in de eerste 
lijn. Dit is de eerste studie die een directe vergelijking tussen de CCQ en de CAT 
deed in een poging om de eerste lijn clinici te helpen bij de selectie van het 
beste instrument voor het dagelijkse klinische gebruik. De vergelijking van de 
twee vragenlijsten met de SGRQ als de gouden standaard toonde aan dat beide 
vragenlijsten een uitstekende betrouwbaarheid, een goede discriminerende va-
liditeit en een hoge reproduceerbaarheid hebben. Beide vragenlijsten evenals de 
SGRQ toonden een zwakke tot bescheiden samenhang met de FEV, wat de eerder 
beschreven gegevens in de meta-analyse verder ondersteunt.
Hun hoge Cronbach’s alfa geeft aan dat er homogeniteit bestaat tussen de af-
zonderlijke items in beide vragenlijsten. Zowel de CAT als de CCQ waren in staat 
om verschillen in de ernst van COPD te detecteren zoals is aangetoond door hun 
goede discriminerende validiteit. Beide vragenlijsten hadden een hoge correlatie 
met de SGRQ wat hun optimale convergente validiteit bevestigt. Zoals verwacht 
hadden de totaal score van de CCQ en de CAT ook een zeer sterke correlatie, wat 
ondersteunt dat ze beiden hetzelfde construct meten. Dit toont aan dat hoewel 
beide vragenlijsten een aantal verschillen vertonen (energie en slaap voor de 
CAT en mentaal voor de CCQ) zij in het geheel genomen vrij goed correleren. De 
bevindingen van ons onderzoek bevestigen wat de oorspronkelijke ontwikkeling 
van de vragenlijsten al toonde namelijk dat zowel de CAT als de CCQ sterke as-
sociaties hebben met de SGRQ.
In onze studie zijn de symptomen en functionele domeinen van de CCQ signifi-
cant gecorreleerd met de respectievelijke domeinen van de SGRQ (symptomen en 
activiteit). De inhoud van de CCQ had meer overeenkomsten met de SGRQ dan 
met de inhoud van de CAT. Zowel de SGRQ als de CCQ hebben een onderverde-
ling in domeinen terwijl de CAT is ontwikkeld als een eendimensionale vragen-
lijst. Het voordeel van domeinen is dat individuele behandelplannen opgesteld 
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kunnen worden op basis van de individuele domeinen. Een patiënt met bijvoor-
beeld een verminderde mentale toestand zal mogelijk anders behandeld worden 
dan een patiënt met een verminderde functionele status.
De MCID is voor de CAT voor de eerste maal officieel berekend in deze studie 
en bleek groter te zijn dan de CAT ontwikkelaars hadden gespeculeerd (3,76 vs. 
2,00 respectievelijk) terwijl de CCQ waarden vergelijkbaar waren met eerder 
gepubliceerde studies.
Een belangrijk voordeel van de studie was dat er ook een kwalitatieve onderzoek 
werd uitgevoerd door gebruik te maken van eenvoudige open vragen met be-
trekking tot de uitvoerbaarheid en het nut van alle vragenlijsten. Alle patiënten 
(100%) ervoeren de CAT en de CCQ als eenvoudiger metingen in vergelijking 
met de SGRQ in termen van complexiteit en tijd die het in beslag neemt. De 
SGRQ werd beschouwd als nogal ingewikkeld en tijdrovend. Op de vraag ‘welk 
hulpmiddel, de CAT of de CCQ zou u kiezen voor de beoordeling van uw ge-
zondheid?’ gaf 61,1% aan (55 patiënten) van mening te zijn dat de CCQ hun 
status beter weergaf dan de CAT omdat het meer details bevat over de ademhal-
ingsproblemen die belangrijker voor hen zijn dan slaap of energie. Antwoorden 
van patiënten toonden op die manier aan wat voor een belangrijke invloed die 
ademhalingsproblemen (weergegeven door verschillende vragen in CCQ) heb-
ben voor het bepalen van de gezondheidstoestand bij COPD patiënten. Tien 
patiënten gaven aan dat de CCQ eenvoudiger te begrijpen antwoordmogelijkh-
eden heeft ten opzichte van de CAT. Dit onderzoek is in overeenstemming met 
een recente studie waaruit bleek dat de behoefte aan hulp bij het invullen van de 
twee vragenlijsten (CCQ-CAT) bij COPD lager was voor de CCQ, wat bevestigt 
dat CCQ een eenvoudiger meetinstrument is.
Het laatste hoofdstuk beschrijft een initiatief om een gemeenschappelijke 
internationale COPD-databank te ontwikkelen. Het onderzoeksprotocol en de 
eerste resultaten worden gepresenteerd. We waren als onderdeel van dit initia-
tief geïnteresseerd te weten te komen wat de gezondheidstoestand is van COPD-
patiënten in verschillende Europese landen. De relatie tussen de gezondheids-
toestand zoals gemeten door de CCQ met de FEV1 werd beoordeeld.
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Deze studie bevestigd wat gespeculeerd werd in de meta-analyse, dat de vragen-
lijsten voor het meten van de gezondheidstoestand, in dit geval de CCQ, vaak 
onstabiel-ernstig tot zeer instabiel-ernstig aangeeft zelfs bij matig milde COPD. 
Er wordt voorgesteld om de gezondheidstoestand naast spirometrie te beoorde-
len, aangezien veel patiënten met een relatief milde verminderde longfunctie 
lijdt aan ernstige gevolgen van de ziekte. Verder toonde deze studie aan dat de 
CCQ gemakkelijk verschillen binnen GOLD stadia kan opsporen. 
Dit onderzoek is nog in volle gang en ook uit andere landen als Griekenland, 
Cyprus enz. worden meer gegevens verzameld. De verwachting is dat wanneer 
dit onderzoek zal eindigen er ook andere vragen te beantwoorden vallen zoals 
de correlatie van de gezondheidstoestand (CCQ) en het medicijngebruik/de ex-
acerbaties/co morbiditeit en verschillen tussen landen. Hoewel dit nog steeds 
een lopende studie is, is dit de eerste studie waarbij een dergelijk hoog aan-
tal patiënten uit de eerste lijn geïncludeerd zijn waarbij gelijktijdig de CCQ en 
spirometrie waarden bij COPD beoordeeld zijn.
Toekomstperspectieven
Tot nu toe is de meerderheid van de artsen vooral gericht op een goed beheer 
van COPD op basis van het GOLD-stadium en op het jaarlijkse aantal exacerba-
ties, zoals voorgesteld in de GOLD richtlijnen. De bijgewerkte GOLD richtlijnen 
stellen een beoordeling van dyspneu met de MRC voor en de beoordeling van 
de gezondheidstoestand met de CAT. De FEV1 is erkend als een onbetrouwbare 
marker en hoewel beperkt tot een suggestie voor de CAT krijgt de gezondheids-
toestand de plaats die het vanaf het begin had moeten krijgen en dit werd ook 
onderstreept door dit proefschrift.
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De recente GOLD richtlijnen verdeelt patiënten als volgt in groepen in:
Patiënt Groep A-laag risico, 
minder klachten
Typisch GOLD 1 of GOLD 2 en/of  0-1 exacerbaties per jaar en 
mMRC 0-1 of CAT score < 10
Patiënt Groep B-Laag risico, 
meer symptomen
Typisch GOLD 1 of GOLD 2 en/of  0-1 exacerbaties per jaar en 
mMRC ≥ 2 of CAT score ≥ 10
Patiënt Groep C-hoog risico, 
minder klachten
Typisch GOLD 3 of GOLD 4 en/of ≥ 2 exacerbaties per jaar en
mMRC 0-1 of CAT score < 10
Patiëntengroep D-hoog risico, 
meer symptomen
Typisch GOLD 3 of GOLD 4 en/of  ≥ 2 exacerbaties per jaar en  
mMRC or ≥ 2 of CAT score ≥ 10
Een nieuwe horizon is geopend. Verwacht wordt dat clinici de gezondheidstoe-
standsmeting zullen gebruiken in de dagelijkse klinische praktijk. Onze meta-
analyse en het eerste verslag van de internationale studie toonde de zwakke 
relatie aan tussen FEV1 en verschillende vragenlijsten die de gezondheidsstatus 
meten en de aanzienlijke percentages van COPD-patiënten GOLD stadium I en II 
waarbij de kwaliteit van leven sterk was aangetast. We hopen dat de resultaten 
van dit proefschrift in samenhang met de recente GOLD richtlijnen clinici zal 
richten op een geïntegreerde zorg voor COPD patiënten die de beoordeling van 
de gezondheidstoestand zal omvatten. De CCQ is als het beste meetinstrument 
bevonden tijdens de IPCRG workshop, het heeft goede psychometrische eigen-
schappen en heeft de voorkeur van patiënten. Verdere studies zijn nodig en 
misschien nemen de volgende GOLD richtlijnen de inclusie van ook de CCQ 
op naar aanleiding van de overweging van de voordelen die in dit proefschrift 
zijn weergegeven. Voor een goed beheer van depressie en angst, zullen idealiter 
capaciteiten oefening, familie problemen en strategieën om met COPD om te 
gaan, worden opgenomen in een holistische benadering van COPD-patiënten in 
de nabije toekomst.
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Περίληψη και Συζήτηση στα Ελληνικά
Οι ασθενείς με Χ.Α.Π. (Χρόνια Αποφρακτική Πνευμονοπάθεια) έχουν συχνά 
επηρεασμένη ποιότητα ζωής. Πρωταρχικός στόχος στη θεραπεία της νόσου είναι 
η διασφάλιση της ποιότητας ζωής τους. Πολλοί παράγοντες επηρρεάζουν την 
ποιότητα ζωής των ασθενών με Χ.Α.Π.: ηλικία, φύλο, πνευμονική λειτουργία, 
κατάθλιψη, άγχος, συνοσηρότητα. Μέχρι σήμερα δεν υπάρχουν επαρκείς 
αποδείξεις και μια οργανωμένη προσέγγιση ώστε ο ιατρός να γνωρίζει σε ποιο 
βαθμό και με ποιο τρόπο οι ανωτέρω παράγοντες επηρρεάζουν την ποιότητα 
ζωής. Η συσχέτιση των παραγόντων αυτών με την ποιότητα ζωής (μετα-ανάλυση) 
αναλύεται στο κεφάλαιο δύο. Η βασική ιδέα αυτής της μετα-ανάλυσης ήταν η 
ανάδειξη όλων εκείνων των παραγόντων που επηρρεάζουν την ποιότητα ζωής 
ώστε οι ιατροί να τους αναγνωρίζουν έγκαιρα και να τους αντιμετωπίζουν 
κατάλληλα. Η FEV1 και ο λόγος FEV1/FVC θεωρούνται θεμέλιοι λίθοι για την 
διάγνωση και την παρακολούθηση της νόσου. Η μετανάλυση που παρουσιάζεται 
στο κεφάλαιο δύο έδειξε ότι η FEV1 και ο λόγος FEV1/FVC συσχετίζονται από 
ήπια εως μέτρια με τα περισσότερα ερωτηματολόγια ποιότητας ζωής με μόνη 
εξαίρεση το ερωτηματολόγιο CCQ (Clinical COPD Questionnaire) που ανέδειξε 
την καλύτερη συσχέτιση. Η μετα-ανάλυση αυτή επιβεβαίωσε την υπόθεση μας ότι  η 
σπιρομέτρηση δεν αντικατοπτρίζει την ποιότητα ζωής των ασθενών. Αντίθετα αυτή 
η μετα-ανάλυση ανέδειξε την δύσπνοια, την κατάθλιψη, την αγχώδη διαταραχή και 
τη μη ανοχή στην άσκηση ως τους παράγοντες εκείνους που παρουσιάζουν τις πιο 
ισχυρές συσχετίσεις με σχεδόν όλα τα ερωτηματολόγια ποιότητας ζωής.  Το CCQ 
ερωτηματολόγιο έδειξε τις υψηλότερες συσχετίσεις με την κλίμακα κατάθλιψης-
άγχους HADS (Hospital Anxiety Depression Scale). Η ιδιαιτερότητα αυτή της 
CCQ πιθανόν να οφείλεται στο γεγονός ότι περιέχει ερωτήσεις για την κατάθλιψη 
και συνεπώς μπορεί να χρησιμοποιηθεί για την ανίχνευση της. Πιθανόν με αυτήν 
την μετα-ανάλυση οι ιατροί να αρχίσουν να περιλαμβάνουν την εκτίμηση της 
κατάθλιψης και του άγχους στην καθημέρα κλινική πράξη. 
H ποιότητα ζωής φάνηκε να επηρρεάζεται και από δημογραφικούς και 
ανθρωπομετρικούς παράγοντες (ηλικία, φύλο, BMI), καθώς και από άλλους 
πολύ- παραγοντικούς δείκτες όπως ο δείκτης BODE. 
Greek summary & general discussion. Future perspectives
194 195
Το κεφάλαιο τρία περιγράφει την προσπάθεια εφαρμογής ενός προγράμματος 
ολοκληρωμένης παροχής τηλειατρικής φροντίδας σε ασθενείς με X.Α.Π. 
στην Ελλάδα. Η Ελλάδα είναι μια χώρα όπου το άσθμα και η Χ.Α.Π. είναι 
υποδιαγνωσμένα και υποθεραπευόμενα. Το πρόγραμμα αυτό έχει δημιουργηθεί 
και εφαρμόζεται στο Labnoord, στο Groningen (πρώτα μη δημοσιεύμενα 
αποτελέσματα για την αποτελεσματικότητα του συστήματος παρουσιάζονται). Όλο 
το πρόγραμμα μεταφράστηκε στα Ελληνικά και η προσπάθεια εφαρμογής του 
στην Κρήτη έχει ξεκινήσει. Αυτή η προσπάθεια θεωρείται εξαιρετικά σημαντική 
αφού η Ελλάδα είναι μία χώρα με πολλές απομονωμένες και νησιώτικες περιοχές 
με τους  γενικούς ιατρούς χωρίς πρόσβαση σε σπιρομέτρηση/υποστήριξη από 
δευτεροβάθμια-τριτοβάθμια περίθαλψη. Επιπλέον ο επιπολασμός της ΧΑΠ και 
του άσθματος στην χώρα μας είναι ιδιαίτερα υψηλός. 
Η Ελλάδα αυτήν την στιγμή βρίσκεται σε δεινή θέση λόγω της οικονομικής κρίσης 
και της ιδιαίτερης γεωμορφολογίας της με εκατοντάδες νησιά και απομονωμένες 
ορεινές περιοχές. Η χρήση και η εφαρμογή επομένως ενός τηλειατρικού 
συστήματος για την διάγνωση και παρακολούθηση της Χ.Α.Π και του άσθματος 
είναι ιδιαιτέρως σημαντική. Εκτιμούμε ότι η εφαρμογή αυτού του προγράμματος 
θα βοηθήσει τους γενικούς ιατρούς να συνεργαστούν με τους ειδικούς ακόμη και 
από απόσταση με στόχο την έγκαιρη διάγνωση και θεραπεία καθώς και την παροχή 
μιας ολοκληρωμένης φροντίδας υγείας που θα περιλαμβάνει και ερωτηματολόγια 
ποιότητας ζωής (CCQ/ ACQ).
Το κεφάλαιο τέσσερα περιγράφει την προσπάθεια αναζήτησης και ταξινόμησης 
των μεθόδων εκείνων που χρησιμοποιούνται προκειμένου να αξιολογηθεί η 
λειτουργική ικανότητα των ασθενών με Χ.Α.Π. (εργαστηριακές δοκιμασίες-
ημιεργαστηριακές-κ.α.). Οι δοκιμασίες ταξινομήθηκαν ανάλογα με το εάν είναι 
αξιόπιστες, ευαίσθητες, πρακτικές, δοκιμασμένες στην πράξη, με γνωστή MCID 
(ελάχιστα σημαντική κλινική διαφορά) καθώς και από το εάν αναφέρονται σε 
πληθυσμό πρωτοβάθμιας φροντίδας υγείας. Η μελέτη μας έδειξε ότι υπάρχει μια 
ποικιλία 32 διαφορετικών εργαλείων. Κανένα από αυτά τα εργαλεία όμως δεν 
πληρούσε όλα τα κριτήρια ώστε να είναι το μοναδικά προτεινόμενο για χρήση 
στην Π.Φ.Υ.  Tο τεστ της βάδισης για 6 λεπτά αναγνωρίστηκε ως το πιο αξιόπιστο 
έχοντας όμως ως κύριο μειονέκτημα την έλλειψη πρακτικότητας. Το βηματόμετρο 
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ήταν η καλύτερη δοκιμασία για την εκτίμηση της λειτουργικής επίδοσης, ενώ η 
MRC και η  CCQ (τμήμα λειτουργικότητας) ήταν τα καλύτερα εργαλεία  για τη 
μέτρηση της λειτουργικής αποτελεσματικότητας. 
Η σημασία της καλής φυσικής κατάστασης και της ικανότητας για άσκηση είναι 
ιδιαίτερα σημαντικές για τον ασθενή με Χ.Α.Π. και συστήνεται και από τις 
GOLD κατευθυντήριες οδηγίες. Τα προγράμματα πνευμονικής αποκατάστασης 
μπορούν να βελτιώσουν σημαντικά την φυσική αντοχή και την δραστηριότητα, να 
μειώσουν την δύσπνοια και να βελτιώσουν την ποιότητα ζωής και την κατάθλιψη. 
Προκειμένου να εξασφαλιστεί μια ολοκληρωμένη φροντίδα για τους ασθενείς 
με ΧΑΠ η πνευμονική λειτουργία, η φυσική κατάσταση και η ποιότητα ζωής θα 
πρέπει να συνεκτιμούνται. 
Με το κεφάλαιο πέντε προσπαθήσαμε να καλύψουμε το κενό που υπάρχει στην 
υπάρχουσα βιβλιογραφία όσον αφορά στο ποια είναι τα διαθέσιμα ερωτηματολόγια 
εκτίμησης της ποιότητας ζωής στην Χ.Α.Π., ποια είναι τα κριτήρια για την 
επιλογή και ποια είναι τα καταλληλότερα για χρήση στην Π.Φ.Υ.  Η προσπάθεια 
δημιουργίας από την IPCRG ενός οδηγού αξιολόγησης και ανεύρεσης των 
καλύτερων ερωτηματολογίων εκτίμησης της ποιότητας ζωής στην Χ.Α.Π. στην 
Π.Φ.Υ παρουσιάζεται. 
Τα κριτήρια που χρησιμοποιήθηκαν για την αξιολόγηση των περίπου 40 
ερωτηματολογίων ήταν: η αξιοπιστία, η εγκυρότητα, η χρήση τους στην Π.Φ.Υ., 
η πρακτικότητα τους και η διαθεσιμότητα τους σε μεταφράσεις. Αυτός ο οδηγός 
είναι προσανατολισμένος αποκλειστικά για χρήση στην Π.Φ.Υ. και έχει ως στόχο 
να παρουσιάσει και να αξιολογήσει τα ερωτηματολόγια. Με αυτόν τον τρόπο ο 
γενικός ιατρός μπορεί να επιλέξει το καταλληλότερο για αυτόν ανάλογα με τις 
ανάγκες του: π.χ. ορισμένα ερωτηματολόγια είναι εύκολο να συμπληρωθούν 
στην καθημέρα κλινική πράξη ή να συμπληρωθούν από τους ασθενείς στην 
αίθουσα αναμονής,  χρήσιμα στους ιατρούς εκείνους που τους ενδιαφέρει 
κυρίως η πρακτικότητα του ερωτηματολογίου. Άλλοι ιατροί για παράδειγμα θα 
επιλέξουν ερωτηματολόγια μεταφρασμένα και αξιολογημένα για τη χώρα τους. 
Γίνεται γρήγορα αντιληπτό ότι η επιλογή ανάμεσα στα 40 ερωτηματολόγια είναι 
μια ιδιαίτερα δύσκολη υπόθεση για τους κλινικούς ιατρούς. Με αυτόν τον οδηγό 
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μπορούν εύκολα όχι μόνο να επιλέξουν το καταλληλότερο  αλλά και να πάρουν 
πληροφορίες για μεταφράσεις καθώς και για το που μπορούν να τα βρουν. Το 
ερωτηματολόγιο CCQ (COPD clinical questionnaire) εκτιμήθηκε ως το καλύτερο 
σε όλα τα προαναφερθέντα κριτήρια ακολουθούμενου από το CAT (COPD Assess-
ment Test). Το ερωτηματολόγιο SGRQ (St George Respiratory Questionnaire) είναι 
το πιο ευρέως χρησιμοποιούμενο αλλά είναι εξαιρετικά δύσχρηστο με απαραίτητη 
την διαδυκτιακή υποστήριξη προκειμένου να υπολογιστεί το συνολικό σκορ. 
Για αυτούς τους λόγους δεν κατείχε μία από τις πρώτες θέσεις στον οδηγό παρά 
την ευρεία χρήση του. Η σύνοψη του οδηγού αυτού παρουσιάζεται στο πρώτο 
μέρος του πέμπτου κεφαλαίου και το άρθρο που περιγράφει την όλη διαδικασία 
περιγράφεται στο δεύτερο μέρος.  
Το ερωτηματολόγιο CCQ αποτελείται από 3 κατηγορίες (συμπτώματα, 
λειτουργικότητα, πνευματική λειτουργία) με συνολικά 10 ερωτήσεις. Το 
ερωτηματολόγιο CAT έχει 8 ερωτήσεις με θέματα όπως συμπτώματα, ενέργεια, 
ύπνος, δραστηριότητα κ.α. Και τα δύο ερωτηματολόγια είναι σύντομα, αξιόπιστα, 
εύκολα στην χρήση (λιγότερο από δυο λεπτά για να συμπληρωθούν), διαθέσιμα 
σε πολλές μεταφράσεις και διατίθενται δωρεάν. Το CCQ δημιουργήθηκε το 2003 
και είναι διαθέσιμο σε 53 μεταφράσεις. Επιπλέον ιατροί και ερευνητές μπορούν 
να το χρησιμοποιήσουν χωρίς κόστος, και να το βρουν εύκολα στην ιστοσελίδα 
www. ccq.nl. 
Το κεφάλαιο έξι συνέχισε το ερευνητικό ερώτημα του κεφαλαίου πέντε δηλ: 
ποιο ερωτηματολόγιο να επιλέξει κανείς? Περιγράφει την σύγκριση των δύο 
ερωτηματολογίων (CCQ-CAT) που ο οδηγός ανέδειξε ως τα καταλληλότερα. 90 
ασθενείς συμμετείχαν στην μελέτη αυτή όπου τα ερωτηματολογία CAT, CCQ, 
SGRQ χορηγήθηκαν σε τρεις επισκέψεις σε ασθενείς με Χ.Α.Π. Το CCQ και το 
CAT ερωτηματολόγιο βρέθηκαν να έχουν παρόμοιες ψυχομετρικές ιδιότητες και 
υψηλή επαναληψιμότητα με ένα μικρό προβάδισμα για το CCQ κυρίως σε ότι 
αφορά την προτίμηση των ασθενών. 
 Όλα τα ερωτηματολόγια βρέθηκαν να έχουν από ήπια έως μέτρια συσχέτιση με την 
FEV1 επιβεβαιώνοντας τα αποτελέσματα της μετα-ανάλυσης που παρουσιάστηκαν 
στο κεφάλαιο δύο. Tα CAT και CCQ βρέθηκαν να συσχετίζονται ισχυρά με το 
Greek summary & general discussion. Future perspectives
SGRQ αλλά και μεταξύ τους. Στην μελέτη μας δύο από τις τρείς υποκατηγορίες του 
CCQ συμπτώματα και λειτουργικότητα συσχετίζονταν σημαντικά με τις αντίστοιχες 
υποκατηγορίες του ερωτηματολογίου SGRQ (συμπτώματα και δραστηριότητα). 
Το περιεχόμενο δηλαδή του CCQ βρέθηκε όπως άλλωστε αναμένονταν να έχει 
περισσότερες ομοιότητες με το SGRQ απ’ ότι το CAT. Το SGRQ και το CCQ έχουν 
ερωτήσεις που μοιράζονται σε αντίστοιχα τμήματα ενώ το CAT έχει αναπτυχθεί 
ως ένα μονοδιάστατο ερωτηματολόγιο. Το σημαντικό πλεονέκτημα  των SGRQ και 
CCQ είναι ότι με την χρήση τους μπορεί ο ιατρός να διαπιστώσει ποιο ακριβώς 
τμήμα του ερωτηματολογίου είναι επηρρεασμένο και αντίστοιχα να αποφασίσει 
για την διαχείριση και αντιμετώπιση του ασθενούς. Για παράδειγμα ένας ασθενής 
με επηρεασμένη πνευματική λειτουργία θα αντιμετωπιστεί διαφορετικά από 
κάποιον άλλο με έντονη συμπτωματολογία. 
Η MCID (ελάχιστη κλινικά σημαντική διαφορά) για το CAT υπολογίστηκε για 
πρώτη φορά διεθνώς στην μελέτη μας και βρέθηκε υψηλότερη από αυτήν που 
είχε αρχικά υποτεθεί για το CAT (3.76 αντί 2.00) ενώ για το CCQ οι τιμές ήταν 
παρόμοιες με άλλες μελέτες (περίπου 0.4). 
Ένα σημαντικό πλεονέκτημα της μελέτης μας ήταν ότι πραγματοποιήσαμε και 
ποιοτική ανάλυση σχετικά με την πρακτικότητα και χρησιμότητα των τριών 
ερωτηματολογίων. Ερωτήσεις ανοικτού τέλους απαντήθηκαν από όλους τους 
συμμετέχοντες. Όλοι οι ασθενείς (100%) θεώρησαν το CAT και το CCQ ως 
τα πιο εύκολα ερωτηματολόγια (λιγότερο πολύπλοκα-λιγότερο χρόνο για να 
συμπληρωθούν) σε σχέση με το SGRQ.  Το SGRQ θεωρήθηκε από το σύνολο 
των ασθενών ως ιδιαίτερα πολύπλοκο, και χρονοβόρο στην συμπλήρωση του. 
Στην ερώτηση ‘Ποιο ερωτηματολόγιο το CAT ή το CCQ θα επιλέγατε προκειμένου 
να εκτιμηθεί καλύτερα η ποιότητα ζωής σας?’ το 61.1% (55 ασθενείς) είπαν ότι 
το CCQ αντικατόπτριζε καλύτερα την ποιότητα ζωής τους απ’ ότι το CAT αφού 
είχε περισσότερες ερωτήσεις όσον αφορά την δύσπνοια η οποία θεωρήθηκε 
πιο σημαντική για αυτούς από προβλήματα όπως ο ύπνος και η ενέργεια. Δέκα 
ασθενείς εξέφρασαν την άποψη ότι το σύστημα απαντήσεων της CCQ ήταν πιο 
εύκολο απ΄ότι του CAT. 
Το κεφάλαιο επτά περιγράφει μια πρωτοβουλία για την ανάπτυξη μιας κοινής 
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διεθνούς βάσης δεδομένων με ασθενείς με Χ.Α.Π. που περιλαμβάνει δεδομένα 
όσον αφορά την εκτίμηση της ποιότητας ζωής με το ερωτηματολόγιο CCQ.  H 
ιδέα της μελέτης αυτής αποτέλεσε την βάση για την δημιουργία της UNLOCK, μιας 
πρωτοβουλίας της IPCRG για την ανάπτυξη μιας κοινή βάσης δεδομένων για την 
Χ.Α.Π. στην Π.Φ.Υ. προκειμένου να απαντηθούν διάφορα ερευνητικά ερωτήματα. 
Το πρωτόκολλο της μελέτης (πρώτο μέρος) και τα πρώτα αποτελέσματα (μέρος 
δεύτερο) παρουσιάζονται. Τρεις Ευρωπαικές χώρες (Ολλανδία, Ηνωμένο Βασίλειο, 
Σουηδία) συμμετέχουν στην μελέτη. Τα πρώτα αποτελέσματα επιβεβαίωσαν την 
ασθενή συσχέτιση της FEV1 με τα ερωτηματολόγια ζωής που είχαμε βρεί στο 
κεφάλαιο δύο.  Αυτή η μελέτη έδειξε ότι ακόμη και ασθενείς με ήπια-μέτρια 
Χ.Α.Π. έχουν συχνά σημαντικά επηρρεασμένη ποιότητα ζωής οπότε θα πρέπει 
να αντιμετωπίζονται κατάλληλα. Ως εκ τούτου η εκτίμηση της ποιότητας ζωής 
θα πρέπει να γίνεται επιπρόσθετα με την σπιρομέτρηση αφού ασθενείς με ήπια 
σύμφωνα με  την σπιρομέτρηση Χ.Α.Π. μπορεί να έχουν ιδιαίτερα επηρεασμένη 
ποιότητα ζωής. Αυτή η μελέτη συνεχίζεται ώστε να συλλεχθούν περισσότερα 
δεδομένα και από άλλες χώρες όπως η Ελλάδα, η Κύπρος κ.α. Στόχος είναι με 
την ολοκλήρωση αυτής της μελέτης να μπορέσουμε να απαντήσουμε και σε άλλες 
ερωτήσεις όπως: η συσχέτιση της ποιότητας ζωής (CCQ) με την θεραπευτική 
αγωγή/ τις παροξύνσεις/την συνοσηρότητα καθώς και την ανάδειξη πιθανών 
διαφορών ανάμεσα στις χώρες. Παρότι αυτή η μελέτη δεν έχει ολοκληρωθεί 
ακόμη είναι η πρώτη μελέτη όπου σπιρομέτρηση και CCQ εκτιμώνται σε ένα τόσο 
μεγάλο αριθμό ασθενών της Π.Φ.Υ. 
Η βασική ιδέα για την διδακτορική αυτή διατριβή ήταν η πεποίθηση ότι η εκτίμηση 
της ποιότητας ζωής στους ασθενείς με Χ.Α.Π. είναι εξαιρετικά σημαντική για την 
αποτελεσματική αντιμετώπιση της νόσου και θα πρέπει να συμπεριλαμβάνεται 
στην καθημέρα κλινική πράξη. Αυτό που πραγματικά θέλαμε να αποδείξουμε είναι 
το ότι για την διαχείριση των ασθενών με Χ.Α.Π. εκτός από την σπιρομέτρηση 
και η ποιότητα ζωής θα πρέπει να συνεκτιμάται. Η συνήθης διαγνωστική και 
θεραπευτική προσέγγιση της Χ.Α.Π. όταν ξεκίνησε αυτή η διατριβή βασιζόταν 
κυρίως στην εκτίμηση της FEV1 καθώς και της FEV1/FVC. Με αυτήν την 
διδακτορική διατριβή αποδείξαμε την σημασία της εκτίμησης της ποιότητας ζωής 
στην καθημέρα κλινική πράξη καθώς και ποια συγκεκριμένα ερωτηματολόγια 
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είναι τα πλεόν κατάλληλα για χρήση στην Π.Φ.Υ.  Όταν η διατριβή αυτή ξεκίνησε 
οι GOLD κατευθυντήριες οδηγίες είχαν μόνο μια μικρή αναφορά στην σημασία 
της εκτίμησης της ποιότητας ζωής και δεν πρότειναν την χρήση ερωτηματολογίων 
ποιότητας ζωής στην καθημέρα κλινική πράξη. Σήμερα οι ίδιες κατευθυντήριες 
οδηγίες κατατάσσουν τους ασθενείς σε 4 ομάδες κινδύνου λαμβάνοντας υπόψιν 
και την ποιότητα ζωής των ασθενών με Χ.Α.Π. Αυτή η τροποποίηση στις 
κατευθυντήριες οδηγίες αποδεικνύει ότι η ερευνητική μας ιδέα ήταν σωστή. 
 Τα ερευνητικά ερωτήματα που απαντήθηκαν ήταν: Ποιοι είναι οι παράγοντες που 
επηρεάζουν την ποιότητα ζωής των ασθενών με Χ.Α.Π.; Ποιοι από αυτούς τους 
παράγοντες είναι οι πιο σημαντικοί; H σπιρομέτρηση συσχετίζεται σημαντικά με τα 
ερωτηματολόγια ποιότητας ζωής; και με ποια; Με ποιο τρόπο ένα ολοκληρωμένο 
σύστημα τηλειατρικής που θα περιλαμβάνει και ερωτηματολόγια ποιότητας ζωής 
όπως το CCQ μπορεί να εφαρμοστεί σε χώρες όπως η Ελλάδα; Ποια είναι τα 
ερωτηματολόγια που χρησιμοποιούνται για την εκτίμηση της ποιότητας ζωής 
στην Χ.Α.Π.; Ποιο ερωτηματολόγιο και με ποιον τρόπο θα πρέπει να επιλέξουν 
οι ιατροί μιας και υπάρχουν πάνω από 40 διαθέσιμα ερωτηματολόγια; Ποια 
είναι τα βασικά κριτήρια που θα πρέπει να ακολουθούνται ώστε να επιλεγεί το 
καταλληλότερο για χρήση στην Π.Φ.Υ; Ποιο είναι το καλύτερο ερωτηματολόγιο 
(CCQ ή CAT); Έχουν διαφορετικές ψυχομετρικές ιδιότητες και ποιο προτιμούν 
οι ασθενείς; Πότε θα πρέπει οι γενικοί ιατροί να χρησιμοποιούν ερωτηματολόγια 
ποιότητας ζωής; Θα πρέπει να τα χρησιμoποιούν μόνο σε προχωρημένα στάδια 
της νόσου ή και σε πρώιμα στάδια;  
Μελλοντικές προεκτάσεις
Μέχρι πρόσφατα η πλειονότητα των κλινικών ιατρών διαχειρίζονταν θεραπευτικά 
την Χ.Α.Π. βασιζόμενοι στην GOLD σπιρομετρική σταδιοποίηση και στον ετήσιο 
αριθμό παροξύνσεων. Οι πρόσφατες κατευθυντήριες οδηγίες της GOLD συνιστούν 
την εκτίμηση της δύσπνοιας (MRC) και την εκτίμηση της ποιότητας ζωής (CAT). Η 
FEV1 αναγνωρίστηκε για πρώτη φορά ως ένας ανεπαρκής δείκτης και η εισαγωγή 
της εκτίμησης της ποιότητας ζωής παρότι προτείνεται μόνο το CAT επιβεβαιώνει 
την υπόθεση αυτής της διδακτορικής διατριβής.  Οι πρόσφατες κατευθυντήριες 
οδηγίες της GOLD κατατάσσουν τους ασθενείς σε 4 κατηγορίες (Α εως D) ανάλογα 
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με την σπιρομέτρηση, τις ετήσιες παροξύνσεις, και τα αποτελέσματα της εκτίμησης 
της MRC και του CAT. 
Ελπίζουμε τα αποτελέσματα αυτής της διατριβής σε συνδυασμό με τις πρόσφατες 
κατευθυντήριες οδηγίες της GOLD να καθιερώσει την εκτίμηση της ποιότητας 
ζωής στην καθημέρα κλινική πράξη. H CCQ εκτιμήθηκε ως το καλύτερο 
ερωτηματολόγιο. Έχει καλές ψυχομετρικές ιδιότητες και προτιμάται από τους 
ασθενείς. Περισσότερες μελέτες χρειάζονται και ίσως οι επόμενες κατευθυντήριες 
οδηγίες να συμπεριλαμβάνουν και το ερωτηματολόγιο CCQ.
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